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General introduction
Thymidine kinase (TK) is a key enzyme in the salvage pathway of nucleotide metabolism.
The salvage pathway reuses free deoxyribonucleosides originating from DNA breakdown
and recycles them back to DNA precursor deoxyribonucleoside triphosphates (dNTPs).
TK catalyzes the initial step of the salvage pathway - transfer of y-phosphoryl group from
ATP to thymidine thereby forming thymidine monophosphate, TMP. Intracellular TMP is
quickly phosphorylated to TDP and further to TTP. As a feedback inhibitor of thymidine
kinase and an allosteric effector of ribonucleotide reductase, TTP regulates both the
thymidine salvage pathway and de novo supply of purines and pyrimidines for DNA
synthesis and repair. Two genetically distinct thymidine kinase isoenzymes are known in
mammalian cells - TK1 and TK2. TK1 is cytoplasmic and cell cycle regulated and its
activity is associated with the dividing cell. TK2 is localized to mitochondria and
constitutively expressed. Many viruses carry their own thymidine kinase, and in malignant
cells thymidine kinases with altered enzymatic properties have been described. Thymidine
kinases phosphorylate several clinically important nucleoside analogues with antibacterial,
antiviral and anti-leukaemic activity. Knowledge about tissue distribution, regulation,
enzymatic properties and three-dimensional structure of thymidine kinases from normal
cells and virus-infected or cancer cells is necessary in order to perform rational design and
rational use of drugs for selective treatment of the affected cells. A classical example of a
selective nucleoside analogue is acyclic guanidine - acyclovir (trade name Zovir), that has
a potent anti-herpes virus activity. Acyclovir is phosphorylated by virus encoded thymidine
kinase, but not by thymidine kinases encoded by the host. Accordingly, acyclovir
phosphate is solely incorporated into DNA and inhibits DNA replication of virus infected
cells.
TK1 has up to now been refractory to crystallization and no structural data have been
reported for human TK1, nor for any other poxviral or cellular thymidine kinases to which
it shows close homology. The investigation described in this thesis was undertaken in order
to advance the understanding of structure-function relation of human TK1 with special
focus on 1) the importance of amino acid 106 for oligomerization and kinetic properties
and 2) the role of the C-terminal of TK1.
10
Aims of the present investigation
To elucidate the structure-function relation of human TK1 by:
o Identification of the naturally occurring amino acid at position 106 in human TK1
and examination of the significance of valine or methionine at this position by
characterization of recombinant TK1 with Val-106 (V106WT) and with Met-106
(V106M) with respect to enzymatic and oligomerization properties. This study
was started due to divergence between the TK1 amino acid sequence obtained
from DNA sequencing in our laboratory and the TK1 amino acid sequence
deposited in the NCBI GenBank database.
o Further investigation of the role of size, conformation and polarity of amino acid
106 for the function and structure of human TK1 by examination of nine
recombinant mutant enzymes created by site-directed mutagenesis at amino acid
site 106.
o Cloning, expression and characterization of the putative interface fragment of
TK1.
o Examination of the role of the last 40 C-terminal residues of TK1 for in vitro
kinetic and oligomerization properties of the enzyme. The C-terminal is known to
have a regulatory role in vivo for cell cycle-regulated expression of TK1.
PARTI
INTRODUCTION
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Chapter 1
Synthesis of DNA precursors: de novo versus
salvage pathways
All living cells contain DNA as the repository of the genetic information. The synthesis
and repair of DNA requires continuous and balanced supply of DNA building blocks - the
four deoxyribonucleoside triphosphates, dNTPs (Fig. 1.1).
1-3 Phosphates
Purine (adenine, guanine) or
Pyrimidine (cytosine, thymine) base
Deoxyribose (ribose in RNA)
Nucleoside
Nucleotide
Figure 1. 1. A deoxynucleoside consists of a base and sugar deoxyribose. A nucleotide is a
nucleoside with at least one phosphate group attached to it.
Mammalian cells have two pathways for the synthesis of deoxyribonucleotides (Fig. 1 2):
de novo pathway, by which most of the deoxyribonucleotides arise, and salvage pathway.
SALVAGE PATHWAYS
Deoxyribonucleosides ^
DENOVO SYNTHESIS
_ Deoxyribonucleotides
Bases
Ribonucleosides
Ribonucleotides
Ribose-P, amino acids, CO2, NH3
Figure 1.2. Salvage and de novo pathways of nucleotide metabolism. De novo synthesis includes
pyrimidine and purine ribonucleotide synthesis and reduction of ribonucleotides. Salvage pathways
indicate utilization of bases and nucleosides from extracellular precursors and from degraded
nucleic acids. (After Kornberg & Baker, 1992)
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In the de novo pathway the purine ring is build on a ribose-5-phosphate moiety (PRPP) by
a sequence of reactions with specific amino acids (glycine, aspartate, glutamine) and CO2.
The pyrimidine ring in the de novo pathway is synthesized first, from carbamoyl phosphate
and aspartate to orotate, which is then linked to ribose-5-phosphate. The end products of
the de novo pathway are monophosphates of ribonucleosides (NMPs), also called
ribonucleotides, and they have not occurred as free bases or ribonucleosides. The
ribonucleoside monophosphates are phosphorylated to ribonucleoside diphosphates
(NDPs), that in turn are substrates for an enzyme ribonucleotide reductase. Ribonucleotide
reductase converts NDPs to dNDPs by reduction of ribose to deoxyribose. The (deoxy)
nucleoside diphosphates get phosphorylated to triphosphates (NTPs and dNTPs) by a
ubiquitous and non-specific (neither for the base, nor for the pentose sugar) nucleoside
diphosphate kinase. The salvage pathway, in contrast to the de novo pathway, reuses free
bases and deoxyribonucleosides released from damaged DNA (internal sources), or from
dead cells and food digestion (external sources), and recycles them back to
deoxyribonucleotides. Bases and deoxyribonucleosides, unlike deoxyribonucleotides, can
freely pass the cell membrane. Actively dividing cells get nearly all DNA precursors from
de novo pathway, but in resting cells, de novo nucleotide synthesis is absent, and cells are
dependent on salvage enzymes for DNA repair and synthesis of mitochondrial DNA
(Arner & Eriksson, 1995). The relative contribution of de novo and salvage pathways to
the pyrimidine nucleotide pools is different for different tissues and organs of an organism.
De novo synthesis for example, makes the larger contribution to the intestine uracil
nucleotide pool, de novo and salvage synthesis make roughly equal contribution to the liver
pool, and salvage synthesis makes the larger contribution to the kidney pool (Zaharevitz et
ah, 1992). Salvage pathway also provides majority of pyrimidine deoxynucleotides in S-
phase thymocytes (Cohen et al., 1983) and of deoxyliponucleotides in fibroblasts (Spyrou
& Reichard, 1987) and lymphocytes (Spasokoukotskaja et al., 1991). Some parasitic
Protozoa like Giardia lamblia and Trichomonas vaginalis lack de novo pathway for
synthesis of dNTPs and have to salvage DNA precursors from the host cell (Berens et ah,
1995). A strong indication for the importance of the pyrimidine nucleotide salvage
pathway in vivo are the changes caused by thymidine kinase deficiency in Tk / knockout
mice: kidney pathology and abnormal immune system resulting in shortened life spans
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(less than one year) when compared with the wild type or heterozygous siblings
(Dobrovolsky et al, 2003).
Role of ribonucleotide reductase in the de novo pathway
Ribonucleotide reductase catalyses the committed step in the de novo synthesis of DNA
precursors - a direct transformation of ribonucleotide diphosphates to corresponding
deoxyribonucleotides - and is the central control element in this pathway. The enzyme has
three remarkable features: it is cell cycle regulated, it involves free radicals to transform its
substrate, and it is under allosteric control by both ribonucleotides and
deoxyribonucleotides.
Cell cycle regulation
hi accordance to its role in DNA synthesis, the activity of ribonucleotide reductase attains
its maximum during S-phase and the highest reduction of ribonucleotides was reported in
rapidly growing malignant cells (Elford et al, 1970). The two subunits are differentially
regulated during the cell cycle and the variation in holoenzyme activity is regulated by de
novo synthesis and breakdown of the small R2 subunit with a half-life of 3 hours (Eriksson
et al, 1984). The concentration of R2 protein increased 3 - 7 - fold with the onset of S-
phase (Eriksson et al, 1984), while the level of protein Rl was found to be constant, with a
half-life of at least 15 hours throughout the cell cycle (Engstrom et al, 1985). The mitotic
proteolysis of the R2 protein has been recently demonstrated to occur via a ubiquitin-
proteasome pathway and to depend on a KEN box sequence recognized by an ubiquitin
protein ligase - the anaphase promoting complex (APC) and its activator protein Cdh-1
(Chabes et ah, 2003). The immunocytochemical studies localized ribonucleotide reductase
to the cytoplasm, and showed, that the R2 protein was present only in S-phase cells, while
the Rl protein was present in both S- and Gl phase of actively dividing cells, but not in
terminally differentiated cells that stopped synthesis of DNA (Engstrom et al., 1984;
Engstrom & Rozell, 1988; Mann et al., 1988). Recently, the localization of mammalian
ribonucleotide reductase, especially after DNA damage, became questionable. A DNA
damage-inducible homologue of the R2 subunit has been identified by screening a colon-
cancer cell line for p53-inducible differentially expressed genes (Tanaka et al., 2000;
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Lozano & Elledge, 2000). The p53R2 protein was reported to translocate to the nucleus
where it supplied the precursors for DNA synthesis and was directly involved in the
process of DNA repair within the damaged resting cells (Tanaka et ah, 2000).
Structural and reaction mechanism aspects
Mammalian ribonucleotide reductase is a tetrameric protein composed of two different
homodimers: the large subunit RI and the small subunit R2. Both subunits are important
for the catalytic activity of ribonucleotide reductase. The small R2 subunit contains an
oxygen-bridged diferric iron center that forms and stabilizes the tyrosine free radical
required for catalysis (Fontecave et al., 1992; Fontecave 1998). The Rl subunit provides
the catalytic site that contains redox-active dithiols and the binding site for the NDP
substrates. During catalysis the radical function from the tyrosine of the R2 gets transferred
through a cysteine residue in the catalytic site of Rl to the NDP substrate, and generates a
reduced nucleotide. The RI subunit also contains two separate allosteric specificity sites
that bind ribonucleotide and deoxyribonucleotide effectors: the activity site and the
specificity site (Fig. 1.3 A).
Allosteric regulation
The activity site of the RI subunit regulates the overall catalytic activity of the enzyme by
binding either ATP (the positive effector), or dATP (the negative effector), and the
substrate specificity site binds ATP, dATP, dTTP and dGTP, and determines which one of
the four nucleotides will be reduced (Fig. 1.3A). Evidence for the independent activity and
specificity sites in mouse ribonucleotide reductase was provided by characterization of
separate mutations of the Rl protein with altered allosteric regulation (Eriksson et al.,
1981).
The rationale of ribonucleotide reductase regulation is as follows: the presence of ATP
signals a high level of biosynthesis and abundance of ribonucleotides, whereas
accumulation of dATP means abundance of deoxyribonucleotides and renders the enzyme
inactive. ATP, as well as dATP in low concentrations bound to the substrate specificity site
(Eriksson et al., 1981), favor reduction of pyrimidines (Fig. 1.3B). dTTP bound at the
specificity site, inhibits reduction of the pyrimidines CDP and UDP, and activates
reduction of the purine GDP. Binding of dGTP stimulates ADP reduction and inhibits
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reduction of GDP, CDP and UDP. Of the four dNTPs, only dCTP lacks properties of an
allosteric effector for ribonucleotide reductase. (On the other hand, dCTP acts allosterically
on dCMP deaminase and deoxycytidine kinase). Binding of any of the allosteric effectors
was found to increase the interaction between Rl and R2 subunits (Ingemarson &
Thelander, 1996).
B
Activity site CDP
UDP
GDP
ADP
Specificity site
• dCDP dCTP
dUDP
I
dTTP
dGDP.
> dADP
I
dGTP
dATP
I
Figure 1.3. A. A simplified model for the allosteric regulation of the mammalian ribonucleotide
reductase (after Jordan & Reichard, 1998). B. Scheme of the regulation of deoxyribonucleotide
synthesis. The broken arrows stand for positive effects, the solid arrows and bars stand for negative
effects. Modified after Thelander & Reichard (1979).
As can be seen, the allosteric sites communicate with the catalytic site regarding choice of
the substrate and the activity of the enzyme. When ribonucleotide reductase reactions were
monitored in the presence of four substrates simultaneously, also the binding of NDP
substrates at the catalytic site influenced dNTP binding at the specificity site (Chimploy &
Mathews, 2001). Interactions between the two allosteric effector-binding sites, i.e. the
activity and specificity site of the RI subunit, were also reported (Reichard et al., 2000). It
is probable, that these interplays between the two allosteric sites and the catalytic site
ensure that the four deoxynucleotides are synthesized according to the need of the cell, and
that disturbances in the dNTPs pool size are prevented (Thelander and Reichard, 1979;
Jordan and Reichard, 1998).
A new, and controversial, model for allosteric control of mammalian ribonucleotide
reductase activity, based on molecular mass, ligand binding and enzyme kinetics studies
has been presented recently. In this model, the most active form of the enzyme is depicted
as an R16R26 heterohexamer, and not as typically in the literature, as an RI2R22
heterodimer. Formation of the hexamer is proposed to be driven by ATP binding to a third
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allosteric site on the RI subunit (called hexamerization site), while dATP binding to the
activity site induces formation of inactive RI4 tetramer, and nucleotide binding to the
specificity site of the RI subunit drives formation of an active RI2R22 dimer (Kashlan et
al., 2002; Kashlan & Cooperman, 2003). By estimation of the distribution of Rl among
dimer, tetramer and hexamer forms in vivo, the authors suggest that Rl6 may predominate
in the cytoplasm of mammalian cells, while RI2 may be important for the nuclear activity
of ribonucleotide reductase (Kashlan & Cooperman, 2003).
Biosynthesis of thymidylate
A thymine ribonucleotide as a precursor for (deoxy)thymidine does not exist, therefore the
use of the prefix "deoxy" is optional (Kornberg & Baker, 1992). Most of dTMP in
mammalian cells is derived from methylation of dUMP by the enzyme thymidylate
synthase. dUMP in turn is supplied by deamination of dCMP or by action of a dUTPase on
dUTP. Over 80% of dUMP originates from deamination of dCMP, which is the major
pathway for dTMP synthesis (Nicander & Reichard, 1985). The de novo reactions
responsible for synthesis of dTMP are shown in Fig. 1.4:
dUTP
dUDP
dCMP
dUTPase
dUMP
dCMP deaminase thymidylate synthase
- • dTMP
Figure 1.4. Synthesis of dTMP in mammalian cells by de novo pathway. The mammalian dUTPase
is so effective that dUTP could not be detected in cell extracts (Reichard, 1988).
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Salvage pathways
The salvage enzymes save the cell resources of energy, carbon and nitrogen by utilization
of preformed bases and nucleosides. Bases can be converted into nucleosides, directly
converted into ribonucleotides, or interconverted as for example cytosine to uracil. Also,
enzymes engaged in transport of nucleosides across the cell membrane are classified as
salvage enzymes. All animal cells possess nucleoside and nucleobase carrier proteins with
wide substrate specificity, that facilitate entrance of nucleosides and bases into the cell
either by non-concentrative diffusion system or by active transport (Plagemann et ah,
1988; Belt et al, 1993; Cass et al, 1999). Some specialized cells in the body, like
erythrocytes or brain cells, are deficient in de novo synthesis and depend on nucleosides
synthesised in for example liver, to be taken up from extracellular fluid and salvaged. The
next step in the salvage pathway, phosphorylation of nucleosides to monophosphates, is
considered as the key regulatory step, since the phosphorylated nucleotides are trapped
intracellularly due to their negative charge (Arner & Eriksson, 1995). The essential salvage
pathways are shown in Fig. 1.5.
transport carrier protein
• dN * • N
kinase J T 5'-nucleotidase
dNMP < • dNDP^ • dNTP
extracellular space \ . cytosol
Figure 1.5. Salvage pathways for uptake and phosphorylation of nucleosides. dN is a
deoxyribonucleoside, N is a base; dN and N are interconverted by nucleoside phosphorylases (the
predominant direction is degradative). Nucleoside monophosphate kinases and nucleoside
diphosphate kinases phosphorylate nucleotides of both the de novo and salvage pathways.
The four mammalian deoxyribonucleoside kinases - TK1, TK2, dCK and dGK, will be
described in the next section, hi this section 5'-nucleotidases and deoxyribonucleoside
phosphorylases will be described (se Fig. 1.5).
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5'-Nucleotidases
Reactions catalysed by deoxyribonucleoside kinases are irreversible, but their action is
opposed by 5'-nucleotidases. A kinase and a 5'-nucleotidase catalyse interconversion
between deoxyribonucleosides and their corresponding 5'-phosphates - these two enzymes
participate in a "substrate cycle", where opposing reactions balance the concentration of
the dNTPs by affecting flow of deoxyribonucleosides into the cell and phosphorylating
them when dNTPs are in short supply, or by degrading surplus of dNTPs and sending them
out of the cell as nucleosides (Bianchi et al, 1986; Hoglund et al., 1988; Bianchi et al,
1994).
Several types of 5'-nucleotidases have been described (reviewed by Arner & Eriksson,
1995; and by Bianchi & Spychala, 2003). The 5'-nucleotidases differ in protein structure,
substrate specificity and subcellular localization, some are ubiquitous, others have tissue-
specific expression, and their nomenclature is quite confusing. For example, the cytosolic
purine 5'-nucleotidase, also called high Km nucleotidase, has been shown to participate in
the regulation of the pools of ribonucleotides IMP and GTP, but not in the regulation of
deoxyribonucleotides (Gazziola et al, 2001), while the cytosolic 5'(3')-deoxynucleotidase
(dNT-1) was shown to be involved in substrate cycles of pyrimidine ribo- and
deoxyribonucleotides (Rampazzo et al., 2000a; Gazziola et al., 2001). A recently identified
mitochondrial enzyme, dNT-2, related to dNT-1, was suggested to participate together with
thymidine kinase 2 in a substrate cycle that protects mitochondrial DNA polymerase from
an excess of dTTP (Rampazzo et al., 2000b; Gallinaro et al, 2002; Rampazzo et al, 2004).
The gene for dNT-2 was localized in a region of chromosome 17 which is affected in most
cases of Smith-Magenis syndrome (a multiple congenital anomalies syndrome with
moderate mental retardation), and the loss of dNT-2 was proposed to be involved in
etiology of this disease (Rampazzo et al., 2000b). Nucleotidases are also of clinical
interest, because they may alter the therapeutic efficacy of certain nucleoside analogues
(Hunsucker et al., 2001).
Cells that are naturally low in nucleotidase activity, as for example T lymphocytes, are
especially sensitive to accumulation of dNTPs, if any other enzyme that removes
nucleosides (deaminases, phosphorylases) is inhibited or missing (Carson et al., 1981). For
instance, adenosine deaminase (ADA) deficiency leads to a severe combined
immunodeficiency disorder. ADA catalyses the deamination of adenosine and
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deoxyadenosine, and it is known that ADA deficient patients have a 1000-fold increased
dATP level in their erythrocytes (Coleman et ah, 1978). Since dATP is a powerful
inhibitor of ribonucleotide reductase, the levels of other three nucleotides are greatly
reduced, DNA replication and repair inhibited, resulting in DNA double strand breaks and
cell death (Yoshioka et ah, 1987).
Deoxyribonucleoside phosphorylases
Two deoxyribonucleoside phosphorylases are known: purine nucleoside phosphorylase
(PNP) and pyrimidine nucleoside phosphorylase (Kornberg & Baker, 1992; Pugmire &
Ealick, 2002). The purine phosphorylase catalyses the phosphorolytic cleavage of (deoxy)
inosine and (deoxy)guanosine, but not (deoxy)adenosine, which needs first to be
deaminated to (deoxy)inosine (Kornberg & Baker, 1992). The mammalian pyrimidine
phosphorylase is specific for thymidine, and is also called thymidine phosphorylase, or TP
(Pugmire & Ealick, 2002). Similarly to the 5'-nucleotidases, the phosphorylases function
against accumulation of to big pools of (deoxy)ribonucletides.
Purine nucleoside phosphorylase (PNP) deficiency is associated with a severe defect of T-
lymphocyte function, that results from more than 10-fold accumulation of dGTP in T cells
(Cohen et ah, 1978). dGTP, in rum, is an allosteric regulator of ribonucleotide reductase
and the result is a genotoxic pool imbalance. Arpaia et ah (2000) have proposed that the
severe combined immune deficiency in PNP knockout mice is due to selective
accumulation of dGTP in the mitochondria of T cells, leading to defective mitochondrial
DNA repair and T cell apoptosis.
Recently, a severe mitochondrial dysfunction, mitochondrial neurogastrointestinal
encephalomyopathy (MNGIE), has been associated with mutation in the gene specifying
thymidine phosphorylase. TP activity in leukocytes from MNGIE patients was less than
5% of controls, and the normally undetectable plasma levels of thymidine and
deoxyuridine were dramatically increased in all patients (Nishino et ah, 1999; Spinazzola
et ah, 2002; Marti et ah, 2003). The increased levels of dThd and dUrd have been
associated with site-specific mitochondrial DNA point mutations observed in MNGIE
patients with TP deficiency (Marti et ah, 2003; Nishigaki et ah, 2003), and with multiple
deletions and depletion of mtDNA in skeletal muscle (Hirano et ah, 1994). Multiple
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deletions in mtDNA were also found in HeLa cells cultured in medium supplemented with
50 uM thymidine for 8 months, which supported the hypothesis that dNTP pool imbalance
is responsible for mtDNA mutagenesis (Song et al., 2003). On the other hand, increased
levels of TP have been reported in many tumours, and are considered to confer poor
prognosis (Ackland & Peters, 1999). Thus, too little or too much enzyme activity may lead
to disease.
Human deoxyribonucleoside kinases
Basic properties
The four human deoxyribonucleoside kinases have been cloned and expressed in bacteria
(TK1 by Bradshaw & Deininger, 1984; TK2 by Johansson & Karlsson, 1997a and by
Wang et al, 1999a; dCK by Chottiner et al, 1991, and dGK by Johansson & Karlsson,
1996 and by Wang et al, 1996). The comparison of the predicted amino acid sequences
showed, that deoxycytidine kinase - dCK, deoxyguanosine kinase - dGK, and the
mitochondrial thymidine kinase - TK2, are closely related , while the cytosolic thymidine
kinase - TK1, cannot be included in this enzyme family (Eriksson et al, 2002). Alignment
of the dGK amino acid sequence with the dCK, and the Herpes virus thymidine kinase
amino acid sequences suggested a close evolutionary relationship (Wang et al., 1996;
Johansson & Karlsson, 1996; Eriksson et al., 2002). As early as in 1991, it was suggested
that higher and lower vertebrate herpesvirus TKs have evolved from a captured cellular
dCK gene (Harrison et al, 1991).
The functional similarities and differences within deoxynucleoside kinases are
substantiated by the fact that dCK, dGK and TK2, but not TK1, have relaxed
stereospecificities against their nucleoside substrates: in contrast to TK1 they do not
distinguish between D- and L-isomers of (3-nucleosides (Wang et al., 1999b). Each kinase
phosphorylates several deoxyribonucleoside substrates, with the name referring to the
preferred one. The final products of deoxyribonucleoside phosphorylation, the
corresponding dNTPs, regulate enzyme activity by feedback inhibition - the best inhibitor
is the triphosphate of the preferred substrate (Arner & Eriksson, 1995).
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Deoxynbonucleoside kinases play an essential role in activation of anticancer and antiviral
nucleoside analogues - the drugs must be converted to the corresponding triphosphates in
order to interfere with viral or cellular DNA replication and repair, and eventually lead to
apoptosis of malignant cells (Leoni et al, 1998). Because the first phosphorylation step,
catalysed by deoxynucleoside kinases, is considered to be rate limiting, it is important to
know the substrate specificity and tissue distribution of the particular enzyme to achieve
successful therapy (Eriksson et al, 1994).
Thymidine kinases - TKl and TK2
TKl and TK2 (EC 2.7.1.21) are two different proteins and they certainly deserve a
separate EC number. They are coded by different genes, have different substrate specificity
and different substrate kinetics, differ in phosphate donor specificity and are located in
different cellular compartments. Besides, TKl is strictly cell cycle regulated and is absent
from non-dividing cells, while TK2 is constitutively expressed.
Cytosolic thymidine kinase - TKl
The cytosolic thymidine kinase, TKl, (EC 2.7.1.21.) is probably the most studied among
the salvage pathway enzymes due to the fact that its expression is cell cycle regulated and
cancer tissues show higher activity, and because it can activate some clinically important
analogues (Arner & Eriksson, 1995). TKl is widely distributed in human tissues, but being
S-phase correlated, it is only detected in proliferating cells, either normally growing or
malignant (Munch-Petersen & Tyrsted, 1977; Tyrsted & Munch-Petersen 1977; Arner et
al, 1992; Arner & Eriksson, 1995). The human TKl gene has been localized to
chromosome 17 (Miller et al., 1971), more precisely to its long arm (McDougall et al.,
1973), at the position 17q23.2-q25.3 (Solomon et al, 1993).
The first human TKl cDNA clone, derived from SV40 transformed human fibroblasts, was
characterized by Bradshaw and Deininger (1984). The cDNA was 1421 bases long
(exclusive the polyA tail and the polyG tail), the open reading frame had 702 bases pairs
and coded for a protein of 234 residues with a calculated molecular size of 25.5 kDa. The
complete human TKl gene, that originated from HeLa cells, was cloned by Bradshaw
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(1983), and sequenced and characterized by Flemington et al. (1987). The genomic TK1
was 12.9 kb long, was composed of 7 exons and had 13 repetitive Alu sequences within its
introns, comprising about 25% of the total sequence of the human tk gene (Flemington et
al, 1987). This is one of the highest densities of the Alu containing sequences in the
human genome (Flemington et al., 1987; Slagel et al., 1987). The sizes of the exons were
130, 32, 111, 94, 90, 120 and 851 base pairs for exons 1 through to 7 respectively
(Flemington et al., 1987). A detailed description of the human TK1 promoter and of the
complicated regulation of TK1 expression on several levels is presented in the Chapter 3:
"Regulation of TK1 expression".
The TK1 protein was reluctant to purification due to its low abundance and high
instability, and in early investigations addition of ATP has been used to stabilize the
enzyme (Lee & Cheng, 1976; Munch-Petersen, 1984). The early observations diverged
with regard to the molecular weight of the native TK1 (from 55 to 200 kDa) and its subunit
size (24 to 65 kDa), as summarized by Munch-Petersen (1996). The discrepancies were
probably due to contaminating proteins and ability of TK1 to oligomerize in the presence
of ATP: the size of the active, partly purified TK1 increased from 75 to 175 kDa when
eluted from G-200 Sephadex column in the presence of 2 mM ATP (Munch-Petersen,
1984). The first purifications of human TK1 to homogeneity, where the size of the pure,
substrate-free enzyme was in agreement with the predicted subunit size from the cloned
gene, were reported when TK1 from S-phase HeLa cells was stabilized by digitonin
(Sherley & Kelly, 1988a), and TK1 from PHA stimulated human lymphocytes, was
stabilized with the detergent CHAPS (Munch-Petersen et al, 1991). The molecular size of
native TK1 as found by Sherley & Kelly (1988a) was 96 kDa, indicating a tetramer, as the
subunit molecular mass estimated in SDS-PAGE was 24 kDa. The same subunit molecular
mass of 24 kDa was found for the pure homogeneous preparation of TK1 from PHA
stimulated human lymphocytes (Munch-Petersen et al, 1991). Native TK1 eluted from a
Superose 12 column with an estimated molecular mass of 55-56 kDa in the absence and
110-120 kDa in the presence of 2 mM ATP (Munch-Petersen et al, 1991; Munch-Petersen
et al, 1993). Use of Superdex 200, a different gel-matrix, for the same enzyme preparation
gave higher molecular size estimates: 70 kDa and 150 kDa without and with ATP
respectively (Jensen & Munch-Petersen, 1995; Munch-Petersen et al, 1995a), in
agreement with the above mentioned earlier results (Munch-Petersen, 1984). Discrepancies
25
in the estimation of molecular size due to the choice of chromatographic material have also
been reported for the purified mouse TK2 and the related deoxynucleoside kinase from
Drosophila melanogaster, and are mentioned later.
When pure, substrate free TKl was isolated, and stabilized in the presence of CHAPS, a
new ATP effect on enzyme activity was observed (Munch-Petersen et al., 1993; Munch-
Petersen et al., 1995a). Incubation of TKl or storage with 2 mM ATP induced a reversible,
enzyme concentration-dependent transition from a form with low substrate affinity (Km =
12 uM) and a non-hyperbolic biphasic kinetics to a form with high substrate affinity (Km s
0.7 uM) and hyperbolic Michaelis-Menten kinetics (Munch-Petersen et al., 1993). Similar
shifts could not be induced by thymidine. Because the effect of ATP on the size of TKl
was reversible as well, it was reasoned that the tetramer was associated with the high-
affinity form, and the dimer with the low-affinity form (Munch-Petersen et al., 1993).
Surprisingly, the recombinant TKl expressed in E. coli from a plasmid that contained the
amino acid coding sequence from the TKl clone of Bradshaw and Deininger (1984),
showed no ATP effect and behaved as a permanent tetramer with high affinity to
thymidine (Km = 0.4 uM) irrespective of the preexposure to ATP (Jensen & Munch-
Petersen, 1995; Munch-Petersen et al., 1995a). At that time, the divergent properties of the
recombinant TKl were explained by absence of post-translational modification of TKl
when expressed in E. coli (Jensen, 1994; Munch-Petersen et al., 1995a). When the amino
acid coding region of TKl from normal human lymphocytes was cloned into the pGEX-2T
vector (described in Paper I, Berenstein et al., 2000), it turned out that the recombinant
lymphocyte TKl (rLy-TKl) behaved like the endogenous enzyme regarding the ATP
transition effect on oligomerization and thymidine affinity. Explanation of these
conflicting results came with sequencing of the lymphocyte TKl cDNA which showed
presence of GTG codon for valine at amino acid position 106 and not the ATG codon for
methionine which is present at this position in the cDNA clone of Bradshaw and Deininger
(1994). The first sequencing reactions were run by Tina Kristensen, at that time a Ph.D.
student (Kristensen, 1996). The project was continued by me, Jacob Fromberg Christensen
and Hanne Frederiksen, at that time M. Sc. students (Frederiksen, 1999; Christensen,
2000). The results are presented in Chapter 6 "The role of amino acid 106 in the catalytic
mechanism and oligomerization pattern of human thymidine kinase 1 "and have already
been published (Paper I and II; Berenstein et al., 2000; Frederiksen et al, 2004).
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The substrate specificity of TK1 is more restricted than of the other salvage enzymes. TK1
accepts only thymidine and deoxyuridine, but it has the highest specificity constant kcat/Km
with its primary substrate, dThd, which is equal to 8xlO6 M^sec"1, about 40 times higher
than that of dCK with dCyd (Munch-Petersen, personal communication). The preferred
phosphate donors are ATP and dATP, while dTTP is the feedback inhibitor (Munch-
Petersen, 1984; Munch-Petersen et ah, 1995b). Analogues of dThd and dCyd with minor
substitutions at the 5-position, e.g. FdUrd, 5-fluorodeoxyuridine, or at the 3'-position of
the sugar, e.g. the anti-HTV compounds FLT, 3'-fluoro-2',3'-dideoxythymidine and AZT,
3'-azido-2',3'-dideoxythymidine are also allowed (Munch-Petersen et ah, 1991; Arner &
Eriksson, 1995). Bulkier substitutions such as 5-propenyl in 5-propenyldUrd, and
arabinofuranosyl- or acyclic sugars are not accepted (Eriksson et al., 1991; Arner &
Eriksson, 1995). AZT was an efficient substrate, with Km values in the same range as that
obtained with thymidine (Munch-Petersen et ah, 1995b). AZT substrate kinetics displayed
a hyperbolic reaction mechanism, and it was proposed that the TK1 form reacting with
AZT was the tetrameric, high-affinity form (Munch-Petersen et ah, 1995b).
Several studies have shown that activity of TK1 fluctuates with the cell cycle and is highly
correlated to DNA synthesis (Bello, 1974; Munch-Petersen & Tyrsted, 1977). TK1 has
therefore been suggested as a tumour marker/indicator of malignancy (Hallek, 1992;
Romain et ah, 2000; Mao et ah, 2002; Mizutani et ah, 2003) and as a predictor of tumour
recurrence (O'Neill et ah, 1995).
The three-dimensional structure of TK1 is not known, nevertheless, in Chapter 4:
"Structure of the human TK1", 1 will approach to describe its putative 3D structure based
on the prediction of the secondary structure and comparison to the available 3D structures
of the multisubstrate deoxynucleoside kinase from Drosophila melanogaster, dNK, the
human deoxyguanosine kinase, dGK (Johansson et ah, 2001) and the Herpes simplex virus
thymidine kinase (Wild et ah, 1995; Wild et ah, 1997).
Mitochondria] thymidine kinase - TK2
Mitochondrial thymidine kinase, TK2, shares up to now its EC number with TK1 (EC
2.7.1.21). TK2 is present in most tissues, in correlation to the number of mitochondria and
independent of the growth state of the cell (Arner & Eriksson, 1995). When compared to
the level of TK1 in proliferating cells, the level of TK2 is low, but TK2 becomes
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significant in resting and terminally differentiated cells, such as muscle or brain and
unstimulated lymphocytes, where TK1 activity is barely detectable (Munch-Petersen &
Tyrsted, 1977; Eriksson & Wang, 1997). Presence of thymidine kinase activity in
mitochondria was detected in mouse TKT fibroblasts, deficient in the cytoplasmic TK
activity and resistant to BrdUrd (5-bromodeoxyuridine). The TK~ cells incorporated
thymidine or BrdUrd into mitochondrial, but not nuclear DNA (Attardi & Attardi, 1972;
Berk & Clayton, 1973). The human gene for TK2 has been located to chromosome 16 of
the nucleus using mouse/human hybrid cells (Willecke et al, 1977), and later mapped to
region 16q22 (Johansson & Karlsson, 1997a).
Initial attempts to clone the human TK2 gene resulted in incomplete human TK2 cDNA
which did not include a mitochondrial translocation signal (Johansson & Karlsson, 1997'a;
Wang et al, 1999a). The cloning of full-length human TK2 cDNA containing the 5'-
region with the mitochondrial leader sequence was reported by Wang et al. (2003). The
human TK2 gene was shown to occupy a 45 kb DNA fragment and to consist of 10 exons,
from 32 bp to 1304 bp, and 9 introns, from 0.572 kb up to 11.1 kb (Wang et al, 2003). The
mitochondrial leader sequence was coded by exon 1 (Wang et al., 2003). The size of the
TK2 polypeptide deduced from its coding sequence was about 30 kDa (Wang et al., 1999a;
Wang et al., 2003), in agreement with the subunit size of the purified native TK2
determined by SDS electrophoresis (Munch-Petersen et al., 1991). As to the molecular size
of native TK2, diverging observations have been reported. Native TK2 purified from
leukemic spleen eluted as a monomer of 30 kDa from Superose 12 column (Munch-
Petersen et al., 1991). Also recombinant human TK2 subjected to gel filtration on a
Superdex 200 column eluted as a peak of 30-40 kDa, indicating a monomer (Wang et al.,
2003). But partially purified lymphocyte TK2 (DEAE fractions) eluted from Superdex 200
before bovine serum albumine, with an apparent size of 70 kDa, indicating a dimer
(Munch-Petersen, 1984; Munch-Petersen, 1996). Similar discrepancies have been reported
for the purified mouse TK2 and the related deoxynucleoside kinase from Drosophila
melanogaster (Dm-dNK): both enzymes eluted as a dimer when judged by Superdex 200
chromatography, but as a monomer when judged by Superose 12 (Wang & Eriksson, 2000;
Munch-Petersen, et al, 1998; Knecht et al, 2002a). Because Dm-dNK, dGK and dCK are
dimeric proteins in crystals (Johansson et al, 2001; Sabini et al, 2003), and dCK and dGK
were also shown to be dimers by gel filtration (Datta et al, 1989a; Wang et al, 1993), it is
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now believed that TK2 and Dm-dNK are dimers. The artefactual result on Superose 12
might be explained with interaction of the enzymes with the hydrophobic matrix of the gel
filtration column (Rnecht et al., 2002a; Munch-Petersen, personal communication).
TK2 has broader substrate specificity than TK1, it phosphorylates all three pyrimidine
nucleosides - deoxythymidine, deoxyuridine, deoxycytidine and their analogues (Munch-
Petersen et al., 1991). TK2 shows negative cooperative reaction mechanism with
thymidine, as the affinity of TK2 to the substrate decreases with increasing substrate
concentration. Two apparent Km values for thymidine were calculated from biphasic
Hofstee plot at low and at high substrate concentration: 0.3 uM at substrate concentration
below 8 uM, and 16 uM at substrate concentrations above 8-10 uM (Munch-Petersen et
al., 1991). It may be advantageous for resting cells to have an enzyme with negative
cooperativity: at the physiological extracellular thymidme concentration ranging from 0.1
uM to 1.2 uM (Holden et al, 1980), TK2 with high affinity, although present in low
amounts, will supply the cell with thymidine nucleotide for DNA repair and replication of
mitochondrial DNA. On the other hand, decrease of TK2 affinity towards its substrate at
higher substrate concentration will protect the cell against unnecessary nucleotide
production.
TK2 phosphorylated dCyd and dUrd with Michaelis-Menten kinetics, the Km values were
36 uM and 6 uM respectively (Munch-Petersen et al., 1991). ATP and CTP both served as
phosphate donors, and dTTP was a noncooperative, competitive inhibitor. With T or U as
base, TK2 accepts 2'- and 3'- substitutions on sugars, as well as arabinofuranosyl sugars,
but with C as base only 2'- substitutions are allowed (Eriksson et al., 1994). The clinically
important analogues phosphorylated by TK2 are: FdUrd (5-fiuoro-2'-deoxyuridine), where
the monophosphate is an inhibitor of thymidylate synhethase; AraT (1-P-D-
arabinofuranosyl-thymidine), that is neither phosphorylated by TK1, nor dCK and
therefore could be used in a TK2 selective assay in crude cell extracts (Arner et al., 1992);
the anti-hepatitis drug FIAU (l-(2'-deoxy-2'fluoro l-P-D-arabinofuranosyl)-5-iodouracil)
(Wang & Eriksson, 1996); and to a limited extend the antiviral analogue AZT (3'-azido-
2'3'-dideoxythymidine). The Fmax for AZT was 5 - 6 % of that with dThd, and the
substrate kinetics with AZT gave biphasic Hofstee plots indicating negative cooperativity
(Munch-Petersen et al., 1991). The negative cooperativity was not seen with dCyd, dUrd
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or FdUrd, but with dThd and AZT, indicating that this kinetic behaviour might be
associated with the base and not the sugar.
Recently, several mutations in the TK2 gene that reduce enzyme activity to 14-45% have
been identified, and found to be associated with myopathic form of mitochondrial DNA
depletion syndrome (MDS) in homozygous individuals (Saada et al, 2001; Elpeleg et al,
2002; Mancuso et al, 2002; Carrozzo et al., 2003). MDS is phenotypically heterogeneous,
but starts in early childhood and is characterized by tissue-specific reduction in mtDNA
copy number. Mutations in the mitochondrial deoxyguanosine kinase have been associated
with the hepatocerebral form of MDS and will be described later. Introduction of one of
the TK2 gene mutations found in a patient with severe myopathy - HI2IN, to the
recombinant TK2 resulted in an enzyme that lost the negative cooperativity with thymidine
as substrate and displayed Michaelis-Menten kinetics (Wang et al., 2003). This finding
emphasized the significant physiological role played by the enzymatic reaction
mechanism. The indispensability of the deoxyribonucleoside salvage pathways in the
pathogenesis of mitochondrial DNA depletion was further underscored by an observation
of a markedly decreased dTTP content and a reduced dATP content in non-replicating
fibroblasts from two patients with mutations in TK2 (Saada et al., 2003).
Deoxycytidine kinase - dCK
Deoxycytidine kinase (EC 2.7.1.74) activity is found in the cytosol of many cells of the
body: the highest activity in lymphoid tissues and the lowest in nerve, liver and muscle
tissues (Spasokoukotskaja et al., 1995; Eriksson & Wang, 1997). Human dCK cDNA was
cloned in 1991 (Chottiner et al., 1991) and the gene has been mapped to chromosome 4,
band ql3.3-q.21.1 (Song et al, 1993; Stegmann et al, 1993). The substrate specificity of
dCK is broad, and includes purine deoxyribonucleosides and clinically important
analogues in addition to deoxycytidine (Eriksson et al, 1994). Probably due to the high
expression of dCK in lymphoblasts, nucleoside analogues, that are efficient substrates for
dCK, such as CdA (2-chloro-2'-deoxyadenosine), are efficient anti-leukemic drugs (Arner
& Eriksson, 1995). With C as the base, dCK accepts analogues with acyclic sugars and
analogues with both 2'- and 3'- modifications, as for example the anti-HIV drug ddC (2'-
3'-dideoxycytidine). With A or G as the base, dCK is much more restricted on the sugar,
30
and for example accepts AraA (9-P-D-arabinosyladenine), but not acyclic sugars and 3'-
substitutions (Eriksson et al, 1994; Eriksson & Wang, 1997).
dCK does not follow Michaelis-Menten kinetics, but shows negative cooperativity towards
deoxycytidine and ATP (Ives & Durham, 1970; Bohman & Eriksson, 1988). dCK
phosphorylates its natural nucleosides with different specificities: lowest Km values for
deoxycytidine (0.8 ^M), and much higher for deoxypurines (approximately 500 uM)
(Bohman & Eriksson, 1988; Datta et al, 1989a,b). Still, with the specificity constant
kcJKm equal to 2xl05, 8xlO4, and 6xlO4 (in M"'sec"') for dCyd, dAdo and dGuo
respectively (numbers from Eriksson et al, 2002), all the substrates are efficiently
phosphorylated. Any endogenous cellular nucleoside triphosphate, except dCTP which is
a feedback inhibitor, could function as a phosphate donor for dCK (Shewach et al, 1992;
Datta et al, 1989a; White & Capizzi, 1991; Hughes et al, 1997). UTP, or a combination of
UTP and another nucleotide, was the preferred phosphate donor, and more efficient than
ATP: Km values for nucleoside substrates decreased when UTP, and not ATP, was used as
the phosphate donor (Shewach et al, 1992). Other investigations also indicated UTP to be
the preferred intracellular phosphate donor for dCK (White & Capizzi, 1991; Krawiec et
al, 1995). In later studies from Shewach's group, Km values of 1.2^M and 54 uM for UTP
and ATP respectively were found, and ATP was shown to be the poorest phosphate donor
when compared to UTP, GTP, CTP and dTTP (Hughes et al, 1997). The reaction
mechanism with ATP as phosphate donor was bi-bi random, but with UTP it was ordered -
binding of UTP prior to deoxycytidine was strongly preferred (Hughes et al., 1997).
A model for dCK action based on stopped-flow fluorescence spectroscopy was developed
(Turk et al., 1999): From the fluorescence changes induced by binding of various
phosphate donors and deoxycytidine to dCK, the authors conclude that UTP binds to dCK
before dCyd and that binding of UTP induces a conformational change in the enzyme
enabling efficient phosphoryl transfer. Binding of dCyd to dCK-UTP complex is followed
by additional conformational rearrangement and subsequent phosphoryl transfer (Turk et
al., 1999). Recently, Krawiec et al. (2003) have reported that inorganic tripolyphosphate
(PPPj) is a good ATP-competitive donor with deoxycytidin, but not with deoxyadenosine
as substrate. The authors conclude that interaction of the base moieties of 5'-NTPs with the
enzyme is not essential for donor activity and phosphate transfer reaction (Krawiec et al.,
2003).
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With the crystal structure of dCK lately solved (Sabini et al., 2003), the molecular nature
of its substrate specificity became available, and dCK mutants catalytically superior toward
anticancer and antivirus prodrugs are being designed. The protein structure can also be
used to develop improved antiviral and anticancer drugs (Sabini et al., 2003).
Human dCK is a homodimers of two 30 kDa subunits (Bohman & Eriksson, 1988; Datta et
al, 1989a) coded by an ORF of 780 bp in the cloned cDNA (Chottiner et al, 1991). The
promoter sequence of the human dCK gene has one imperfect E2F factor binding site to
which E2F factor binds only weakly (Song et al., 1993; Chen et al, 1995; Johansson et al.,
2000). This might be a part of the explanation why dCK, despite its functional similarity to
thymidine kinase 1, is not cell cycle regulated. Besides the E2F binding site, the dCK
promoter contains two GC-boxes and an E-box, the binding sites for transcription factors
Spl and USF (upstream stimulatory factor), respectively (Chen et al, 1995). Physical
interactions between proteins from the Sp and the USF families have been documented and
found to elevate or attenuate the dCK promoter activity depending on the concentration
and the combination of specific Sp and USF factors (Ge et al, 2003). Such interactions
between Sp and USF families of proteins could contribute to tissue-specific pattern of dCK
expression (Ge et al., 2003) and to differential expression of dCK during the cell cycle. In
fact, the results regarding cell cycle regulation of dCK are conflicting. Mitchell et al.
(1993), for example, found the same dCK mRNA level in resting and proliferating T
lymphocytes, and a constant dCK mRNA level through the cell cycle. Two of four cell
lines investigated by Hengstschlåger et al. (1993) displayed a 10-fold increase in the
activity of dCK at the Gl/S boundary, but as none of the cell lines demonstrated
differences in the level of dCK mRNA, a post-transcriptional mechanism involving
stability of dCK protein was proposed to regulate expression of dCK in certain cell types
(Hengstschlåger et al., 1993). Actually, Spasokoukotskaja et al. (1995) have concluded
from expression of dCK detected by quantitative immunoblotting and by enzymatic assays,
that variability between various cell types in dCK expression is much larger than that
between cell cycle phases. On the other hand, increased dCK expression and activity levels
have been found in some solid tumours (Spasokoukotskaja et al., 1995). Also, an increase
in dCK enzyme activity without any increase in the dCK protein level was reported in
lymphocytes treated with inhibitors of DNA synthesis, deoxynucleoside analogues and
gamma-irradiation, as well as with protein phosphatase inhibitors (Sasvåri-Székely et al.,
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1998; Spasokoukotskaja et al, 1999; Csapo et al, 2001a; Csapo et al, 2003). The elevated
dCK activity was suggested to be due to reversible phosphorylation of the enzyme (Csapo
et al, 2001b; Csapo et al, 2003), and assumed to be a mechanism compensating for DNA
damage through increased supply of all dNTPs needed for DNA repair (Keszler et al,
2003; Csapo et al, 2003). Free cytosolic calcium was found to be necessary for the
activation of dCK and maintaining its active state, not as a cofactor, but presumably
through regulation of a putative kinase which phosphorylates and activates dCK (Keszler
et al, 2004). Because a correlation was found between the dCK activity and the intensity
of dCK signal in native, but not in denaturing, Western blots, the activation process was
suggested to be accompanied by a more open enzyme conformation, where the epitope
becomes more accessible to the antibody (Keszler et al, 2004). These results indicate that
dCK can exist in different conformational states, and by this support the conclusion from
the above mentioned fluorescence quenching experiments of Turk et al. (1999).
Unexpectedly, overexpressed dCK was found not in the cytosol but almost exclusively in
the cell nucleus, and a nuclear localization sequence, KRSCPSFSASSEGIRIKK was
identified in the N-terminal of dCK (Johansson et al, 1997b). Because endogeneous dCK
was found only in the cytosol, presence of a cytoplasmic retention mechanism for dCK,
that involves another, up to now unknown, protein has been suggested (Hatzis et al, 1998).
Deoxyguanosine kinase - dGK
Deoxyguanosine kinase (EC 2.7.1.113) is a mitochondrial enzyme found in most tissues:
brain, muscle, liver, spleen, skin, resting and mitogen-stimulated lymphocytes (Wang et
al, 1993). The gene for the human dGK has been cloned (Johansson & Karlsson, 1996;
Wang et al, 1996) and localized to the short arm of chromosome 2, 2pl3 (Johansson et al,
1996). The level of dGK activity seems to be correlated to the amount of mitochondria
found in a cell or tissue (Arner & Eriksson, 1995). The highest activity of dGK, up to 10 -
fold higher as compared to other tissues, is found in the brain (Wang et al, 1993). A
cDNA from a human brain cDNA library was found to encode a 30 kDa protein (Wang et
al, 1996; Johansson & Karlsson, 1996). The N-terminal of the deduced amino acid
sequence had similarities to mitochondrial targeting signal peptide, and cleavage during
mitochondrial import would result in mature protein of 28 kDa (Wang et al, 1996;
Johansson & Karlsson, 1996). Western blotting of mitochondrial and cytosolic fractions
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with polyclonal antibody raised against human recombinant deoxyguanosine kinase, and in
situ immunofluorescence studies with the same antibody, confirmed the localization of the
dGK to the mitochondrial matrix (Jiillig & Eriksson, 2000). Surprisingly, dGK was found
to relocate to the cytosole together with cytochrome c during apoptosis (Jiillig & Eriksson,
2001). As dGK is involved in dATP synthesis, and dATP facilitates formation of the
apoptosome complex (Purring-Koch & McLendon, 2000), dGK might assist in amplifying
the apoptotic cascade (Jiillig & Eriksson, 2001).
dGK accepts the three naturally occurring purine deoxyribonucleosides and purine
analogues as substrates - Km values for dGuo, dAdo and dlno are respectively 2.5-7.6 jxM,
60 nM, and 21 uM (Arner & Eriksson, 1995), and the kcJKm value is 6xlO4 M '^sec"1 for
dGuo , and 4xlO3 M^sec'1 for dAdo (Eriksson et ah, 2002). dCyd can also be accepted as a
substrate, but with very limited efficiency (Wang et ah, 1996; Sjoberg et ah, 1998), the
kcJKm value is lxlO3 M^sec"1 (Eriksson et ah, 2002). Similarly to dCK, the recombinant
dGK can use both ATP and UTP, as well as the inorganic polyphosphate (PPPO as
phosphate donors (Krawiec et ah, 2003), and UTP improved the phosphorylation
efficiency in comparison with ATP for all dGK substrates investigated (Zhu et ah, 1998;
Sjoberg et ah, 2001). The end products dGTP and dATP are feed-back inhibitors (Gower
et ah, 1979; Sjoberg et ah, 2001).
As can be seen, the substrate specificity of dGK is partially overlapping with dCK, but
dGK is more restrictive. dGK accepts bases with minor 2-or 7-substitutions (for example
CdA, i. e. 2-chloro-2'-deoxyadenosine), and sugars with 2'-substitutions and
arabinofuranosyl (for example AraA and AraG). But neither 3'-substitutions, nor acyclic
sugars are allowed (Wang et ah, 1993; Sjoberg et ah, 1998). The crystal structure of
human dGK has been determined (Johansson et ah, 2001), and the reason for its restrictive
substrate specificity was suggested. Presence of Arg-118 in the active site of dGK provides
hydrogen bonds to ring N7 and carbonyl 06 of guanine, while an amino group at 6-
position of adenine makes the binding of this base less favourable. Arg-118 is held tightly
in place by Asp-147, and the presence of Arg-Asp couple is not suitable for binding dT
with a methyl group in this position (Johansson et ah, 2001). The human dGK was present
as a dimer in the crystals (Johansson et ah, 2001), in accordance to the previously
determined dimeric structure of native bovine dGK (Wang et ah, 1993).
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Recently, several mutations in the dGK gene were ascribed to be the cause of the
hepatocerebral form of MDS, characterized by liver failure and neurological abnormalities
(Mandel et al. 2001; Salviati et al, 2002; Taanman et al, 2002; Mancusso et al, 2003).
Four mutations resulted in premature termination of translation and absence of dGK
activity in liver homogenates. One patient had greatly decreased dGK activity and was a
heterozygote for two missense mutations (R142K and E227K) affecting critical residues of
dGK (Salviati et al, 2002). The effect of the mutations on the activity of dGK has been
analysed in recombinant enzymes (Wang & Eriksson, 2003). 11-, 18- and 22 amino acids
C-terminal truncations led to inactive proteins, R142K had very low activity with dGuo
(about 8% of the wild type), and no activity with dAdo, while E227K had unchanged Km
values but very low Vm!LX values for all its substrates, resulting in 2% catalytic efficiency of
the wild type (Wang & Eriksson, 2003). Even with such low dGK activity, the clinical
symptoms were milder than in patients totally devoid of dGK activity, and the disease
developed later in life. Experiments with one of the patients dGK-deficient fibroblasts have
shown that decline in mtDNA content can be prevented by dGMP and dAMP
supplemented to the growth medium (Taanman et al, 2003). The described correlations
between activity of dGK, availability of deoxynucleotides and disease underline the crucial
role of salvage pathways.
Compartmentalization of deoxynucleoside kinases and dNTPs
pools
De novo synthesis of deoxyribonucleotides occurs in the cytoplasm and the dNTPs pass
freely into the nucleus (Leeds et al, 1985; Leeds & Mathews, 1987; Wawra, 1988). The
dNTP pools of nucleus and cytoplasm are in equilibrium because the nuclear membrane
allows diffusion of ions and molecules up to 60 kDa through nuclear pore complexes
(Nigg, 1997), and mediates the selective transport of macromolecules bearing the specific
nuclear localization signal (Wente, 2000; Rout & Aitchison; 2001).
The mitochondrial membrane, on the contrary, is not permeable to charged molecules such
as nucleotides, and several studies concluded that mitochondrial dNTPs are physically
separated from cytoplasmic dNTPs (Bogenhagen & Clayton, 1976; Bestwick et al, 1982).
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Zhu et al. (2000) have shown that nucleoside analogues phosphorylated in the cytosol or
nucleus were predominantly incorporated into nuclear DNA, while nucleoside analogues
phosphorylated in mitochondria became trapped in this compartment, and were
incorporated into mitochondrial DNA. The mitochondrial dGK and TK2 phosphorylate all
four deoxyribonucleosides and may contribute most of the deoxyribonucleotides required
for mitochondrial DNA replication and repair. A single report describes presence of
ribonucleotide reductase activity in extracts of washed mitochondria (Young et al., 1994a),
but the report has not been followed up, and the gene for mitochondrial ribonucleotide
reductase is not known. On the other hand, the results of Chen & Cheng (1992) indicated
that the anti-HFV compound, ddC, was phosphorylated in the cytoplasm by the cytoplasmic
dCK, and then, as ddCTP was imported into mitochondria. Also, mitochondria isolated
from rat liver were shown to possess the capacity for inward transport of thymidine and 2'-
deoxyguanosine (Cass et al., 1999 and references therein). Purification of a carrier protein
transporting dCTP from cytoplasm to mitochondria (Bridges et al., 1999) supports the
possibility that cytoplasmic dNTPs and phosphorylated nucleoside analogues could be
utilized by mitochondria. Another mitochondrial deoxynucleotide carrier protein (DNC)
was shown to catalyze transport of all four dNDPs (also NDPs and dNTPs, but with lower
affinities) and their dideoxyanalogues from cytoplasm into mitochondria in exchange for
ATP or ADP (Dolce et al., 2001). A mutated DNC protein, devoid of transport activity,
was associated with a congenital disorder, Amish microcephaly (Rosenberg et al., 2002).
Recently, a deoxynucleoside transporter protein has been localized to the mitochondrial
membrane, and found to enhance the mitochondrial toxicity of nucleoside drugs (Lai et al.,
2004). The earlier view of physically separated cytoplasmic contra mitochondrial
nucleotide pools must be revisited, especially in the light of recent evidence that the two
compartments are in rapid exchange: de novo synthesized thymidine phosphates enter
rapidly from cytosol to mitochondria, and thymidine phosphates phosphorylated inside
mitochondria move rapidly into the cytosol (Pontarin et al., 2003; Rampazzo et al., 2004).
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The dNTP pool sizes
A knowledge of physiological metabolite concentration is necessary in order to understand
the kinetics of enzymes involved. It is also important for pharmacological studies, because
analogues compete with the natural compounds in vivo. Concentrations of dNTPs have
been determined by different methods, with different cells or tissues (most rodent and
human), quiescent or growing, and of course with very different results (summarized by
Munch-Petersen, 1996). For example, mouse embryo cells were determined to contain 2.5
pmol of dATP and 3.0 pmol dTTP per ug of DNA during DNA synthesis phase, and the
pools were calculated to suffice for 2 to 4 minutes of DNA synthesis (Nordenskjold et al,
1970; Reichard, 1988). dNTP pools in quiescent GO mouse L cells were approximately 0.2,
0.1, 0.02, and 1.2 (in pmol/ug DNA) for dATP, dTTP, dGTP and dCTP respectively, and
for dividing cells 0.5, 2.0, 0.2, and 7 respectively (Skoog et al, 1974). In Gl Chinese
hamster ovarian cells pool levels were 2.8, 2.0, 0.2, and 5 pmol/ug DNA, respectively, and
their amounts in S-phase cells varied between 4 (dATP) and 7 (dCTP) times those
observed in Gl cells (Skoog et al, 1973). In spite of the different results, there was a
general correlation that the pools increase with the rate of DNA synthesis, and that the
dCTP pool was the highest and the dGTP pool the lowest in the studied rodent cell lines.
However, in the phytohemagglutinin (PHA) stimulated human lymphocytes the dTTP
pool, and not dCTP pool, was consistently found to be the highest (Munch-Petersen et al.,
1973; Tyrsted, 1975; Tyrsted & Munch-Petersen, 1977). The dGTP pool seemed to be the
lowest in both the unstimulated and PHA-stimulated human lymphocytes (Tyrsted, 1975).
The natural asymmetry in the dNTP pool sizes has been repeatedly observed in cultured
cells (Mathews & Ji, 1992), and also in extracts of whole rat embryos (Mole et al., 1998),
with dGTP representing 5 - 10% of the sum of the four dNTP pools, and dTTP
representing 40 - 60%. Recent estimates of cytosolic dNTP pools in human and mouse cell
lines showed that that the two pyrimidine pools were always larger than the two purine
pools: dTTP + dCTP constituted 70% of all dNTPs, and dGTP only 7% (Rampazzo et al,
2004). A possible explanation for this asymmetry was suggested by Chimploy et al.,
(2000) based on experiments showing that the activity of mouse ribonucleotide reductase
toward GDP reduction was more sensitive to oxygen depletion than reduction of the three
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other ribonucleotides. Due to natural oxygen limitation in vivo, this could lead to
underrepresentation of dGTP in mammalian cells.
Traut (1994a) has compared concentrations of bases, nucleosides and nucleotides from 600
published values for mammalian systems. For deoxynucleotides in dividing cells the
following average concentrations ± SD are given: dATP, 24 ± 22; dTTP, 37 ± 30; dGTP,
5.2 ± 4.5; and dCTP, 29 ± 19. The concentration in tumour cells was 6-11 fold over normal
cells, and the concentrations in the extracellular fluids were usually lower than
corresponding intracellular concentrations (Traut, 1994a).
Recently, the mitochondrial dNTP pools have been estimated to amount between 3 and 7%
of the corresponding cytosolic pools: 3% of dTTP and dCTP, 4% of dATP, and 7% of
dGTP (Rampazzo et al., 2004).
Significance of dNTPs pool imbalance
The salvage pathway enzymes, together with the de novo pathway are responsible for the
maintenance of balanced dNTP pools. Deficiencies of salvage enzymes or exogenous
addition of deoxyribonucleosides may unbalance the corresponding dNTP pool and result
in increased mutagenesis (Weinberg et al., 1981; Meuth, 1989; Wilkinson & McKenna,
1989; Lei et al., 1998a), influence the sensitivity to mutagens (Kunz, 1988; Kunz &
Kohalmi, 1991), and on the cellular level induce chromosome rearrangements, breakage
and loss, and oncogenic transformation (Kunz et al, 1994; Lei et al., 1998b). Thymidine
kinase deficient cell lines, that showed significant decrease in dTTP pools, were more
sensitive to the mutagenic and lethal effect of alkylating agents than the wild type strain
(Wakazono et al., 1996). Similar results were obtained with TK deficient Raji cells (Best
et al., 1997), and TK deficient Friend mouse leukaemia cells (McKenna et al., 1991). that
showed decreased survival and increased mutant frequency relative to wild type cells
following mutagen treatment. In the same investigation, McKenna et al. (1991) have found
a greater than 6-fold increase in the dCTP : dTTP ratio in TK deficient cells and suggested
a role for thymidine kinase in balancing dNTP pools. Increase of intracellular dTTP pool
by exogenous addition of thymidine resulted in increased mutation frequency at the
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adenine phosphoribosyl trasferase (aprt) locus, which was relieved by addition of
deoxycytidine to the medium (Goncalves, et al., 1984). More than 97% of mutations
occurring at the aprt locus in the presence of excess dTTP were explained by the
misincorporation of the dTTP in place of dCTP, the mutations were predominantly C to T
transitions and G to T transversions (Phear & Meuth, 1989). Interestingly, analysis of the
spontaneous mutation spectra at the {aprt) gene locus in TK1-deficient Friend murine
eryhroleukemia cells has revealed increased mutagenicity, but has not shown mis-
incorporation of dCTP during DNA replication (Hyland et ah, 2000). The predominant
mutations found were GC to AT transitions, and because the TK~ cells may have a reduced
activity of the uracil-DNA glycosylase, their occurrence was suggested to result from
deamination of the cytosine and the reduced efficiency of repair by uracil-DNA
glycosylase of uracil residues that arise following cytosine deamination (Hyland et al.,
2000).
Molecular analysis of mutations in the hprt (hypoxanthine-guanine
phosphoribosyltransferase) gene have shown that unbalanced dNTP pools can affect RNA
splicing by causing base substitutions in the splicing consensus sequence and aberrant
processing of mRNA (Daré et ah, 1995). Pool imbalances induced by addition of
thymidine and hydroxyurea to cultured dog cells infected with retroviruses, spleen
necrosis- and murine leukaemia virus, were found to increase the retrovirus mutation
frequency (Julias & Pathak, 1998). This finding may have implications for treatment of
HIV patients with hydroxyurea (Julias & Pathak, 1998).
Regulation of the dNTP supply was also suggested to be a control point in apoptosis
(Oliver et al, 1997). Withdrawal of the cytokine interleukin-3 (IL-3) from haemopoietic
cells resulted in rapid decrease of dTTP, dGTP and dATP levels, decrease in thymidine
kinase activity and in precursor uptake, and was followed by DNA fragmentation and
apoptosis. Readdition of IL-3 resulted in a rapid restoration of normal dNTP pools and
enhanced TK activity (Oliver et al., 1996). Overexpression of herpes simplex virus-1
thymidine kinase in the haemopoietic cells protected them from apoptosis induced by
either inhibitors of dNTP synthesis, or by IL-3 deprivation (Oliver et al, 1997). The results
suggested that TK may be important for the regulation of apoptosis in haemopoietic cells.
As mentioned above, a role for dGK in amplifying the apoptotic cascade also has been
proposed (Jiillig & Eriksson, 2001).
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Folate deficiency, which is the most common vitamin deficiency, is also associated with
unbalanced dNTP pools (Koury & Home, 1994). The folate-deficient proerythroblasts
underwent apoptosis when cultured in folate-free medium, the apoptosis was prevented by
addition of either folic acid or thymidine. While folate concentration in excess had no
effect on proliferation of erythroblasts, addition of more than 10 uM thymidine increased
apoptosis. Simultaneous addition of deoxycytidine prevented apoptosis and indicated that
imbalanced deoxypyrimidine pools were detrimental to erythroblasts (Koury & Home,
1994).
The severe diseases that result from the lack of the salvage enzymes adenine deaminase,
thymidine phosphorylase, and the mitochondrial TK2 and dGK have already been
mentioned above. The hypothesis that imbalanced mitochondrial dNTP pools are
responsible for mutagenesis of mtDNA has been tested and confirmed by the finding of
deletions in mtDNA of HeLa cells growing for 8 months in thymidine-supplemented
medium (Song et al., 2003).
Role of thymidine kinase 1 for regulation of dNTP pools -
a short summary
TKl phosphorylates thymidine to thymidylate (dTMP) and deoxyuridine to deoxyuridylate
(dUMP) that subsequently gets methylated to thymidylate (Fig. 1.4). Due to the ubiquitous
nucleotide kinases, dTMP is quickly phosphorylated to dTTP, and so thymidine kinase is
an important enzyme for the synthesis of dTTP. Also, TKl regulates the size of dTTP pool
through "substrate cycles" involving phosphorylation of deoxynucleosides by their
corresponding kinases and dephosphorylation by nucleotidases (Fig. 1.5). dTTP, in rum, is
an important effector controlling the specificity of ribonucleotide reductase: increase in
dTTP pool down-regulates the reduction of pyrimidine ribonucleotides and shifts the
specificity towards reduction of purine ribonucleotides (Fig. 1.3). A cell with deficient
TKl activity has thus diminished ability to control its dTTP pool and to balance its supply
of all four DNA precursors.
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Chapter 2
The mammalian cell cycle
Since the activity of TK1 fluctuates with the cell cycle, I will first review the general
mechanisms that control the events of the cell cycle. In the next chapter I will describe the
regulatory mechanisms of TK1 expression. Here, I will concentrate on the features of the
cell cycle that are relevant for induction of TK1 in mammalian cells. The nomenclature
generally used for mammalian proteins will also be used here.
The cell cycle is characterized by two ordered events essential for cellular reproduction:
duplication of the genome and cell division. Four distinct phases are recognized in the cell
cycle: Gl - growth phase, S phase - the period of DNA synthesis, G2 - gap phase between
the S and M phases, and M phase - mitosis, where sister chromatids segregate to opposite
poles of the cell. These phases are followed by the physical division of the cytoplasm, the
cytokinesis, resulting in two identical daughter cells with 2N DNA content. A Gl cell may
continue to grow and proliferate, or, if growth factors or nutrients are insufficient, it may
become quiescent and enter a GO stage. Quiescent (GO) cells are either differentiated to
perform some specific function, or, especially in cell culture, they become senescent and
eventually die. Some GO cells, like peripheral blood lymphocytes or liver cells, have the
potential to re-enter the cell cycle if appropriately stimulated. Lymphocytes for example
become mitotic after exposure to specific antigens. Terminally differentiated cells, like
nerve cells or muscle cells, are likewise in non-dividing stage, but they have no potential to
re-enter the cell cycle.
The commitment to progress through Gl and to enter the S phase requires accumulation of
specific proteins and occurs late in Gl at a "restriction point", or R-point, as originally
proposed by Arthur Pardee (1974). After passage of the R-point neither mitogenic signals
nor intracellular protein synthesis are required by cells for further progression through the
cell cycle.
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Transition from GO to Gl
Most cells of an adult mammalian organism are quiescent cells. They are smaller than Gl
cells and their rate of macromolecular synthesis is about one-third as that of Gl cells
(Pardee, 1989). Also, nutrient deprived non-cancer cells in culture are GO cells. Addition
of growth factors, such as PDGF (platelet-derived growth factor), EGF (epidermal growth
factor), IGF-1 (insulin-like growth factor-1) in a defined sequence, activates GO cells to
progress into Gl. Very early changes that occur in the growth factor stimulated cell include
increased transport of nutrients through the membrane, changes in chromatin structure and
production of novel mRNA (Pardee, 1989). Gl for cells leaving GO, especially if they were
in GO for a long time, is much longer than for normally cycling cells, as synthesis of
mRNA and proteins needed for the next cell cycle must be enhanced (Hofbauer &
Denhardt, 1991).
Growth factors act by binding to their specific receptors on the cell membrane. This
binding activates the receptor's tyrosine kinase activity and subsequently leads to
activation of a GTP-binding protein Ras1. Ras resides at the inner surface of the plasma
membrane and provides a link between the cell surface and the nucleus (Vojtek & Der,
1998; Ewen, 2000). Ras proteins switch between inactive GDP- and active GTP- bound
states, the switch is catalysed by additional cytoplasmic signalling proteins. Activated Ras,
in turn, induces a phosphorylation cascade that involves Raf kinase and MAPK (mitogen
activated protein kinases) pathway (Schaeffer & Weber, 1999; Chang & Karin, 2001).
Some of the phosphorylated MAPKs translocate into the nucleus (Fukuda et ah, 1997;
Khokhlatchev et al, 1998) where they, directly or indirectly, phosphorylate several
different transcription factors, among others, the products of the proto-oncogens c-jun, c-
fos and c-myc (Kerkhoff & Rapp, 1998; Ewen, 2000).
1
 There are multiple Ras proteins, different ones act in different cell types, and all work in the same way.
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Gl phase: early- and late-response genes
c-jun, c-fos and c-myc are members of a set of "early-response" genes induced within the
first few minutes (immediate early) or hours (delayed early) after entrance to Gl phase.
Induction of early-response genes is independent of protein synthesis, because early-
response proteins (often transcription factors) are present in GO cells and are activated by
post-translational modification such as phosphorylation. Fos and Jun belong to the bZIP
(basic region leucine zipper proteins) family of transcription factors that bind to
palindromic AP-1 regulatory elements and activate many genes involved in cell growth
and differentiation (Karin et al., 1997; Shaulian & Karin, 2001). Fos-Jun heterodimers
interact with different transcription factors and can bind in opposite orientations to AP-1
sites, and in this way alter promoter selectivity and transcriptional activity of the
transcription complexes (Ramirez-Carrozzi & Kerppola, 2001). Among the proteins
regulated by AP-1 are cell cycle regulators like cyclin Dl, p53, p21 (cipl/wafl) and pl9
(ARF).
The c-myc gene product is a transcription factor that contains a basic-helix-loop-helix -
leucine zipper dimerization domain (Dang, 1999). Myc upregulates activity of cyclin
E/CDK2, antagonizes the function of p27Kipl (Obaya et al, 1999; Obaya et al, 2002) and
stimulates E2F-dependent transcription (Beier et al., 2000a). The action of Myc in
activation of cyclin E/CDK2 and E2F has been found to synergize with the action of Ras
(Leone et al, 1997).
Proteins encoded by early-response genes induce the transcription and expression of "late-
response" genes, which appear later in Gl and are not expressed if protein synthesis is
inhibited (Hofbauer &. Denhardt, 1991). Many of the late-response genes encode proteins
that are linked to DNA replication - histones, thymidine kinase, thymidylate synthase,
dihydrofolate reductase and ribonucleotide reductase. Transcription factor E2F, Gl phase
cyclins and cyclin dependent kinases also belong to the late-response proteins. Besides the
requirement for protein synthesis, the late-response genes require continuous presence of
growth factors for their transcription. Withdrawal of the growth factors before expression
of the late-response genes prevents the cells to pass the restriction point and to enter a new
cell division.
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Proteins coordinating the progression of the cell cycle
The key enzymes that regulate the transition between the various phases of the cell cycle
are cyclin-dependent kinases (CDKs). Several mechanism are known that regulate their
activity: interaction with cyclins, regulation of cyclin gene expression, post-translational
modification of CDKs by phosphorylation-dephosphorylation, interaction of cyclin/CDK
complexes with CDK inhibitor proteins (CKIs) and degradation of the intrinsic cell cycle
proteins by the ubiquitin/proteasome pathway.
Cyclins and cyclin- dependent kinases during the cell cycle
Binding of a cyclin subunit to a CDK is usually the primary mechanism of CDK activation
and a prerequisite for phosphorylation/dephosphorylation reactions. A cyclin/CDK
complex is only partially active. It attains full activity after phosphorylation of the CDKs
on specific conserved Thr residues by a CDK-activating kinase CAK and its partner cyclin
H (Martinez et al., 1997), followed by removal of inhibitory phosphates on Tyr or Thr
residues by a phosphatase from the Cdc 25 family (Jinno et al., 1994). The level of CDKs
remain constant during the cell cycle, but cyclins are unstable and fluctuate in abundance
during the cell cycle. In higher eukaryotes, at least eight different cyclin classes (cyclins A
to H) have been identified based on sequence similarity and association with different
stages of the cell cycle (Noble et al., 1997). I will concentrate here on the best known and
mostly investigated cyclin/CDK complexes (Fig. 2.1).
CycD
CDK4/6
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Figure 2.1. Major CDK/cyclin complexes involved in cell cycle control in mammalian cells.
Modified after Morgan (1997).
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The Gl progression in mammalian cells depends on three D-type cyclins (Dl, D2 and D3),
which assemble with either CDK4 or CDK6, and on cyclin E, which combines later in Gl
with CDK2 (Sherr, 1994). The cyclin Dl promoter has been shown to be activated by bZIP
superfamily of transcription factors, including c-Jun, c-Fos, ATF2 (activating transcription
factor) and ATF3 (Beier, et al, 1999a; Allan et al, 2001). Cyclin D2 was found to be
transcriptionally induced by Myc binding to a highly conserved E-box element in D2
promoter (Bouchard et al, 1999).
The synthesis of D-type cyclins and their assembly with CDK4/6 depends on continuous
mitogenic stimulation. Mitogen withdrawal leads to cessation of cyclin D synthesis, and
because cyclins are unstable, their holoenzyme activities decay rapidly and the cells exit
the cell cycle (Sherr, 1996). Absence of cyclin D-dependent kinase activity after the cells
passed restriction point is without effect. Because the major substrate of cyclin D/CDK4 or
cyclin D/CDK6 complexes is the Retinoblastoma protein (Rb) and the related Rb pocket
proteins, pl07 and pl30 (Kato et al, 1993), it was concluded that phosphorylated Rb
proteins are required for exit from Gl (Sherr, 1996).
The synthesis of cyclin E is maximal at the Gl to S phase transition, and cyclin E
associated CDK2 activity shifts pRb phosphorylation from being mitogen-dependent
(cyclin D-driven) to mi to gen-independent (cyclin E-driven) (Sherr, 1996). Cyclin E/CDK2
phosphorylates the Rb proteins on different sites than cyclin D/CDK4/CDK6;
phosphorylation on both CDK2 and CDK4/6 sites is required for full inactivation of the Rb
proteins (Kitagawa et al., 1996; Zarkowska & Mittnacht, 1997). Recently, a controversial
report demonstrated some cancer cells to proliferate when cyclin E/CDK2 activity was
inhibited by overexpression of inhibitor protein p27 (Tetsu & McCormick, 2003), thus
questioning the essential role of cyclin E/CDK2 in cell cycle control (Grim & Clurman,
2003).
Induction of cyclin A has been shown to depend on the presence of cyclin E activity
(Rudolph et al., 1996). Cyclin A is first detectable during late Gl, and functions in S-
phase, G2 and mitosis. Once cells enter S phase, cyclin D and E are degraded and CDK2
forms complexes with cyclin A (Sherr, 1994; Sherr, 1996). To obtain maximal expression
of cyclin A, its promoter had to be activated by transcription factors ATF2 and E2F (Beier
et al., 2000b). In the S-phase, cyclin A/CDK2 is believed to be important for initiation of
DNA replication and to restrict the initiation to only once per cell cycle (Yam et al., 2002).
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Cyclin A/CDK2 activity appears to be the major cyclin/CDK activity in G2 and this
activity was demonstrated to be limiting for the initiation of mitosis and for progression
through mitosis until the middle of prophase (Furuno et al., 1999) when chromosomes
condensate. Recently, several novel proteins interacting with cyclin A/CDK2 have been
identified by a yeast triple-hybrid approach, co-immunoprecipitation and GST pull-down
assays (Diederichs et al., 2004). These proteins link the cyclin A/CDK2 complex to diverse
cellular processes such as DNA repair, signalling and splicing (Diederichs et ah, 2004).
Cyclin A also controls the half-life and degradation of cyclin B: Accumulation of cyclin B
is dependent on cyclin A (Lukas et ah, 1999). Levels of cyclin B increase in G2 and
activity of cyclin B/CDK1 is crucial for G2/M progression and for progress of mitosis,
especially for the breakdown of the nuclear envelope and formation of the mitotic spindle.
An important regulator of cyclin B is its activator cdc25 phosphatase, that in turn is
regulated by cytoplasmic protein 14-3-3 (Forrest & Gabrielli, 2001). The protein 14-3-3
might prevent mitosis by sequestering Cdc25 in the cytoplasm and thus separating it from
its substrate cyclin/CDKl kinase (Pines, 1999), and/or by blocking access of the substrate
to the catalytic site of Cdc25 (Forrest & Gabrielli, 2001). Dephosphorylation of cyclin
B/CDK1, and in consequence its activation, is inhibited by damaged or unreplicated DNA;
in this way initiation of mitosis is inhibited and cells have time to repair the damage.
Cyclin A is almost completely degraded before the metaphase to anaphase transition
(Geley et al., 2001), while the degradation of cyclin B is delayed until cells enter anaphase
and all of the chromosomes are correctly aligned on a well-formed mitotic spindle (Geley
et al., 2001). Degradation of the mitotic cyclins triggers exit from mitosis and starts
cytokinesis.
hi summary, Gl specific CDKs activate S phase specific CDKs and promote synthesis of
proteins needed for chromosome replication, hi turn, S phase specific events trigger
mitosis and cell division.
Cyclin-dependent kinases inhibitors (CKIs)
CKIs are small proteins that per definition impose negative control on activity of cyclin-
dependent kinases. CKIs are currently divided into two families based on their structures
and CDK targets (Sherr & Roberts, 1999). The first class consists of p21, p27 and p57
proteins, also known as Cip/Kip family, that can bind both to cyclin and CDK subunit of
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cyclin D-, E-, and A-dependent kinases. The second class includes the INK4 proteins, that
inhibit only GI kinases - CDK4 and CDK6, but no other CDKs, and cannot bind to the
cyclin subunit, as exemplified by pi6 (Sherr & Roberts, 1999).
Initially it was assumed that CKIs act solely as inhibitors of cyclin-dependent kinases
(Harper et al, 1993; Peter & Herskowitz, 1994), later p21 was found in both catalytically
active and inactive cyclin/CDK complexes (Zhang et al, 1994), and was shown to promote
the assembly of CDK4 with cyclin D, and activity of CDK4, but not the assembly or
activity of CDK2/cyclin E (LaBaer et al, 1997; Chang & McCubrey, 2001). Accordingly,
low doses of y-irradiation that induced p21, resulted in specific inhibition of CDK2, but not
CDK4, phosphorylation activity (Brugarolas et al., 1999). p21 was also shown to bind to
PCNA (proliferating cell nuclear antigen), the processivity subunit of DNA polymerase 8,
and thereby inhibit DNA replication, but not DNA repair (Chuang et al., 1997).
Similarly to p21, p27 was found to be a positive regulator of the assembly, stability and
nuclear localization of D-type cyclins, and a negative regulator of cyclin E-CDK2 and A-
CDK2 (Cheng et al, 1999). The preferential binding of p21 and p27 to D-cyclins keeps
other cyclins, especially cyclin E, free from the inhibitors (Cheng et al, 1999; Perez-Roger
et al, 1999). Mitogenic stimulation that induces CDK2 activity was shown to down-
regulate p27 (Mohapatra et al, 2001; Chang & McCubrey, 2001), and in mitogen-starved
fibroblasts, p27, and to a minor extent p21, were found responsible for inhibition of CDK2
activity (Coats et al, 1999). When expression of p27 was antisense inhibited, the cells did
not respond to mitogen withdrawal by cell cycle arrest (Coats et al, 1996). Low or absent
p27 in tumour cells is an important clinical marker correlating with bad prognosis of
disease (Clurman & Porter, 1998).
Recently, a hypothesis has been proposed that in parallel with their role in down-regulating
the CDK activity, p21 and p27 inhibitor proteins might be targeted to gene promoters,
interact with several transcription factors and in this way inhibit genes like Myc, E2F and
AP-1, that are involved in cell cycle progression (Coqueret, 2003).
p i 6 ^ accumulates progressively as cells age and approach the limit of their life span in
vitro, possibly being induced by a senescence timer (Sherr & Roberts, 1999). pi6 binds to
CDK4/6, prevents its association with D-type cyclin and so phosphorylation of its
substrate, the Retinoblastoma protein. CDK4/6 can thus be imagined to partition between
the inactive INK4 bound state and the active Cip/Kip bound state (Sherr & Roberts, 1999).
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Increased amounts of INK4 proteins would release Cip/Kip proteins from CK4/6 and can
lead to cyclin E/CDK inhibition and to cell cycle arrest (Sherr & Roberts, 1999).
Retinoblastoma tumour suppressor protein and transcription
factor E2F as substrates for cyclin /CDK complexes
The already mentioned Retinoblastoma tumour suppressor protein is one of the most
important cyclin-CDK substrates for Gl progression. Early in Gl, pRb and the related
pocket proteins plO7 and pl30, are hypophosphorylated and bind to transcription factors of
the E2F family. E2F proteins are heterodimers containing a subunit encoded by the E2F
gene family, of which 7 are now known (E2F1-E2F7), and a subunit encoded by one of the
three members of DP family (Dyson, 1998; Tamrakar et al, 2000; Bracken et al, 2004).
Heterodimerization enhances the ability of E2F to bind to DNA and stabilizes the
interaction between E2F and pRb (Kaelin, 1999). Because the transactivation domain of
E2F1-E2F5 contains a pRb binding site, the E2F/Rb complex blocks transcription (Dyson,
1998;; Bracken et al, 2004). The repression by pRb/E2F is also performed, at least in part,
through recruitment of chromatin modifiers - histone deacetylase (HDAC), histone
methyltransferase and DNA methyltransferase - to the E2F-regulated promoters (Luo et
al, 1998; O'Connor et al, 2001; Bracken et al, 2004). Binding of these chromatin
modifying enzymes prevents the binding of other proteins required for transactivation and
promotes formation of nucleosomes that inhibit transcription (Luo et al, 1998; Brehm &
Kouzarides, 1999; Bracken et al, 2004).
Phosphorylation of Rb and Rb family members (pi07 and pi30), at multiple sites during
Gl, first by cyclin D-dependent kinases, and later by cyclin E-dependent kinases,
inactivates their capacity to interact with E2F transcription factors, thus allowing gene
transcription and progression from the Gl to the S phase of the cell cycle. The disruption
of E2F/Rb complex is also a common mechanism of action for oncoproteins encoded by
DNA tumour viruses (Nevins, 1992). The purpose here is to enhance virus replication, and
activation of both DHFR and thymidine kinase has been demonstrated in adenovirus and
SV40-infected cells (Nevins, 1992).
The target genes of E2F include those whose products are important for DNA synthesis:
dihydrofolate reductase, thymidine kinase, DNA polymerase a and PCNA (Dyson, 1998;
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Brehm & Kouzarides, 1999), and also cell-cycle regulators like cyclin E, cyclin A and E2F
itself. The phosphorylation of E2F by cyclin D-dependent kinase, release of free E2F and
increase of cyclin E transcription results in a positive feedback loop that generates a rapid
rise in E2F-dependent transcription and the onset of S phase (DeGregori et al., 1995;
Morgan, 1997). As cells leave S phase, the activity of E2F decreases due to its ubiquitin-
directed degradation (Martelli & Livingston, 1999), and to phosphorylation of E2F/DP
dimers on both subunits by cyclin A/CDK2, what inhibits DNA-binding activity of E2F
(Dyson, 1998). Late in mitosis pRb is dephosphorylated by a holoenzyme complex
containing protein phosphatase type 1 (PP1), thereby restoring the growth suppressive
function of pRb (Rubin et al., 1998). PP1 appears to be indispensable for mitotic exit
(Tamrakar et al., 2000).
Connection between pl6INK , p21Cip and tumour suppressors
pRb and p53
The already mentioned pi 6 ^ causes hypophosphorylation of the Retinoblastoma protein,
and so inactivation and prevention of Gl to S transition, through inhibition of cyclin
D/CDK kinases. The genetic locus INK4a encodes, from a distinct promoter, another
growth inhibitory protein, pl9ARF (for alternative reading frame), that in turn controls the
tumour suppressor protein p53 (Kamijo et al., 1997). p53 is a key regulator in a wide range
of cellular processes, including cell cycle control, apoptosis and DNA repair, and functions
to integrate cellular responses to stress (Levine, 1997; May & May, 1999). p53 is a
sequence specific transcriptional activator and among its transcriptional targets is the CDK
inhibitor p21 (Levine, 1997). pl9ARF is not a CDK inhibitor, but neutralizes oncoprotein
Mdm2, an inhibitor of p53 (Kamijo et al, 1998; Honda & Yasuda, 1999) and in this way
leads to transcriptional activation of p21 and cell cycle arrest or apoptosis. The Mdm2
protein has been recently shown to interact physically with the p21 inhibitor and to
facilitate proteasome-mediated p21 protein degradation independent of p53 (Zhang et al.,
2004).
When p53 upregulates p21 expression in response do DNA damage, p21 promotes pRb
activation and cell cycle arrest in order to allow DNA to be repaired. Another link between
p53 and pRb was pointed out by Bates et al. (1998): the transcription factor E2F1 was
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shown to activate directly the expression of pl4ARF, the human analogue of pl9ARF, while
the transactivation defective E2F1 mutants had no activity. The authors suggested that
E2F1, a protein activated by cell-cycle progression, is part of fail-safe mechanism to
protect against aberrant cell growth (Bates et al., 1998). The human analogue of pl9ARF
has been shown to interact physically with E2F1 and to inhibit its transcriptional activity
(Karayan et al, 2001). Thus, pARF can be viewed as a dual-acting tumour suppressor in
both the p53 and pRb pathways.
Proteolysis in cell cycle control
Ubiquitin cascade
Proteolysis during the cell cycle is mediated by two distinct ubiquitin-conjugation
pathways, each mediated by a different multisubunit protein complex . Ubiquitin is a small
(76 residues) highly conserved protein, essentially identical from yeast to humans. The
proteolytic pathways involve two successive steps: attachment of multiple ubiquitin
molecules to the substrate protein, and degradation of the tagged protein by the 26S
proteasome (Ciechanover, 1998, Ciechanover & Ben-Saadon, 2004). Conjugation of
ubiquitin to the substrate proceeds via a three-step cascade: 1) ubiquitin is activated on its
C-terminal by the ubiquitin-activating enzyme, El. 2) several species of ubiquitin-
conjugating (E2 or Ubc) enzymes, transfer the activated ubiquitin to a member of the
ubiquitin ligase family (E3 or Ubl) enzymes. 3) E3 catalyzes the covalent attachment of
ubiquitin to a lysine residue of the substrate protein. In most cases, the Lys residues that
serve as ubiquitination sites are not specific or part of the recognition motif (Ciechanover,
1998). Recent findings indicated, that for several proteins (for example the inhibitor p21),
the first ubiquitin moiety is fused not to an internal lysine, but to the a-NH2 group of the N-
terminal residue (Ciechanover & Ben-Saadon, 2004).
Each E2 acts with several E3s, interactions among different E2s and different E3s generate
a large number of specific substrate targeting complexes (DeSalle & Pagano, 2001). The
human genome contains -1000 different E3 ligases (Ciechanover & Ben-Saadon, 2004).
As shown by in vitro reconstitution experiments, El, E2, E3 enzymes and the 26S
proteasome are the minimal requirements for protein degradation. Several novel accessory
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proteins have been described that recognize and bind to both the multi-ubiquitin chain and
the proteasome and optimise degradation of many substrates (Hartmann-Petersen et al.,
2003). Probably the only function of polyubiquitin chain is targeting and tethering
substrates to the proteasome, as it was demonstrated that localization of a substrate to the
purified proteasome was sufficient for degradation in a ubiquitin-free in vitro system
(Janse et ah, 2004).
SCF complex
One of the ubiquitin-conjugation protein complexes, best characterized in budding yeast,
promotes passage from Gl to S phase by initiating DNA replication through degradation of
S phase cyclins inhibitor (SIC in yeast, p27 in mammals). This ligase complex is
designated SCF from the names of the major compound proteins: Skpl-cullin/Cdc53-Fbox
(Fig.2.2).
+ ATP + ATP
UUquttln chain
Ubiquitin chain
Figure 2.2. Schematic representation of yeast SCF complexed with E2 Cdc4 (left) and mammalian
SCF complexed with E2 Ubc3, each binding their specific phosphorylated substrates: Cdc4 binds
Sicl, and Skp2 binds p27. After DeSalle & Pagano (2001).
SCF ligases also contain a small protein subunit called Hrtl, Rbxl or Rod, that contain a
conserved C-terminal RING finger2, a cysteine-rich fold surrounding zinc atoms, through
which Cdc53/Cullin binds the E2 enzyme (Fig. 2.2; Tyers & Jorgensen, 2000; DeSalle &
Pagano, 2001). The SCF compound proteins in yeast indispensable for SIC degradation
' The RING domain mediates protein-protein interaction and is distinct from Zn-finger motif of DNA
binding proteins (Saurin et al., 1996).
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are: Cdc53, Skpl and Cdc4. The Cdc53 ortholog3 in human cells is the cullin protein
CULL Cullins are highly conserved during evolution and have been identified in
organisms from C. elegans to humans (Peters, 1998; Ciechanover, 1998). Cdc53/CUL1
acts as a docking site on which other proteins of the SCF complex assemble (Fig. 2.2;
Peters, 1998; Obaya & Sedivy, 2002). Skpl is a critical scaffold protein, it binds both to
Cdc53/cullin and to so called F-box proteins. F-box proteins serve as receptors and define
specificity for ubiquitination substrates. They are linked to Skpl by common F-box motif,
a conserved domain of approximately 40 amino acids (Tyers & Jorgensen, 2000). Some of
the F-box proteins, as for example Cdc4 and Met30 in yeast, bind their substrates via Trp-
Asp (WD) repeats, other as Grrl in yeast via leucine rich repeats, and SKP2 protein in
human uses still another domain (Fig. 2.2; Tyers & Jorgensen, 2000; Pfleger et al, 2001
and references therein). Cdc53 and Skpl are constitutive subunits of the SCF, Cdc4 is
indispensable for degradation of SIC, but dispensable for degradation of Gl cyclins, while
Grrl is essential for Gl cyclin proteolysis (Peters, 1998 and references therein). The Cdc4
protein, was not required for the SCF mediated degradation of human TK1 in yeast cells,
while functions of Cdc53 and Cdc34 were required (Ke et al, 2003).
The SCF ubiquitin ligases are constitutively active, regulation occurs at the level of
substrate recognition, where phosphorylation of the substrate is necessary to convert it to a
form susceptible to the action of the SCF ligase complex. The SIC inhibitor must be
phosphorylated on several of the nine putative phosphorylation sites to be recognized by
Cdc4 and ubiquitinated (Harper, 2002 and references therein). On the contrary, in HeLa
cells, phosphorylation of the p27 inhibitor on a single site was necessary and sufficient for
interaction with the SKP2 protein and for ubiquitin-dependent degradation by the SCF
complex (Tsvetkov et al., 1999). SKP2 was also suggested to be the F-box receptor for
other cellular regulators like cyclin Dl, p21 and E2F-1 (DeSalle & Pagano, 2001, and
references therein). Also, in ovarian cancer cells exposed to vitamin D3, decreased
abundance of SKP2 resulted in increased p27 stability and arrest of cells in Gl (Li et al.,
2004a).
3
 Genes in two separate species that derive from the same ancestral gene are said to be orthologs
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APC complex
The second ubiquitin-conj ugation pathway initiates chromosome segregation and exit from
mitosis by degrading anaphase inhibitors (now called securins) and mitotic cyclins. It
involves a large protein complex (over 10 different subunits) called the anaphase-
promoting complex (APC) or cyclosome, that uses a different set of E2s, than those used
by the SCF pathway (DeSalle & Pagano, 2001). There are notable structural similarities
between SCF and APC subunits (Fig.2.3).
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Figure 2.3. Structure comparison of SCF and APC complexes. Cullin-homology domain containing
proteins are yellow, RING-H2 proteins red assemble with the E2, homologs of Skpl adapter
protein purple are unknown for APC. After Harper et al., 2002.
The formation of the APC complex is nucleated on a cullin-related large protein called
APC2, which shares a 180-residue cullin-homology domain with Cdc53 (Fig. 2.3; Obaya
& Sedivy, 2002; Harper et al., 2002). Two related WD (Trp-Asp) repeat proteins
collaborate with APC and confer substrate specificity to APC-dependent degradation
reactions: Cdc20 and Cdhl/Hctl in yeast, or hCDC20 and hCDHl in humans (Peters,
1998; Zachariae, 1999; Morgan, 1999 and references therein). Cdc20-APC has ubiquitin
ligase activity towards proteins containing a nine amino acid motif RXXLXXXXN
designated the "destruction box", or D-box (Pfleger et al., 2001; Harper et al., 2002 and
references therein), while Cdhl-APC recognizes proteins that contain a D-box or a KEN
box (Pfleger & Kirschner, 2000). The KEN box like the D-box is transposable to other
proteins (Pfleger & Kirschner, 2000). Both Cdc20 and Cdhl have been shown to bind the
substrates via their N-termini, and not via the WD repeats (Pfleger et al., 2001). Cdc20 is
itself a Cdhl-APC substrate (Pfleger & Kirschner, 2000). Vertebrate Cdc20 lacks a D-box
(though the budding yeast Cdc20 contains two D-boxes) and is recognized by a KEN
53
signal sequence. Mutations in the KEN box stabilized proteins against ubiquitination and
degradation (Pfleger & Kirschner, 2000). Also, a KEN box located in the C-terminal of
human TKl has been found necessary for interaction with APC-Cdhl and for the mitotic
degradation of hTKl (Ke & Chang, 2004).
APC and cell cycle phases
The amount of Cdc20 bound to the APC increases between S phase and mitosis, while
Cdhl is predominantly bound to the APC in Gl (Peters, 1998 and references therein).
Binding of Cdc20 to APC leads to metaphase - anaphase transition through cleavage and
dissociation of cohesin complex that holds the sister chromatids together. This allows them
to separate and to move to opposite poles of the mitotic spindle (Fig. 2.4).
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Figure 2.4. Model of cell cycle progression regulated by SCF and APC. Pro, prophase, Meta,
metaphase, Ana, anaphase and Telo, telophase. After Peters, 1998. Inset: Continuous suppression
of M-cyclin through inhibition of Cdc20-APC and activation of Hctl-APC (Hctl=Cdhl). From
"The Cell" 4th Edition, Alberts et ah, 2002.
The mitotic cyclin B/CDK1 complex stimulates Cdc20-APC activity kinase -
phosphorylation of APC core subunits is required for activation of APC (Zachariae, 1999
and references therein). At the same time the active Cdc20-APC complex promotes
destruction of the mitotic cyclins. Low level of the mitotic cyclins means low level of
Cdc20-APC activity and rapid accumulation of new M phase cyclins for the next cycle. In
order to allow for a Gl phase in the next cycle, Cdhl-APC complex starts to accumulate in
late mitosis as Cdc20-APC destructs the mitotic cyclins - in contrast to the activity of
Cdc20-APC, the activity of Cdhl-APC is inhibited by mitotic cyclins (Morgan, 1999 and
references therein). The level of the mitotic cyclins is kept low after mitosis and during
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next Gl by Cdhl-APC (Fig. 2.4). Unlike B-type cyclins, Gl cyclins are immune to the
action of the APC and accumulate when Cdhl-APC activity is high.
The ability of Cdhl to bind to APC inversely correlates with its phosphorylation state
(Peters, 1998) - the cyclin proteolysis at the end of mitosis depends on Cdhl
dephosphorylation by a late mitotic gene product, the phosphatase Cdcl4 (Morgan, 1999
and references therein). The accumulation of the mitotic cyclin B has been shown to
require the E2F-dependent S-phase cyclin A/CDK2 mediated phosphorylation of Cdhl.
This in turn prevents its assembly with APC, and blocks APC-dependent proteolysis
allowing accumulation of APC targets (Lukas et al, 1999). Assembly of APC with a
phosphorylation-deficient mutant of Cdhl resulted in a complex active even in S-phase
cells (Lukas et al, 1999).
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Chapter 3
Regulation of TK1 expression
Several reports have demonstrated that TK1 enzyme activity is extremely low in resting
cells, but is highly expressed in growing and malignant cells (Bello, 1974; Johnson et al.,
1982; Coppock & Pardee, 1985; Hallek et ah, 1992). The activity of TK1 has been found
to exhibit a periodic increase pattern, starting to increase in Gl, continuing to increase in S
and G2, and decreasing at about the time of mitosis (Bello, 1974). Experiments using
actinomycin D - inhibitor of RNA polymerase - and cycloheximide - inhibitor of protein
synthesis, have shown that the increase of TK1 activity is due to de novo synthesis of TK1
mRNA and TK1 protein (Johnson et al., 1982).
TK1 promoter and transcriptional regulation
TKl activity and TK1 mRNA are not detectable in quiescent cells, but up to 40-fold
increase in TKl mRNA level has been shown after mitogenic stimulation or during SV40
virus infection (Stuart et ai, 1985; Coppock & Pardee, 1987; Roehl et al, 1993). In PHA
stimulated human lymphocytes the levels of TKl activity were similarly elevated, the
maximal increases reported varied between the different research groups from 20 fold to
about 200 fold as compared to the unstimulated lymphocytes (references in Munch-
Petersen, 1996). The level of TKl mRNA was about 100-fold higher in PHA stimulated
human lymphocytes than in quiescent lymphocytes (Kristensen et al., 1994).
The significance of the human thymidine kinase gene promoter in cell cycle regulation has
been demonstrated by Kim et al. (1988) and Travali et al. (1988). They have constructed
hybrid genes containing the human TKl promoter and a non cell cycle regulated reporter
gene, respectively the bacterial neomycin resistance gene and the bacterial CAT
(chloramphenicol acetyltransferase) gene. Expression of both bacterial genes in hamster
cells was then cell cycle regulated and attained maximum as cells entered the DNA
synthetic phase.
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The functional promoter of the human thymidine kinase was delimited by Kreidberg &
Kelly (1986) by construction of mutant plasmids with promoter deletions from both the 5'
and 3' directions. The mutants were tested for the ability to transform mouse LTK~ cells to
the TK+ phenotype. This analysis delimited the functional promoter to within a 83 base-
pair region upstream of the mRNA cap site (Kreidberg & Kelly, 1986). This region
contained the AT rich TATA box, about 20 bases upstream of the transcriptional start site
where general transcription factors are bound and position RNA polymerase II for
transcription initiation, several GC rich hexanucleotides involved in binding of the
transcription factor SP11, and two CCAAT boxes in inverted orientation (Kreidberg &
Kelly, 1986; Flemington et ah, 1987). A schematic drawing of the regulatory elements
known in the human TK1 promoter are shown in Fig. 3.1.
E2F-like-2
GG-GGGGGCGGGCTGCGGCCAAATCTCCCGCCAGGTC
Sp1 E2F-like-1 E2F-like-3
-118/-113 -109/-101 containing Sp1 -97/-92
GCCGGGCG-ATTGG-GCGGCGGGGC-ATTGG-TTTAAA -
GC CCAAT GC CCAAT TATA Transcription start
-71/-67 -40/-36 -21/-16 +1
Figure 3.1. Regulatory elements of the human TK1 promoter. Modified after Kim et al. (1996) and
Chang et al. (1999) with base numbers according to Chang et al. (1999). The sites corresponding to
Yi binding sequences of Kim & Lee (1992) are the same as E2F-like binding sequences 2 and 3 of
YLimetal. (1996).
near
1
 Spl-responsive promoters usually contain multiple GC box recognition sites which are often found nw.»»
binding sites for other transcription factors. This suggests that these factors act in conjunction with each other
to modulate transcription (Kadonaga et al., 1987). DNA binding activity of Spl has been localized to three
contiguous Zn finger motifs located in the C-terminal part of the protein (Kadonaga et al., 1987).
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CCAAT boxes and protein NF-Y
The CCAAT boxes have been associated with transcriptional activation of genes in several
systems (histone genes, Xenopus hsp70 gene); cell cycle specific binding of nuclear
proteins to the two CCAAT sequences in human TKl promoter has been first described by
Knight et al. (1987). Both CCAAT boxes were found important for the expression of the
TKl promoter, but the estimation of their contribution differed, hi a series of experiments
where TKl promoter deletion mutants were fused with a non-cell cycle regulated gene,
Roehl & Conrad (1990) and Kim & Lee (1991) identified a 70 bp region between -135 and
-64 containing the distal -70 CCAAT motif, as a cell cycle regulatory unit sufficient to
confer cell cycle regulation to a heterologous promoter. In a series of a similar TKl
promoter fusions, Arcot et al. (1989) have estimated that each CCAAT element is
responsible for about 20% of the promoter strength, while the distal -70 element with one
GC box maintains two-thirds of promoter activity. Mao et al. (1995) concluded that while
the distal box could substitute for the proximal one, the converse was not true. On the other
hand, transfection assays done by Chang et al. (1999) in HeLa cells showed, that whereas
simultaneous mutations at both CCAAT boxes abolished the TKl promoter activity,
mutations at either the proximal or distal CCAAT box yielded almost 50% reduction of the
promoter activity, suggesting that both boxes are functional and involved in activating the
hTKl promoter in HeLa cells (Chang et al, 1999).
Arcot et al. (1989) demonstrated that a nuclear protein, suggested to be NF-Y, binds to
both CCAAT elements, but has higher affinity for the proximal -40 element. Differential
binding of a nuclear protein thought to be highly specific for the human TKl promoter, and
consequently named CBP/tk (CCAAT Binding Protein for TK gene), was also shown by
Pang & Chen (1993). Here, the CBP/tk had higher affinity to the distal CCAAT box and
this binding was dependent on growth phase of the cells. The DNA-protein complex was
identified in young serum stimulated normal human fibroblasts, but neither in quiescent
young fibroblasts, nor in old serum stimulated fibroblasts (Pang & Chen, 1993). hi
contrast, the expression of TKl CCAAT-binding activity in cancer cell lines, like HeLa
and promyeloleukemia HL-60 cells, was high independently of serum stimulation (Chang
& Cheng, 1993). Later, this group identified the CCAAT binding protein as NF-Y using
Western blot analysis and antibodies specific for the subunits of NF-Y: NF-Ya and NF-Yb
(Chang & Liu, 1994). It was shown that expression of the NF-Ya subunit was high in
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serum stimulated normal human fibroblasts, but absent in quiescent fibroblasts, while the
expression of NF-Yb was the same before and after serum stimulation. Because both
subunits2 are required for DNA binding activity of NF-Y (Hatamochi et al, 1988;
Mantovani et al, 1992), it was concluded that the altered expression of NF-Ya subunit
after serum stimulation was responsible for the fluctuation of TK1-CCAAT binding
activity in normal human fibroblasts (Chang & Liu, 1994) and so for S-phase specific
transcription of TK1. Later experiments confirmed, that CBP/tk binding in human
fibroblasts could be supershifted by antiserum against NF-Ya, but not by antiserum against
plO7, pRB, cyclin A, or a CDK2 protein (Good et al, 1995), and that expression of the
NF-Y was dependent on the age of human fibroblasts, being barely detectable in old cells
(Good & Chen, 1996).
The sites binding NF-Y have also been shown to bind two other serum inducible proteins
dbpA and dbpB, and a protein named CDP/cut3, the CCAAT displacement protein with
known transcriptional repressor activity (Kim et al., 1997a). Overexpression of dbpA
stimulated hTKl promoter activity from the proximal CCAAT box, while CDP/cut could
bind to both CCAAT boxes, and was found bound to the hTKl promoter primarily in
quiescent cells. Thus, a combination of suppression in quiescent cells and activation in
serum stimulated cells mediated through various CCAAT binding proteins is responsible
for the induction of TK1 promoter activity in the S-phase of cell cycle (Kim. et al, 1997a).
Yi, E2F and Spl binding proteins
Another protein-binding site required for S-phase regulated transcription of human TK1,
and different from the above mentioned CCAAT sequence, was identified by Kim & Lee
(1992). This binding site sequence, located between -109 and -84 positions of the human
TK1 promoter, contained two elements with striking resemblance to the murine protein Yi
consensus binding site of the mouse promoter: CCCNCNNNCT, where N is any base (Dou
2
 Now it is known that NF-Y (also called CBP, CBF and CP1) consists of three different subunits A, B and C,
and association of all three subunits is needed for DNA binding (Maity & Crombragghe, 1998).
3
 The mammalian CDB/cut protems are believed to compete for binding sites occupancy at CCAAT and Spl
sites with activating transcription factors (Mailly et al., 1996).
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et al, 1991). Yi binding activity was not detected in GO and Gl extracts, but was observed
as the murine cells crossed the Gl/S boundary (Dou et al., 1991). Deletion of the Yi-
related sequence, simultaneously with the E2F-like motif contained within the human TK1
promoter eliminated S-phase specific transcription of a reporter gene in Chinese hamster
fibroblasts (Kim & Lee, 1992). Later, the Yi protein was renamed Yi2 and was found in a
DNA binding protein complex related to the S phase specific E2F complex (Dou et al.,
1992). At the beginning of the S phase, the Yi2 complex replaced another complex named
Yil, bound to the same promoter sequence (Dou et ah, 1992; Dou et al., 1994a). The Yil
complex contained the murine retinoblastoma protein, cyclinDl and CDK2 kinase, and its
DNA binding sequence was different from the consensus binding sequence for E2F (Dou
etal, 1994a).
Binding sequences for the transcription factor E2F (Fig. 3.1) have been found both in the
human (Nevins, 1992; Anderson et al., 1996; Hengstschlåger et al., 1996) and in the
mouse TK1 promoter (Dou et al., 1994b). The murine E2F-like binding site was found to
interact both with the human E2F protein and mouse nuclear protein complexes containing
E2F, pi07 (pRb-like), CDK2, cyclin A and cyclin E in a cell cycle dependent manner (Dou
et al, 1994b). Gel shift mobility studies with a -109 to -84 fragment of the human TK1
promoter, the fragment found critical for Gl/S transition by Kim & Lee (1992), identified
an S phase specific complex containing pi07 and cyclin A, proteins that are known to
interact with E2F (Li et al., 1993). Though, not all results point to the activation of TK1
promoter by E2F. The overlapping E2F-like sites 2 and 3 at -97 to -84, in contrast to the
E2F-like site 1 (Fig. 3.1), were found to be critical for the transcriptional activity of the
human TK1 promoter and necessary for high specificity binding of nuclear protein
complex to human TK1 promoter DNA affinity column (Kim et al., 1996). But proteins in
this complex were immunologically different from E2F1, E2F2, E2F3 and E2F4, what
suggested presence of a novel protein with preferred binding for the human TK1 promoter
(Kim et ah, 1996). Also, when activation of E2F target genes was measured by infection of
quiescent cells with an adenovirus vector into which the E2F gene has been recombined,
the TK1 gene expression increased only slightly in response to expression of E2F1, while
genes encoding thymidylate synthase, proliferating cell nuclear antigen (PCNA) and
ribonucleotide reductase were clearly induced (DeGregori et al, 1995).
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Tommasi & Pfeifer (1997) examined cell cycle specific binding of transcription factors at
the human TK1 promoter by footprinting experiments in normal human fibroblasts, and
identified 14 putative protein-binding sites. All of these sites, also the E2F recognition
sequences, were constitutively occupied in vivo at all stages of the cell cycle. Similarly,
both the E2F and the Spl binding sites were occupied throughout the cell cycle in mouse
cells (Karlseder et ah, 1996), and because the C-terminal of Spl is necessary for
interaction with the N-terminus of E2F protein, the TK1 promoter activity decreased with
increasing distance between E2F site and Spl sites (Karlseder et ah, 1996). All four factors
of the Spl family were able to bind E2F1 (Rotheneder et ah, 1999), but they differed in
their ability to activate the mouse TK1 promoter: Spl and Sp3 were strong activators, Sp4
was a weaker one, and Sp2 showed no activation at all (Rotheneder et ah, 1999). In
contrast to the mouse promoter, an E2F-like sequence in hamster TK1 promoter was found
not to bind transcriptional factors of the E2F family, and its removal did not affect
promoter activity (Sorensen & Wintersberger, 1999). The hamster promoter was regulated
by a single Spl binding site and one CCAAT box, and in this promoter, NF-Y probably
replaces the function of E2F (Sorensen & Wintersberger, 1999). Also Chang et ah (1999)
have found that mutation at position -106/-102, the E2F-like site 1 in the human TK1
promoter, had little effect on the promoter activity in transfected HeLa cells, while
mutation at the Spl binding site -118/-113, caused about 50% reduction of the human TK1
promoter activity (Chang et ah, 1999). It is then questionable to generally regard TK1 as
an E2F regulated gene.
Comparison of the human, hamster and mouse TK1 promoters
Only the mouse TK1 promoter carries a genuine binding motif for E2F, and the other
promoters have sequences that resemble it more (human) or less (hamster or rat)
(Wintersberger, 1997). All three promoters have GC boxes for binding of Spl, but the
human and hamster promoters, in contrast to the mouse one, also carry a TATA box and
CCAAT boxes for binding of NF-Y. The role of Yi complexes for the expression of the
mouse promoter is not absolutely clear, but most probably the Yil is different from E2F, as
they complex with different DNA binding proteins, and Yil complex contains D1/CDK2
kinase while E2F complex contains cyclin E/CDK2 and cyclin A/CDK2 kinases (Dou et
ah, 1994a; Dou et ah, 1994b; Dou & Pardee, 1996).
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Cyclins and CDKs
Complexes containing cyclin A, pi07 and CDK2, that could bind to human TKl promoter
were also detected in the nuclear extracts from growth-stimulated hamster fibroblasts (Li et
al., 1993). CDKs and its regulators were found to contribute as well to the maximal
activity of the human TKl promoter. In IMR-90 normal human diploid fibroblasts the
activity of the TKl promoter increased by the constitutive overexpression of cyclin A or
cyclin E, but not by cyclin D (Chang et al., 1995). The sequence responsible for the
transcriptional activation by cyclin E was located between -133 and -92 of the human TKl
promoter (Chang et al., 1995). In HeLa cells, where the hTKl promoter was already highly
activated, no further activation could be obtained by ectopic expression of cyclin A or E
(Chang et al., 1995). Still, inhibition of the TKl promoter activity by the tumour
suppressor pi6 could be overcome by overexpressing cyclin A in HeLa cells, and this
implicated a direct role of cyclin A in activation of the TKl promoter (Chang et al, 1999).
Also, activity of CDK2 was found to be required for the induction of TKl mRNA in serum
stimulated young fibroblasts, as presence of CDK2 inhibitor roscovitin abolished this
induction (Chang & Huang, 2001). In contrast to the young cells, aging serum-induced
fibroblasts showed no increase in the activity of CDK2, probably due to upregulation of
p21 and absence of cyclin A expression (Chang & Huang, 2001). The absence of CDK2
activity resulted in 6-fold lower levels of TKl mRNA than those in young cells, and in
impairment of TKl polypeptide synthesis (Chang & Chen, 1988; Chang & Huang, 2001).
This is in agreement with results of Haidweger et al. (2001) that cyclin A/CDK complex
phosphorylates Spl and that the phosphorylated Spl shows increased DNA binding ability
which in turn enhances the expression from the Spl responsive promoter.
Post-transcriptional regulation
Nuclear run-on transcription assays have shown that the rate of TKl transcription increases
2 to 7-fold between the GO and S phases, and can therefore only partly explain the more
than 40-fold increase of the level of mRNA (Coppock & Pardee, 1987; Stewart et al.,
1987). Gudas et al. (1993) synchronized hamster fibroblasts to GO, early Gl and mid Gl,
and investigated the mRNA level and transcription rate upon removal of the respective
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proliferation block. Cells emerging from the quiescent GO state showed a 4-fold increase in
the rate of TKl transcription, while cells restimulated from Gl arrest showed no change in
the rate of TKl transcription, but concomitant increase in mRNA abundance. The
conclusion was that transcriptional and post-transcriptional control mechanisms involved
in regulation of TKl mRNA can be uncoupled, and that the transcriptional component is
responsible for mRNA level during progression from GO to Gl, while the post-
transcriptional component is responsible for mRNA level during progression from Gl to S
phase (Gudas et al., 1993). Mechanisms of post-transcriptional regulation that account for
the increase of TKl mRNA and enzyme activity at the beginning of the S phase include
increased mRNA stability (Coppock & Pardee, 1987) and increased splicing efficiency of
nuclear TKl precursor transcripts (Gudas et al., 1988). Gudas et al. (1988) have found
accumulation of several high molecular weight TKl mRNA precursors and of mature 1.4
kb transcript within the nucleus as cells entered S-phase. Several hours later, the
accumulation of nuclear TKl mRNA was followed by accumulation of cytoplasmic TKl
mRNA. The authors suggested presence of a nuclear factor synthesized or activated at the
beginning of S-phase and responsible for processing of hnRNA (Gudas et al., 1988). Using
reverse transcription coupled to the polymerase chain reaction, Lipson & Baserga (1989)
could not detect TKl hnRNA in quiescent human fibroblasts. The amount of TKl hnRNA
increased transiently upon serum stimulation attaining maximum early in the S-phase. At
its maximum concentration the ratio of TKl hnRNA to TKl mRNA was 1:155 (Lipson &
Baserga, 1989).
Another post-transcriptional mechanism is the growth dependent regulation of TKl mRNA
by specific TKl introns. Rotheneder et al. (1991) have found two DNase hypersensitive
sites in intron 2 of the mouse TKl gene. Addition of these sequences, or all of intron 2, to
CAT constructs led to a marked stimulation of CAT expression over that seen with the
mouse promoter only (Rotheneder et al, 1991). In a further investigation, Sutterluety et al.
(1998) showed the presence of a putative antisense promoter in intron 3 of the murine TKl
gene, and found that TKl specific antisense transcription was enhanced in resting mouse
fibroblasts. The ratio between sense and antisense transcription changed from higher sense
transcription in cycling fibroblasts to predominant antisense transcription in serum
deprived cells. Since antisense transcription is correlated with repression of TKl mRNA in
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resting cells, it is very likely to play a role in the regulation of TK1 expression (Sutterluety
et al, 1998).
Translational regulation
Several studies indicated that expression of TK1 enzyme activity was regulated
independently of TK1 mRNA. Ito & Conrad (1990) examined mRNA, protein and enzyme
expression with constructs where a human TK1 cDNA was transcribed from the human
promoter, the HSV-1 promoter and the SV40 early promoter. While the promoter did
affect the pattern of mRNA expression, it had only a minimal effect on the pattern of
protein or enzyme expression. For example, when Rat3 (TKP) cells were transfected with
SV40-hTKl construct, the mRNA was fully induced after 2-4 h of serum stimulation,
while protein and enzyme activity levels remained low until about 12 h following serum
stimulation, despite the presence of high level of mRNA. Thus, Ito & Conrad (1990)
concluded, that induction of TK1 protein was uncoupled from induction of TK1 mRNA,
and suggested presence of translational or post-translational regulation. Similarly, when
Mikulits & Milliner (1994) transfected mouse fibroblasts with a vector expressing human
TK1 cDNA from a constitutive promoter, they found constant mRNA level, but 8-fold rise
in enzyme activity at Gl/S transition, followed by decline in G2. The results indicated that
in the absence of transcriptional control, the TK1 activity was repressed in all periods of
the cell cycle except the S phase (Mikulits & Milliner, 1994). In further investigation,
Mikulits et al. (1996) studied the consequences of TK1 mRNA abundance on the cell cycle
dependent regulation of TK1 activity in nontransformed mouse cells. Low constitutive
TK1 mRNA expression still resulted in maximal TK1 activity in S-phase. Increasing
concentrations of constitutive mRNA compromised cell cycle regulation of TK1 activity,
and the highest constant mRNA levels (observed after hormone induction of MMTV4
promoter) resulted in constitutively high TK1 activity. These data indicated presence of
factor(s) required for repression of TK1 translation during Gl which can be titrated by high
4
 Mouse mammary tumor virus
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mRNA concentration (Mikulits et al, 1996). 5'UTR of TKl mRNA, when present at high
concentrations, could be the molecule titrating the repression factor, as presence of 5 'UTR
allowed in vitro translation of TKl mRNA in a cap-independent manner (Chou & Chang,
2001). 5'UTR in TKl mRNA was proposed to confer a secondary structure to regulate
ribosome binding during translation without being controlled by the cap-binding step
(Chou & Chang, 2001).
Increased efficiency of translation of TKl mRNA has been demonstrated by Sherley &
Kelly (1988b) to account for the increase of TKl activity in the S-phase of cycling HeLa
cells. Here, the level of TKl mRNA increased less than 3-fold, while the amount of TKl
polypeptide increased about 15-fold between Gl and G2. Changes in the level of TKl
protein were correlated with the changes in TKl enzyme activity. Pulse labelling
experiments where the rate of incorporation of 35S-methionine into TKl polypeptide were
measured, revealed that the rate of synthesis of TKl protein was 10-fold greater in S-phase
than in Gl phase. In addition, the stability of TKl protein decreased upon cell division
resulting in low enzyme level in Gl cells (Sherley & Kelly, 1988b).
Also, Gross & Merrill (1988; 1989) reported that changes in TKl mRNA levels were much
smaller than changes in TKl protein and activity levels in mouse myoblasts withdrawing
from the cell cycle. These cells maintained nearly proliferative mRNA levels, but have
greatly reduced levels of TKl activity due to a 10-fold reduction in the rate of TKl
synthesis. TKl protein stability was unchanged in this system, and the decrease in TKl
protein synthetic rate, in the continuous presence of mRNA, indicated decrease in the
translational efficiency of TKl mRNA. Because distribution of TKl mRNA on polysomes
did not change with differentiation, the authors suggested that translational control
occurred at a post-initiation level (Gross & Merrill, 1989).
Post-translational regulation
Regulation by mitosis specific degradation
As already mentioned, Sherley & Kelly (1988b) demonstrated that the TKl protein in
cycling HeLa cells was degraded during mitosis and early Gl. At different times between
Gl and G2 the TKl was as stable as bulk cellular protein which had a half-life of about 40
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hours. The half-life of thymidine kinase decreased to about 4 hours at the time of cell
division, and decreased further to less than 1 hour in the newly divided Gl cell (Sherley&
Kelly, 1988b). In agreement with the above, a significant increase in TK1 protein levels at
the Gl/S transition in serum stimulated Rat3 cells (stably transfected with hTKl cDNA
linked to SV40/hTKl promoter) was concluded to be primarily the result of a stabilization
of TK1 protein at Gl/S (Carozza & Conrad, 1994).
The timing of TK1 degradation and the half-life of the enzyme were defined more
precisely when cells were arrested between metaphase and anaphase with the reversible
microtubule inhibitor nocodazole (Kauffman & Kelly, 1991). The results indicated that
degradation of wild-type TK1 began between metaphase and cytokinesis and that the half-
life of TK1 during nuclear/cell division could be less than 20 minutes. Deletion of 40 C-
terminal amino acids of human TK1 did not alter its enzymatic activity, but abolished the
specific degradation at the border of mitosis and Gl, and resulted in constitutive expression
of the protein during the cell cycle (Kauffman & Kelly, 1991). When TK1 mRNA was
expressed from a growth-independent heterologous promoter, the same C-terminal deletion
allowed expression of thymidine kinase protein and activity in quiescent GO cells
(Kauffman et al, 1991).
The evidence for changes in the stability of TK1 during cell cycle, and for the importance
of the C-terminal, was also obtained with mouse enzyme. Progressive deletion of up to 20
C-terminal amino acids led to stabilization of TK1 and to a stepwise loss of its growth-
dependent regulation (Sutterluety et ah, 1996; Mikulits et al., 1997). Mouse TK1 with a
mutated, full-length version of its C-terminal, but with 50 aberrant amino acids was
inherently unstable (Mikulits et al., 1997). Removal of the C-terminal 30 residues resulted
in dramatic increase in protein stability which was the same in resting and growth induced
cells (Sutterluety et al., 1996). The cellular half-life estimated in these experiments with
TK1A305 was more than 18 hours, while the half-life of wild type mouse TK1 in quiescent
cells was about 40 minutes (Sutterluety et al., 1996). So, in both the quiescent (Sutterluety
et al., 1996) and mitotic cells (Kauffman & Kelly, 1991), the low wild type TK1 enzyme
levels, are at least partly due to decrease in TK1 protein stability. Later, Sutterluety &
Seiser (1997) have shown that the TK1 protein half-life rose more than six-fold after
addition of thymidine to resting cells, while TK1 mRNA levels and TK1 translation rate
5
 TKl A30 is a polypeptide where the last 30 amino acids were removed
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were unaffected. Binding of thymidine could potentially change the TKl protein
conformation and therefore influence TKl degradation (Sutterluety & Seiser, 1997).
More recently, Posch et al. (2000) reported that the ability of the murine TKl to bind
substrates was essential for both growth-dependent regulation and stabilization in
proliferating fibroblasts. Mutants lacking the binding sites for either ATP or thymidine
were not only enzymatically inactive, but showed no induction of protein levels in
response to serum stimulation due to rapid degradation in exponentially growing cells. By
cross-linking experiments it was shown that TKl proteins with mutated substrate binding
sites existed only as monomers in contrast to active TKl enzyme (TKl wild type and
TK1A30) that existed as dimers and tetramers. It was concluded that substrate binding to
the TKl protein was a prerequisite for stabilization, and the availability of substrates might
offer additional means for fine-tuning enzyme degradation (Posch et al., 2000). These
studies of in vivo properties of murine TKl (Posch et al., 2000) are in excellent agreement
with in vitro studies of Munch-Petersen et al. (1993) on pure human lymphocyte cytosolic
TKl: ATP was found to be not only a stabilizer of thymidine kinase activity, but a positive
effector inducing enzyme concentration-dependent shift from a less active dimer to a
tetramer with higher substrate affinity.
Recently, the mitotic degradation of human TKl was shown to be dependent on a
ubiquitin-proteasome pathway - the anaphase-promoting complex and its activator Cdhl,
controlled destruction of hTKl through a KEN box motif located in the C-terminal of the
protein (Ke & Chang, 2004).
Regulation by phosphorylation
The effect of substrates on TKl stability can be connected to results of Chang & Huang
(1993) and Chang et al. (1994), that have found growth dependent phosphorylation of TKl
in promyeloleukemic HL60 human cells and in several other human cell lines. HL60 cells
showed constitutive expression of the level of TKl polypeptide, but TKl activity increased
during growth stimulation (Chang & Huang, 1993). This increase of activity was
accompanied by increment in the extent of phosphorylation of the enzyme. Phosphoamino
acid analysis indicated that serines were the only phosphorylated residues and that the
serines were situated at two major and several minor phosphorylation sites (Chang &
Huang, 1993). The phosphorylated sites in TKl polypeptide in proliferating and
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mitotically blocked HeLa cells were found to be distinctly different (Chang et al., 1994),
and the hyperphosphorylation of TKl in mitotically blocked cells resulted in decreased
affinity for thymidine: Km was 15.5 uM as compared to 1.49 uM in proliferating cells
(Chang et al., 1994). The reduced thymidine affinity was suggested to be at least partly
responsible for the decreased stability of TKl (Chang et al., 1994).
In a later investigation, Chang et al. (1998) have demonstrated that Ser13 of the human
TKl was the primary site of mitotic phosphorylation, and that the wild type TKl, but not
the mutant TKlAla13, could serve as a good substrate for CDKlor CDK2 kinases in vitro. In
this study, no difference in the catalytic properties of Ser13 phosphorylated and
unphosphorylated TKl was found, and the importance of another residue, Ser l, for the
mitotic phosphorylation could not be excluded (Chang et al., 1998).
Ser13 was also shown to play a crucial role in the mitotic degradation of human TKl
expressed in yeast (Ke et al., 2003). Mutation of Ser13 to Ala resulted in elevated
accumulation of hTKl and in reduced rate of hTKl degradation during mitosis in both
budding and fission yeasts (Ke et al., 2003). Functional intactness of the yeast
proteasomes, more specifically of the so-called SCF-complex, was found to have a major
contribution to the degradation of hTKl in yeast cells (Ke et al., 2003). However, the SCF
complex and Ser13 were not essential for mitotic degradation of hTKl expressed in
mammalian cells. Instead, another ubiquitin ligase, anaphase-promoting complex and its
activator Cdhl, were shown to control destruction of hTKl through a KEN box motif
located in the C-terminal of the protein (Ke & Chang, 2004).
Regulation at the enzymatic level
The apparent Km values of TKl for its substrate thymidine - 15.5 uM and 1.49 uM in
mitotically blocked and in proliferating cells, respectively (Chang et al., 1994) are in very
good agreement with the Km values found in vitro for the pure substrate-free human
lymphocyte TKl: a less active dimeric form with Km about 15 uM associated reversibly
upon incubation with ATP into a more active tetrameric form with Km about 0.7 uM
(Munch-Petersen et al., 1993). This transition was dependent on enzyme concentration,
ATP and thymidine (Munch-Petersen et al., 1993; Munch-Petersen et al., 1995a). Because
the concentration of TKl protein fluctuates during the cell cycle, the low affinity dimer
form was suggested to dominate in Gl, the high affinity tetrameric form in S/G2 phases,
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and the transition was considered as an additional fine tuning of TK1 activity during the
cell cycle (Munch-Petersen et al, 1995a).
Perturbation in ATP-induced transition pattern from low thymidine affinity dimer to high
thymidine affinity tetramer has recently been reported for a recombinant TK1 enzyme in
which Ser-13 was substituted with aspartate (Li et al., 2004). The S13D substitution which
mimics the mitotic phosphorylation of Ser-13 caused an equilibrium shift from a tetramer
to a dimer. Because the dimeric form of TK1 is less active than the tetrameric, it was
proposed that the physiological role of Ser-13 phosphorylation is to counteract ATP-
dependent activation of TK1, thus attenuating its enzymatic function at G2/M phase (Li et
ai, 2004).
Regulation of TK1 expression in malignant cells
The overall regulation of TK1 is different in tumour derived and virus transformed cells
when compared to normal cells (Hengstschlåger et al., 1994a). As already mentioned, there
was little regulation at the mRNA level in human HeLa cells (Sherley & Kelly, 1988b).
Hengstschlåger et al. (1994a, 1994b, 1994c) measured enzyme activity and mRNA levels
during the cell cycle of normal fibroblasts, normal or malignant lymphocytes, other
malignant cell lines like retinoblastoma and carcinoma, and of cells transformed with
different viruses (polyoma, papilloma, adenovirus, SV40 or Epstein Barr virus). In normal
cells both mRNA level and TK1 enzyme activity was transiently induced in early S-phase.
In malignant and virally transformed cells TK1 mRNA level and TK1 activity were
consistently higher in all phases of the cell cycle, and only minor fluctuations in the mRNA
level during the cell cycle could be observed. In contrast to the normal cells, there was no
decrease in TK1 activity during G2: both TK1 polypeptide level and enzyme activity
stayed at the high S-phase levels until mitosis (Hengstschlåger et al, 1994a, 1994b,
1994c).
Malignant chronic lymphatic leukaemic (CLL) cells showed a different mechanism of
deregulation of TK1 mRNA synthesis and of TK1 enzyme activity (Kristensen et al,
1994). In normal PHA stimulated human lymphocytes, an about 100-fold increase in TK1
mRNA level at the entry to S phase was followed by an increase in TK1 activity.
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Surprisingly, in CLL cells, the TK1 mRNA was expressed 30-300 fold higher than in
quiescent lymphocytes, but the TK1 activity stayed low and at the same range as in
quiescent lymphocytes (Kristensen et al., 1994). A defect in processing of the enzyme in
CLL cells was suggested, but the reason for this deregulation is unknown.
TK1 as a modulator of cell cycle progression
The inhibitor of CDK2/cyclinE and CDK2/cyclinA complexes, p21, is known to be a
negative regulator of cell growth. As already mentioned, it could influence promoter
activity of TK1 (Chang & Huang, 2001) and was also shown to suppress mitotic
phosphorylation of TK1 protein (Chang et al, 1998). Huang & Chang (2001) found that
antiserum against human TK1 co-immunoprecipitated p21 indicating that hTKl can form a
complex with p21 polypeptide. TK1 activity was not changed by this association, but the
p21-mediated inhibition of cell proliferation was markedly reversed. Using
immunoprecipitation technique it was shown that elevated expression of TK1 in the cells,
disrupted association of p21 with CDK2. Huang & Chang (2001) hypothesize, that
elevated expression of TK1 in some tumour cells not only provides dTTP for DNA
replication but also attenuates the inhibitory growth function of p21.
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Chapter 4
Structure of the human thymidine kinase 1
Knowledge of protein structure is an invaluable aid for rational design of new
Pharmaceuticals: It should be possible to make drugs that bind tightly to the enzyme and
interfere specifically with its function. Two methods, X-ray crystallography and nuclear
magnetic resonance (NMR), are being widely used for investigations of protein structure.
In principle, each of the methods can position all the atoms in a molecule and their relation
to each other. An advantage of NMR spectroscopy is that it is carried out on molecules in
solution and can show conformational variability and flexibility of protein molecules. X-
ray crystallography is limited to molecules that can be crystallized and describes proteins
frozen into one conformation in their crystalline form.
The crystal structure of Herpes simplex virus type 1 thymidine kinase (HSV1-TK) has
been studied since 1995, and solved in complex with different substrates (Brown et al.,
1995; Wild et al, 1995; 1997; Champness et al, 1998; Bennett et al, 1999; Prota et al,
2000; Vogt et al, 2000). Recently, the crystal structure of thymidine kinase from Varicella
zoster virus (human herpes virus type 3) complexed with bromovinyl-deoxyuridine 5'-
monophosphate (BVDU) and ADP has been determined (Bird et al, 2003). Also, the
structures of crystalline deoxynucleoside kinase from the fruit fly Drosophila
melanogaster - Z)m-dNK, and of crystalline human dGK have been elucidated (Johansson
etal, 2001).
The human TK1 was cloned in 1983 - 1984 (Bradshaw, 1983; Bradshaw & Deininger,
1984), allowing the necessary amounts of TK1 protein for crystallization to be produced.
Unfortunately, attempts to grow TK1 crystals suitable for X-ray crystallography have so
far been unsuccessful.
Large amounts of pure protein are also required for structure determination by nuclear
magnetic resonance. NMR enables determination of 3D-structure of proteins in solution if
their size does not exceed 30 kDa. Because the subunit size of TK1 is 25 kDa, and TK1
exists in solution as a mixture of dimers and tetramers, the available NMR methods do not
offer the required resolution and sensitivity.
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Although the three-dimensional structure of TK1 still awaits to be solved, I will propose a
possible 3D-structure of TK1 based on its amino acid sequence, computer calculations for
probabilities of formation of P-strands and a-helixes, and analogy to the structures of the
already known deoxynucleoside and deoxynucleotide kinases - adenylate kinase and other
NMP kinases, Herpes simplex virus thymidine/thymidylate kinase, the human
deoxyguanosine kinase and Drosophila melanogaster deoxynucleoside kinase.
The primary structure of TK1
The human thymidine kinase has 234 amino acid residues and forms a subunit of 25 kDa.
A search in the protein databases of NCBI (National Center for Biotechnology
Information) with BLAST (Basic Local Alignment Search Tool (Altschul et ah, 1990;
Altschul et ai, 1997) results in a large number of sequences from vertebrata,
nonvertebrata, plants, bacteria and viruses of the pox family. The vertebrate and vaccinia
virus kinases show the highest homology to the human thymidine kinase 1 (Fig. 4.1). The
main difference between the vertebrate and pox virus enzymes is that the former possess
additional N-terminal and C-terminal residues (15 and 42 respectively for the human TK1
(Boyle et ah, 1987; se also Fig. 4.1).
Based on amino acid sequences, Eriksson et al. (2002) divided the known
deoxyribonucleoside kinases into three groups. The human TK1 with vertebrate and
vaccinia kinases form a group of their own. The other mammalian kinases, dCK, dGK,
TK2 and the Drosophila multisubstrate deoxynucleoside kinase, dNK, form a second
group (the so called TK2 group), and Herpes virus kinases form a third group. Sequence
comparison of TK1 to other cellular deoxynucleoside kinases, and to Herpes simplex virus
thymidine kinase show low overall homology confined to the phosphate-binding motif, the
so called P-loop (Eriksson et ah, 2002). The P-loop (Fig. 4.2) is commonly found in ATP-
and GTP-binding proteins, such as mononucleotide kinases, elongation factors, myosin and
Ras proteins (Saraste et al., 1990). This P-loop motif is probably the most ancient motif in
nucleotide-binding proteins and might be the archaic mode of interaction between
nucleotides and proteins (Dreusicke & Schulz, 1986). The consensus sequence for the P-
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Human MSCINLPTVLPGSPSKTRGQIQVILGPMFSGKSTELMRRVRRFQIAQYKCLVIKYAKDTR 60
Mouse MSYINLPTVLPSSPSKTRGQIQVILGPMFSGKSTELMRRVRRFQIAQYKCLVIKYAKDTR 6 0
Hamster MNYINLPTVLPGSPSKTRGQIQVILGPMFSGKSTELMRRVRRFQIAQNKCLVIKYAKDTR 60
Chicken MNCLTVPGVHPGSPGRPRGQIQVIFGPMFSGKSTELMRRVRRFQLAQYRCLLVKYAKDTR 60
Vaccinia MN GGHIQLIIGPMFSGKSTELIRRVRRYQIAQYKCVTIKYSNDNR 45
Mycoplasma MYNRF NKGMIEVITGPMFSGKTEELLRRFRLLNYAKAKTLLIKPAFDTR 49
Bacillus MYLIN QNGWIEVICGSMFSGKSEELIRRVRRTQFAKQHAIVFKPCIBNR 4 9
* * *::* *.*****; **.**.* . * • • • . * . *
Human YSSS-FCTHDRNTMEALPACLLRDVAQEAL--GVAVIGIDEGQFFP-DIVEFCEAMANAG 116
Mouse YSNS-FSTHDRNTMDALPACMLRDVTQEAL--GVAVIGIDEGQFFP-DIVDFCEMMANEG 116
Hamster YSSS-FSTHDRNTMDALPACLLRDVAQEAL--GAAVIGIDEGQFFP-DIVEFCEVMANAG 116
Chicken YCTTGVSTHDRNTMEARPACALQDVYQEAL--GSAVIGIDEGQFFP-DIVEFCEKMANTG 117
Vaccinia YGTG-LWTHDKNNFEALEATKLCDVLESIT--DFSVIGIDEGQFFP-DIVEFCERMANEG 101
Mycoplasma FSKEEIISRAGVKTKTHSVKNTEQIRKILEKEKFDALVIDEIHFFDFDIVYLIEELANSG 109
Bacillus YSEEDWSHNGLKVKAVPVSASKDIFKHIT-EEMDVIAIDEVQFFDGDIVEWQVLANRG 108
Human KTVIVAALDGTFQRKPFGAILNLVPLAESWKLTAVCMECFREAAYTKRLGTEK 170
Mouse KTVIVAALDGTFQRKAFGSILNLVPLAESWKLTAVCMECFREAAYTKRLGLEK 170
Hamster KTVIVAALDGTFQRKAFGSILNLVPLAESWKLTAVCMECFREAAYTKRLGLEK 170
Chicken KTVIVAALDGTFQRKAFGSILNLVPLAESWKLNAVCMECYREASYTKRLGAER 171
Vaccinia KIVIVAALDGTFQRKPFNNILNLIPLSEMWKLTAVCMKCFKEASFSKRLGEET 155
Mycoplasma YHIIVSGLDQNFKREPFEWSYLLSIAEKVTKLQAICVKCQRAATTTFRKVESK 163
Bacillus YRVIVAGLDQDFRGLPFGQVPQLMAIAEHVTKLQAVCSACGSPASRTQRLIDGEPAAFDD 168
:**:.** *: .* : *:.::* *.** *:* * *: : *
Human EVEVIGGADKYHSVCRLCYFKKASGQPAGPDNKENCPVPGKPGEAVAARKLFAPQQILQC 230
Mouse EVEVIGGADKYHSVCRLCYFKKSSAQTAGSDNK-NCLVLGQPGEALWRKLFASQQVLQY 229
Hamster EVEVIGGADKYHSVCRVCYFKKSSVQPAGPDNKENCPVLGQPGEASAVRKLFAPQQVLQH 23 0
Chicken EVEVIGGADKYHSVCRACYFQKRP-QQLGSENKENVPMGVKQLDMPASRKIFAS 224
Vaccinia EIEIIGGNDMYQSVCRKCYIDS 177
Mycoplasma EIKLLGDVDEYEARCRKCHIQGSKDKN 190
Bacillus PI ILVGASESYEPRCRHCHAVPTKQR 194
. . * . * * * * •
Human
Mouse
Hamster
Chicken
Vaccinia
Mycoplasma
Bacillus
SPAN 234
NSAN 233
NSTN 234
Figure 4.1. Alignment of human TKl amino acid sequence with related en2ymes (Clustal W 1.82).
Symbols below the sequences are: "*" - identical residues in all sequences, ":" - conserved
substitutions, "." - semiconserved substitutions. The sequences have following GenBank Identifier
numbers: gi/23503074, human; gi/6678357, mouse; gi/125428, Chinese hamster; gi/125427, chicken;
gi/9791018, vaccinia virus; gi/15828616, Mycoplasma; gi/21397804, Bacillus.
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loop motif, originally called motif A by Walker and co-workers (Walker et al., 1982) and
later "Walker" A motif, is GXXXXGKS/T, with invariable glycines and a key lysine for
providing the positive charge, and followed by a serine or threonine (Fig. 4.2). Another
conserved sequence, Walker B motif, was originally identified as R/KX1.4GX2-
4OXO2OD/E (Walker et al, 1982; Traut, 1994b) and later more simple as ®<D<DOD where
<E> can be any hydrophobic amino acid and D is an invariable aspartate (Myles et al, 1991).
The Walker B sequence is positioned at an average distance of 60 amino acids from the P-
loop (Traut, 1994b) and corresponds to VIGID in the vertebrate TK1 and vaccinia TK1
sequences (Fig. 4.1 and Fig. 4.2). The conserved aspartate has been found to coordinate a
Mg2+ ion required for phospho-transfer reaction (se later).
A: P-loop, the phosphate-binding site B: Mg2+ binding site
(Walker A motif) (Walker B motif)
HSVl (48) TLLRVYIDGPHGMGKTTTT (156) ALTLIFDRHPIAAL
Human TK1 (18) RGQIQVILGPMFSGKSTEL (91) VAVIGIDEGQFFPD
Human TK2 (49) KKSVICVEGNIASGKTTCL (127) SSVRLMERSIHSAR
Vaccinia (3) GGHIQLIIGPMFSGKSTEL (76) FSVIGIDEGQFFPD
ADK (7) KSKIIFWGGPGSGKGTQC (87) SKGFLIDGYPREVK
EF-Tu (11) PHVNVGTIGHVDHGKTTLT (74) RHYAHVDCPGHADY
C: Thymidine binding site D: LID motif
HSVl (151) HAPPPALTLIFDRHPIAAL (2 09) PEDRHIDRLAKRQRPGER
Human TK1 (118) TVIVAALDGTFQRKPFGAI (158) REAAYTKRLGTEKEVEVI
Human TK2 (122) TRPQVSSVRLMERSIHSAR (185) NPETCYQRLKKRCREEEK
Vaccinia (103) IVIVAALDGTFQRKPFNNI (143) KEASFSKRLGEETEIEII
ADK (121) GPETMTKRLLKRGETSGR
EF-Tu
Figure 4.2. Alignment of different thymidine kinases with adenylate kinase (ADK, from vertebrate
muscle) and elongation factor EF-Tu (from E. coli). Conserved residues/regions are in bold; "—"
means absence of the homologous motif. Sequences for human TK2 were aligned with HSVl TK
according to Eriksson et al. (2002). The sequence and numbering of HSVl-TK is after Wild et al.
(1997), vaccinia virus TK after Black & Hruby (1990), and adenylate kinase after Schulz et al.
(1986). Human TK1 has accession nr P04183, TK2 nr 000142 and EF-Tu nr NP_417798
respectively, in the SwissProt databank. This figure is modified after Folkers et al. (1991).
Alignment of different thymidine kinases revealed still another conserved site: The FQRK
sequence in the human TK1 corresponding to FDRH in herpes viral thymidine kinases
(Balasubramanian et al, 1990; Gentry, 1992) and to F/MERS in the TK2 group of
deoxynucleoside kinases (Eriksson et al., 2002). On the basis of sequence analysis and
enzyme kinetic results from mutants in which the conserved residues were replaced, this
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site was suggested to be involved in binding of thymidine (Gentry, 1992). More recent
experiments with murine TK1 confirmed importance of the P-loop and of the putative
thymidine binding site: exchange of lysine 32 with isoleucine, or deletion of residues 28 to
33 (in the putative ATP binding site), and mutations of arginine 130 and phenylalanine 133
to alanine, or deletion of residues 130 to 138 (in the putative thymidine binding site)
resulted in a complete loss of TK1 enzymatic activity (Posch et al., 2000).
An additional region, although not very conserved in eukaryotic and pox thymidine
kinases, is an arginine-rich consensus sequence RXXXRXR present in the so-called LID
motif of the enzyme (the LID closes upon substrate binding like a lid). Alignment of the
conserved regions found in thymidine kinases, adenylate kinase and GTP-binding
elongation factor EF-Tu is shown in Fig. 4.2.
Secondary structure of TK1
It is a general belief that the sequences of amino acids determine if the peptide will form an
a-helix, |3-strand or a random coil, which in turn will fold up into a defined tertiary
structure (Cook, 1967; Anfinsen, 1973). Different amino acids have been found with
different frequencies in a-helices, p-strands, loops, or in turns that break the chain and
ensure that it folds back to form the core. These differences can be essentially explained by
differences in size, conformation and charge of each amino acids, but at the same time the
neighbouring residues and residues involved in tertiary interactions, are found to be
important in determining the secondary structure. Many sequences have been found to
adopt alternative conformations: a-helix in one protein context and P-strand in another1. In
1983 Kabsch & Sander evaluated the accuracy of algorithms generally used for the
secondary structure prediction (Lim, 1974a; Lim, 1974b; Gamier et ai, 1978; Chou &
Fasman, 1978) to be below 56%. Increase of the prediction accuracy to 66% was obtained
when alignment of homologous sequences was used simultaneously with an algorithm
quantifying the degree of conservative substitution at each alignment position, including
insertions and deletions (Zvelebil et al, 1987). Later algorithms, as for example the
1
 If a protein assumes inappropriate conformation for the context, pathological diseases can result as in the
case with prion diseases (mad cow disease, Creutzfeldt-Jacob disease).
75
profile-based neural network program PHD (Profile network from HeiDelberg), used
multiple sequence alignments and reached prediction accuracy greater than 70% (Rost &
Sander, 1993; Rost & Sander, 1994). Since the 1990ies the prediction area is in a constant
state of development. Improvements in computational tools, X-ray crystallography and
NMR spectroscopy have resulted over the past few years in flood of information on protein
sequence and structure homology. The present secondary structure prediction algorithms
obtain their parameters from an analysis of proteins of known three-dimensional structure
and then apply them to the sequence of unknown structure. Novel methods using neural
networks can predict protein secondary structure at about 80% accuracy (Petersen et al.,
2000). I have used the secondary structure prediction provided by JPred server (Cuffed al.,
1998; Cuff & Barton, 1999; Cuff & Barton, 2000). JPred (or JNet) combines several
prediction methods to achieve a consensus prediction that has an improved accuracy when
compared to any single method. JNet is being continuously developed and the averaged Qi
score, where Qs is the percentage of residues predicted correctly for the three
conformational states, strand, helix and loop, increased from 72,9% (Cuff et al., 1998)
through 78% (Cuff & Barton, 1999) up to 84% (Cuff & Barton, 2000). As can be seen in
Fig. 4.3 different methods give different results. The JPred consensus prediction differs as
well from the earlier prediction of Folkers et al. (1991), where model of TK1 was built
based on secondary structure prediction method of Gamier et al. (1978) and with 3D-
structure of adenylate kinase as template. Still, the pattern is clear: By all methods TK1 is
predicted to be an a/p protein built of alternating a-helices and (3-strands, a common
feature in nucleotide binding proteins.
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Figure 4.3. Prediction of TKl secondary structure by Jpred (se text). Jpred is the consensus prediction over all methods. The numbering refers to human TKl.
The sequences have following SwissProt databank accession numbers: P04047, chicken; Q90024, poxvirus; Q9XXF3, C. elegans; P75070, Mycoplasma;
Q03221, Bacillus. HHH, a-helix; EEE, p-strand; —, residues to which no structures could be assigned.
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Supersecondary structure
Most nucleotide binding proteins have a core consisting of several parallel (3 strands
alternating with a-helices. The p-a-p unit formed by two parallel P-strands connected by an
a-helix is called Rossman-fold, after Michael Rossmann who described this domain first
(Rao & Rossmann, 1973; Rossmann et al., 1974), and who defined topologically
equivalent residues in polypeptides that have little sequence similarity, but adopt similar
folds2 (Matthews & Rossmann, 1985). Fig. 4.4 shows a topology diagram (description of
how different structures are connected) for TK1 based on JPred secondary structure
prediction.
Figure 4.4. Proposed topology diagram of TK1 based on JPred prediction (se also Fig. 4.3).
Binding sites for thymidine (dThd) and ATP are also shown.
For comparison, the secondary structure and topology of the Drosophila pyrimidine kinase
Dm-dNK is:
pl-^al-^P 2^ a2-^a3-^a4-^p3-^a5-^a6-^p4^a7-^a8-^35-«9 (Johansson et al.,
2001). dNK is somewhat longer, 250 amino acids as compared to 234 of TK1, and also the
total length of the secondary structure elements is higher: 150 out of 250 (about 60%)
amino acids are found in a-helices or in P-strands, whereas JPred predicts only 70 out of
TKl's 234 amino acids (about 30%) to be in a-helices or in P-strands. Solution of 3D-
structure of TK1 may change this number.
2
 Folds, also called motifs, are defined as arrangements of several elements of secondary structure and the
connections between them
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Tertiary structure
The tertiary structure is defined as the arrangement of all the atoms of the protein in space,
comprising all possible interactions.
The Protein Data Bank , an archive for the structures of all biological macromolecules
(Bernstein et al., 1977; Westbrook et al, 2002), contained in October 2004 about 25000
proteins of known three-dimensional structures, and the number of deposited
experimentally determined protein structures continues to increase exponentially.
Comparison of 3D structures of sequenced proteins revealed that: 1) homologous proteins
show high degree of structural resemblance, and 2) proteins with different sequences (less
than 20% residue identity) can adopt the same fold; i.e. structure is conserved more
extensively than sequence (Lesk & Chothia, 1980; Chothia & Lesk, 1986; Ponting &
Russell, 2002). Also, theoretical calculations estimated the number of distinct structural
folds to be limited to a few thousands (Zhang, 1997). This made homology modelling
possible: a three-dimensional model of a protein sequence is constructed based on known
structures of related proteins. To obtain a reasonable level of accuracy, the sequence
identity between the modelled sequence and at least one known sequence must be higher
than 30%. An analysis of the Protein Data Bank of experimentally determined structures of
proteins reveals that protein pairs with more than 30% pairwise sequence identity (for
alignment length > 80 residues) have homologous three-dimensional core structures, i.e.
the essential fold of the two proteins is identical, but additional loop regions may vary
(Rost & Sander, 1996). In 1999 the best prediction methods based on comparative
modelling could built quite accurate models: <1.5 Å rmsd (root mean square deviation of
Ca positions) if the new protein showed more than 30% identity to the known homolog,
and <4.4 Å rmsd if the new protein showed 17% identity (Sternberg et al., 1999).
Nevertheless, a request in February 2003 at Center for Biological Sequence Analysis
(www.cbs.dtu.dk) for 3D structure of TK1 resulted in following answer: "No similar
sequence found in PDB". However, a similar request in October 2004, retrieved a template
on which a putative model could be build. The template, PDB entry name Iu98, had 33%
3
 at www.rcsb.org/pdb (Research Collaboratory for Structural Bioinformatics)
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identity to TKl, and surprisingly, it was none of the nucleoside kinases with solved 3D
structures (se later), but ATP and DNA binding protein RecA from E. coli. Another
modelling request in October 2004, to a META PredictProtein server of V. Eyrich and B.
Rost (www.predictprotein.org), could not be carried out, because "the degree of similarity
with proteins of known 3D structure may be to low". Still, the META server assigned TKl
to a protein superfamily4 of P-loop containing nucleotide triphosphate hydrolases -
obviously, the P-loop motif is the common denominator.
Overall 3D-structure of TKl
Sequence identity between HSVl-TK and enzymes belonging to the TK2 group is very
low (-10%), despite this, the core structures of HSVl-TK, dGK and Dm-dNK overlap
(Johansson et ah, 2001). The recently solved crystal structure of human dCK (47%
sequence identity with dGK) complexed with dC and ADP shows a fold very similar to
Dm-dNK and dGK (Sabini et al, 2003). It is therefore quite probable that also TKl has a
similar structural fold shared with other nucleoside and nucleoside monophosphate
kinases. This fold consists of three parts: the CORE region that includes the central 5-
pleated parallel P-sheet surrounded by a-helices, the LID region, and the phosphate-
binding region, the P-loop (Fig. 4.5, se also Fig. 4.10 for the open conformation of the
enzyme). Comparison of the topology model of TKl (Fig. 4.4) with the topology and the
solved three-dimensional structure of Dm-dNK (Fig. 4.5) reveals two main differences: 1)
presence of only two helices, a2 and a3, in the right part of the structure, and not five, a2
to a6, as in dNK, and 2) the LID region of Dm-dNK is formed by a7, a8 and the turn
between them, while it seems that a4 and the following turn is the LID region of TKl. The
fold of HSV-1 TK, which has an even bigger subunit of 376 amino acids built of 5 (3-
strands and 12 a-helices (Wild et al., 1997), also shows a clear overlap with dGK and Dm-
dNK (Johansson et al., 2001).
4
 Proteins with significant sequence similarity, and similar structure and function belong to the same protein
family. A strong evolutionary relationship is evident within a protein family (for example the globin family).
If two or more families with little sequence similarity have the same structural motif and functional
similarities they are grouped as superfamily. An evolutionary relationship between the families in a
superfamily is considered probable.
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Lid-region
P-Ioop
Figure 4.5. 3D structure of dNK subunit with bound deoxycytidine and sulfate ion (in yellow, in
ball-and-stick representation. (After Johansson et al., 2001).
The P-loop motif is present between pi and al and forms the phosphate donor site together
with the LID region. In analogy to Dm-åNK and dGK, it might be suggested that a4 of
TKl corresponds to a5 of Dm-dNK, and that the dimers of TKl are formed by two helices
from each subunit: a2 and a3. These two mainly hydrophobic helices contain many P-
branching amino acids, and have been predicted to be involved in dimer formation and
dimer-tetramer transition (Paper II, Frederiksen et al., 2004).
The P-loop of the ATP binding site and binding to the phosphates
The glycine-rich P-loop makes the ATP binding site together with the LID region. The
residues of the loop, GPMFSGKSTEL in the human TKl, form an anion hole that
accommodates the phosphates of ATP. The glycine loop is the most conserved sequence
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among nucleoside and nucleoside monophosphate kinases, presence of amino acids with a
side chain at the positions occupied by glycines would probably collide with the bound
phosphate, and/or make the loop structure to rigid to undergo a conformational change.
The importance of the conserved residues in the P-loop of HSV1 thymidine kinase (amino
acid nr 56-63, sequence: GPHGVGKT) was investigated by Liu & Summers (1988). When
any one of the three glycines was changed to valine, or when lysine was changed to
isoleucine, the corresponding mutant enzyme was inactive. Substitution of threonine by
serine did not abolish the activity, but gave a 4-fold increase of Km for thymidine and a 3-
fold increase of Km for ATP (Liu & Summers, 1988). Interaction of the side chain hydroxyl
groups of serine and/or threonine with Mg2+, as seen in the crystal structures of H-Ras p21
protein (Pai et al., 1990) and in modelling/calculational work on the Mg-binding site of
HSV-1 TK (Kussmann-Gerber et al., 1998) is expected to stabilize binding of the Mg2+ ion
(se later). The invariable lysine makes hydrogen bonds to both p- and y-phosphate groups
of ATP, as shown in the crystal structure of E. coli adenylate kinase (Miiller & Schulz,
1992). Altogether, the P-phosphate makes five hydrogen bonds: three with backbone atoms
of the P-loop, one with the invariable lysine (K13 of the P-loop in E. coli enzyme) and one
with arginine (R123) situated at the beginning of the LID domain. The y-phosphate, which
is transferred during the reaction, is less well bound. It makes only two hydrogen bonds: to
K13 and R123, while a-phosphate makes three hydrogen bonds with the backbone and side
-chain atoms of the P-loop and one with R123 (Miiller & Schulz, 1992). Several types of
NMR experiments (ID proton, 2D - NOESY and COESY) by Byeon et al. (1995) on wild
type and K21R and K21A mutants of adenylate kinase complexed with MgApsA5 provided
evidence that the main function of the invariable lysine is to orient the phosphate chain of
MgATP in proper conformation for catalysis and to ensure interactions between the
substrates and the active site residues. The K13Q substitution in E. coli adenylate
5
 Ap5A, P1,P5-bis(5'-adenosyl)pentaphosphate, a two-substrate-mimicking inhibitor (although ATP and AMP
together have four phosphate groups, their spatial separation seems to be matched by the five phosphate
groups of AP5A).
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Figure 4.6. Sketch of all hydrogen bonds to the phosphate groups and the TMP substrate in the complex of HSV-1 TK with ADP and dTMP according
to Wild et al. (1997).
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kinase resulted in a mutant protem which had greatly reduced catalytic activity (Kcat 0.016
as compared to 305), and produced proton NMR spectra very different from that of the
wild type, suggesting major rearrangements in the protein molecule (Reinstein et al.,
1990). Even conservative replacement of the lysine by arginine resulted in 105 decrease in
the KcJKm value (Byeon et al., 1995). Fig. 4.6 shows the sketch of all hydrogen bonds to
the phosphate groups in the complex of HSV-1 TK with ADP and dTMP according to
Wilder a/. (1997).
ATP interacts with many proteins as a complex with Mg2+ ion. In the early X-ray structure
Mg2+ binding site
2
"
of yeast adenylate kinase with MgAPsA complex, the Mg2+ion was found in proximity to
the phosphates (Egner et al, 1987). An aspartate residue was proposed to coordinate Mg2+
as the reaction proceeds from MgATP to MgADP on the basis of studies combining NMR
and X-ray structure of rabbit muscle ADK (Fry et al, 1986). In the crystal structure of
yeast adenylate kinase the conserved Asp89 (corresponding to the Asp93 in the
mammalian muscle enzyme) was shown to hold Mg2+ ion via two water molecules (Abele
& Schulz, 1995). Experiments with proton NMR indicated that binding of Mg2+ induced
changes in the conformation of AP5A when complexed to WT, but not when complexed to
the D93A mutant (Yan & Tsai, 1991). Similarly, substantial differences in NMR spectra of
WT AKl were found depending on whether the enzyme was combined with AP5A or with
MgAPsA. No such differences were observed in the D93A mutant, suggesting that
Mg2+induced changes in the conformation of WT but not of the D93A mutant (Yan & Tsai,
1991). Kinetically, the substitution D93A resulted in 4-fold higher Km towards MgATP,
and 650-fold decrease in KC3tt. The conclusion was that the carboxylate group of D93 binds
and fixes the Mg2+ ion, which in turn orients the phosphates to proper conformations (Yan
& Tsai, 1991). The same role was assigned to D82 of vaccinia virus TK by mutagenesis
and enzyme kinetics experiments (Black & Hruby, 1992). Modelling/calculational work of
Kussman-Gerber et al. (1998) pointed to D162, together with T63, as the Mg2+ fixing
residue in HSV-1 TK (Fig. 4.7A). Until now there are no crystal structures of HSV-1 TK
containing Mg2+ ion, but crystal structures of Dm-dNK in ternary complex with dTTP and
Mg2+ (Mikkelsen et al, 2003; Fig. 4.7B) and of human dCK in complex with dC, ADP and
Mg2+ (Sabini et al, 2003) have been solved. E127 in dCK (Sabini et al, 2003) aligns with
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El04 in Dm-dNK and with Dl62 of HSV-1 TK (Eriksson et al, 2002). These residues are
similarly placed in the P3 strand of their respective enzymes (Wild et al, 1997; Johansson
et al, 2001), in the ERS motif strictly conserved in dCK, dGK, TK2 and Dm-dNK
(Eriksson et al, 2002). E127 of dCK and E104 of Dw-dNK were shown to coordinate
magnesium in their crystal structures: dCK complexed with ADP, dC and Mg2+ (Sabini et
al, 2003), and Dm-dNK complexed with dTTP and Mg2+ (Mikkelsen et al, 2003; Fig.
4.7B). The analogous and therefore the putative Mg2+ binding residue in human TK2 is
E133, and in human TK1 D97 (Fig. 4.2 and Fig. 4.3). An obvious difference between
human TKl/vacinia TK and HSV-1 TYJDm-dNK is that in the former the Mg2+
coordinating residue is not positioned in the middle of the thymidine binding site (Fig.
4.2).
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Figure 4.7. Mg2" coordination. A. in HSV1 TK resulting from calculations of the most favourable
interaction energies and comparison with ADK structure according to Kussmann-Gerber et al.
(1998). B. to the dTTP phosphate oxygens (to the right), protein atoms and a water molecule in
dTTP interaction with dNK (after Mikkelsen et al., 2003).
LID region and interaction with substrates
The interaction of several conserved LID arginines with the phosphoryl groups of both
substrates was seen in the closed crystal structure of yeast adenylate kinase, complexed
with AP5A (Muller & Schulz, 1992; Abele & Schulz, 1995). In the open structure, the
arginines of the LID could not be reached by the phosphates of ATP. Analogous arginines
are found in motif RvXXRXR (v can be valine, leucine or isoleucine) preserved in
herpesviral thymidine kinases (Balasubramaniam et al, 1990; Gentry, 1992) and in the
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Dm-dNK-dCK-dGK-TK2 family (Johansson et al, 2001). From a kinetic investigation of
point mutants of human AK1, where conserved arginines were replaced with alanyl
residues it was concluded that: R44 (from a2 helix in adenylate kinase, corresponding to
a2 helix in Dm-dNK, and so not in the LED region), R138 and R149 (in the LID) make
closer contact with AMP than with MgATP. R132 (in the LED) makes a similar degree of
contact with both AMP and MgATP, and while R132, R138 and R149 are important for
catalytic activity (mutants show substantial decrease in Kcat), R44 is probably involved in
AMP binding only, and not in catalysis (Kim et al, 1990). Two conserved aspartates,
D140 and D141 in the chicken muscle adenylate kinase (the same numbering as in the
human enzyme) were shown to form salt bridges to R132 and R138, and in this way to
assist the arginines in stabilizing the transition state (Dahnke & Tsai, 1994). Also, several
lysines conserved in mammalian species of ADK were shown to be essential for catalytic
efficiency of the enzyme through interaction with both MgATP and AMP substrates
(Ayabe et al, 1997). The analogous arginines in uridylate kinase (UMPK) have been
shown to interact with the y-phosphate of ATP (Schlichting & Reinstein, 1997). When
compared to AMPK or UMPK the eukaryotic thymidylate kinase contains two fewer
arginine residues that can interact with the transferred phosphoryl groups (Ostermann et
al, 2000), and because activity of the isolated human TMPK is low, the authors speculate
that an additional factor/protein may supply further catalytic residues and accelerate
enzymatic reaction in the cell (Ostermann et al, 2000 compare this situation to p21ras
where GTPase-activating protein GAP, in addition to assembling the residues at the active
site, provides a catalytic residue). Alternatively, at least in the yeast thymidylate kinase, an
arginine residue present in the P-loop could make hydrogen bonds to the phosphoryl
groups (Lavie et al, 1998). Similarly to the thymidylate kinase, the putative LED region of
the human TK1 has two arginines only, R158 and R165 (Fig. 4.2 and Fig. 4.3). The
hydrogen bonds to the phosphates could then be supplied by R38, R39, R41 and R42
present in the al-helix, just next to the P-loop and in the proximity of the reaction centre.
The adenine and ribose of ATP were found not to bind very tightly in several crystal
structures of adenylate kinases (Miiller & Schulz, 1992; Muller-Dieckmann & Schulz,
1994; Abele & Schulz, 1995). The ribose probably does not interact with any protein atom
directly, but rather is stabilized by several water molecules in the crystal structure of
deoxyguanylate kinase (Sekulic et al, 2002). Similarly, in the crystal structure of Herpes
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simplex virus type 1 thymidine kinase, the adenine ring of ATP was found to be
sandwiched between a strongly conserved arginine (R216) and a glutamine (Q331), and so
to make only minimal contacts with the enzyme (Evans et al, 1998). Q331 makes the
single hydrogen bond to the adenosine moiety of ATP, while ribose makes none (Wild et
al, 1997; Fig. 4.6). The weak binding of the adenosine moiety to HSV-1 TK is reflected in
a rather high Km value for ATP of 70 uM (Wild et al, 1997).
In summary, the phosphate donor ATP binding site was found to be very similar in HSV-1
TK and in adenylate kinase, as well as in other so far investigated nucleoside and
nucleotide kinases. The catalytic transfer of a phosphate group to the substrate must then
occur at very similar sites and involve similar amino acid residues. A view of the binding
pattern of ATP in HSV1-TK is shown in Fig. 4.6.
The thymidine binding site
The binding site for the phosphate accepting substrate must be responsible for the substrate
specificity of the enzyme. NMP kinases interact extensively with their NMP substrates
what results in specificity towards the base of the phosphate acceptors. The adenine moiety
of AMP for example, is fixed by as many as five hydrogen bonds in the AMP binding
pocket of adenylate kinases (Yan & Tsai, 1999). Substitution of some critical residues may
result not only in decreased catalytic efficiency but also in alteration of NMP specificity.
For example, replacement of conservative residues that make hydrogen bonds to the
adenme ring (T39 and Q101 of the chicken muscle adenylate kinase) by alanine, caused
remarkable increases in activities (KcJKm) for UMP and CMP with concomitant decrease
in activity-with AMP (Okajima et al., 1993a; Okajima et al, 1993b). Recent results of
Knecht et al. (2002b) have shown that in Drosophila melanogaster a few amino acid
substitutions convert deoxyribonucleoside kinase specificity from pyrimidines to purines.
The specificity of thymidylate kinase became obvious when its crystal structure was
solved: the cavity in which the base of dTMP was bound was too small to accommodate
purine bases, which limited specificity to pyrimidines (Lavie et al, 1997). A hydrogen
bond between O4 of the thymidine base and a conserved arginine (R73 in the human
thymidylate kinase) favoured thymidine and uracil over cytosine (Lavie et al, 1997).
During the 1990s several studies elucidated the importance of amino acid residues at the
nucleoside binding site of HSV1 TK (Munir et al, 1992; Munir et al, 1994; Black &
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Loeb, 1993; Michael et al, 1994; Michael et al, 1995; Black et al., 1996; Pilger et al,
1999). After 1995 these data could be supported by several crystal structures (Brown et al.,
1995; Wild et al, 1995; Wild et al, 1997). The recently solved structures of Drosophila
deoxyribonucleoside kinase, .Dm-dNK, and of the human deoxyguanosine kinase, dGK,
have explained the structure-function relationship regarding the specificity of the
phosphate accepting substrate (Johansson et al, 2001). The wider substrate cleft of Dm-
dNK dominated by hydrophobic residues results in its broad substrate specificity, while the
strict purine specificity of dGK is explained by its tighter binding pocket containing
charged residues, and especially R118, which provides hydrogen bonding interaction with
the N7 and 06 of the purine ring (Johansson et al, 2001).
The substrate clefts in Drø-dNK, dGK and HSV1-TK have some common features: a
conserved Q (Q81, Q l l l and Q125 respectively) residue makes hydrogen bond to the
base, a conserved E-Y couple (E172-Y70, E211-Y100 and E225-Y101 respectively) makes
hydrogen bonds to the 3'OH moiety of the sugar, and a conserved E-R couple (E52-R169,
E70-R208 and E83-R222 respectively) makes hydrogen bonds to the 5'OH of the sugar
(Johansson et al, 2001; se also Fig. 4.6 and Fig. 4.8).
The substrate binding site of Herpes simplex thymidine kinase is composed of amino acid
side-chains derived primarily from a set of roughly parallel helices: a2 (residues 85-89), a3
(residues 96-108), a4 (residues 114-130) and a6 (residues 171-178) (Evans et al, 1998).
The way in which thymidine kinase of Herpes simplex virus accommodates its substrate
has been elegantly summarized by Sulpizi et al. (2001). Their description and the
accompanying figure (Fig. 4.8) is based on both theoretical quantum-mechanical
calculations (Alber et al, 1998) and experimental approaches (Brown et al, 1995; Wild et
al, 1995; Wild et al, 1997; Kussmann-Gerber et al, 1998; Champness et al, 1998;
Bennett et al, 1999; Prota et al, 2000).
Figure 4.8. Structure for the HSV-1 thymidine kinase active site. PI and P2 accomodate the
nucleobase and the sugar moiety respectively. The water molecules are shown as red spheres, and
the hydrogen bonds are depicted as dotted lines. Thymidine and amino acids are displayed as
capped sticks The colour code is: orange, carbon; red, oxygen; blue, nitrogen; yellow, sulfur.
Reproduced from Sulpizi et al. (2001).
Sulpizi et al. (2001) divide the thymidine binding site into two pockets, PI and P2. In PI,
the nucleobase moiety is stabilized by two hydrogen bonds (Fig. 4.6 and Fig. 4.8) with the
highly conserved Q125 from the interface helix a4, and by means of two water molecules
with R176 from helix a6 (Kussmann-Gerber et al., 1998). The thymine is further fixed in a
sandwich-like orientation by Y172 from helix a6 and Ml28 from helix a4 (Alber et al.,
1998; Wild et al, 1997; Kussmann-Gerber et ah, 1998), and also in close proximity to
A168 (Kussmann-Gerber et al., 1998), found just before helix a6. Modulation of the
residue size at position 128 had a direct impact on binding affinity: Ml28A had no
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biological activity, indicating that the small alanine side chain is not sufficient to stabilize
the thymine within the active site (Pilger et ah, 1999). Similarly, exchange of A168 for a
bigger threonine resulted in dramatic reduction in the affinity of the enzyme for substrate
analogues carrying bulky substitutions on the C5, such as BVdU (E-5-bromovinyl-2'-
deoxyuridine) (Darby et ah, 1986). Phenotypically A168T mutant of HSV1 TK resembles
that of HSV2 strain which has A168S substitution (Darby et ah, 1986; Wild et ah, 1997).
In the crystal structure of HSV1 TK wild type enzyme the bound deoxythymidine was
observed to leave a 35 Å3 cavity close to C5 position of the base, and two water molecules
close to position C2. It is proposed that the cavity and water molecules reduce substrate
specificity to such an extent that TK can phosphorylate analogues with modified ribose and
various thymine, guanine (Wild et ah, 1997) and adenine (Vogt et ah, 2000) analogues.
The second pocket in the thymidine binding site, P2 (Sulpizi et ah (2001; Fig. 4.8)
accommodates the sugar moiety of the nucleoside. The 3'-OH forms specific H bonds with
Y101 from helix <x3 (aa 96-108) and with E225 that comes from a loop in the LID region
comprising residues 219-226, whereas 5'-OH forms a direct H-bond or water-mediated
interaction with R163 (positioned just before helix a6), E83 (positioned prior to helix a2)
and R222 (positioned as E225 in the LID) (Fig. 4.8). The importance of E225 for catalysis
was demonstrated in mutant E225L which showed 60-fold increase in ^ m toward
thymidine and 20-fold decrease in KC3X (Pilger et ah, 1999). The O-4' of the sugar ring
(positioned between C-l'and C-4') does not interact with polar or charged groups of the
protein but points toward hydrophobic environment of side chains of W88,197 and Ml28
(Sulpizi et ah, 2001). From modelling and energy calculations of enzyme-substrate
complexes De Winter & Herdewijn (1996) concluded that more than 80% of the total
interaction energy between HSV1-TK and thymidine comes from the interaction with only
six residues, namely the already mentioned four hydrogen bond partners E83, Y101, Q125
and E225, and residues M128 and Y172 which sandwich the nucleobase by means of
stacking interactions. This strong binding of thymidine is in agreement with its low Km
value of 0.2 uM (Michael et ah, 1995) and with its location deeply in the binding pocket
(Champness et ah, 1998).
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The reaction mechanism
Transfer of y-phosphate from ATP to 5'-OH of deoxynucleoside is believed to involve a
nucleophilic attack of the activated 5'-OH group on the y-phosphate of the phosphate
donor. E52 in Dm-dNK (Johansson et al, 2001) and the corresponding E83 in HSV-1 TK
(Wild et al, 1997) supply the carboxylate group in the vicinity of the 5'-OH at the active
site of the enzyme. The residues are suggested to act as a base that deprotonates 5'-OH and
makes the nucleophilic attack possible (Fig. 4.9). The proximity of positive charges from
arginines and the Mg2+makes the phosphorus atom more electrophilic.
Figure. 4.9. The mechanism of action of the deoxyribonucleoside kinases. The phosphate donor
ATP is to the left and the substrate dG to the right. Glu is suggested to act as a general base and
Mg2+ as a counter ion. After Eriksson et al. (2002).
The catalytic glutamates in deoxynucleoside kinases with solved 3D structure, E52 in Dm-
dNK, E70 in dGK and E83 in HSV1 TK are all placed either at the end of the p2 strand
(Johansson et al, 2001) or just after the p2 strand (Wild et al, 1997). D58 in the human
TK1 could then be the active base that deprotonates 5'-OH group (Fig. 4.3).
Conformational changes during catalysis
After elucidation of several structures of adenylate kinases (Pai et al, 1977; Fry et al.,
1986; Diederichs & Schulz, 1990; Schulz et al, 1990; Schlauderer et al, 1996), uridylate
kinase (Muller-Dieckmann & Schulz, 1994; 1995) and guanylate kinase (Blaszczyk et al,
2001; Sekulic et al, 2002) with and without bound ligands it became clear that nucleotide
kinases undergo large conformational changes during the catalytic cycle. Adenylate kinase
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Figure 4.10. Conformatioal changes in adenylate kinase upon bnding of ATP (in ball and stick
representation). P-loop is shown in green and the LID domain in yellow. Reproduced from
Biochemistry, Berg et al. (eds.), 2002.
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became a classic example of induced fit: binding of ATP induced closure of the P-loop on
top of the polyphosphate chain and extensive interaction with the P-phosphoryl group (Fig.
4.10). NMR experiments of Fry et al (1986) estimated that binding of the MgATP
substrate involves displacement of the P-loop by 6 Å, much larger than changes in the
other regions of the adenylate kinase. This movement of the P-loop permits the LID
domain to move down over the bound ATP. On LID closure, its conserved aspartates form
salt bridges with conserved arginines that in turn fix the phosphoryl groups, so that ATP's
y-phosphate is kept in position close to the phosphate acceptor site. Binding of the second
substrate induces additional conformational changes that make possible transfer of the
phosphoryl group from donor to acceptor, and not to water. Various intermediate states of
the movements performed by adenylate kinase during catalysis, starting with substrate-free
crystals, in complex with only one substrate, both substrates, or the bisubstrate inhibitor
AP5A, have been frozen and put together in a video (Vonrhein et al, 1995). The thymidine
kinase of Herpes simplex virus (HSV1) was also shown to exhibit similar structural
movements on binding of thymidine and ATP (Perozzo et al, 2000 - isothermal titration
calorimetry study; Wurth et al, 2001 - thermal denaturation and circular dichroism study).
The interface architecture
While most NMP kinases are monomeric, the thymidine/thymidylate kinase of Herpes
simplex virus exists as a homodimer, and the structure of its dimer interface has been
determined (Wild et al., 1995; 1997; Evans et al, 1998). The interface is dominated by
helices a4, a6 and alO which participate fully and a2 and al2 which are partially involved
(Wild et al, 1997). The contacts include both hydrogen bonds and hydrophobic
interactions and the closest monomer-monomer contacts involve: Q185 to L91 and G92,
VI19 to VI19 and S123, and N306 and V307 to E371 (Evans et al, 1998). The bulk side
chain of tryptophan W310 was found to protrude from one monomer face into the
opposing monomer and to make mostly hydrophobic interactions as its five-membered ring
was exposed to solvent. The polar contacts between N306 in one monomer and E371 in the
other monomer reinforced the hydrophobic interactions. Additional monomer-monomer
contacts were mediated by water molecules (Evans et al, 1998). The interface of HSV-1
TK was found to be exceptionally non-polar, with 65% hydrophobic, 26% polar and 9%
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ionogenic residues (Wild et ah, 1997), as compared to the average amino acid composition
of interfaces of 32 different protein dimers (Jones & Thornton, 1995).
The dimer interfaces of dNK and dGK are very similar (Johansson et al., 2001).
Hydrophobic residues from helices a4 and a6 interact and form a four-helix bundle at the
dimer interface. In dNK these residues include four aromatic, four aliphatic and four small
residues from each subunit, whereas in dGK they contain several aromatic residues
(Johansson et al., 2001; Fig. 4.11).
Figure 4.11. dNK dimer: hydrophobic residues from helices a4 and a6 in each subunit interact
forming a four-helix bundle at the dimer interface. After Johansson et al. (2001).
As mentioned earlier, al and a3 helices (residues 83-85 and 104-113 respectively) of
human TKl presumably correspond to the interface of Dm-dNK, and so to the interface of
HSV-1 TK as well. Besides, these two helices align to ct4 of HSV1-TK in Clustal W, and
to residues 78-98 of vaccinia TK (Fig. 4.1). The D89IVEFCERMA segment of vaccinia TK
was predicted to be an a helix by circular dichroism (Behrends et al., 1996), and a
conserved glycine, G84, was shown to be involved in structural integrity of the enzyme, as
G84V mutant lost both enzymatic activity and tetrameric conformation (Black & Hruby,
1992). The structure of the putative interface of human TKl and the importance of residue
106 for the enzyme kinetics and conformation are investigated in details in the next
chapters.
PART II
EXPERIMENTAL WORK
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Chapter 5
Materials and methods
E. coli bacterial strains and their growth
KY895: F , tdk-1, ilv, a thymidine kinase-deficient derivative of E. coli strain K12
(Igarashi et al, 1967; Hiraga et al., 1967) and BL21: F~ ompT, hsdS (rB~, mf), gal
(Amersham Pharmacia Biotech) were used for propagation of plasmids and expression of
recombinant protein. BL21 is a B strain of E. coli that is naturally deficient in Lon protease
and lacks the endoprotease OmpT due to ompT gene deletion (Grodberg & Dunn, 1988).
The strains were grown in LB medium at 37°C (unless indicated otherwise) and with 50
ug/ml ampicillin for the plasmid containing strains.
Epicurian Coli XLl-Blue supercompetent cells: recAl, endAl, gyrA96, thi-1, hsdR17,
supE44, relAl, lac[F', proAB, lacIaZbM15, TnlO (tetR)] (Stratagene) were used for
transformation of DNA after site directed mutagenesis. Epicurian Coli have much higher
transformation efficiency than the parental strains thanks to EndA phenotype. The strain
was grown in NZY+ (casein hydrolysate with yeast extract broth) and treated according to
the instructions from the supplier.
MT102: MCI000, r m+, MacX74 A(ara-leu)7697 strA (from Ole Skovgaard, originally
from Mogens Trier Hansen, Novo) was used for transformation of ligation mixtures.
DH5« max efficiency competent cells: F~, <p80d/acZAM15 A(lacZYA-argF) recAl endAl
thi-1 (Life Technologies, now Invitrogen) were used by Tina Kristensen for transformation
of recombinant PCR products in construction of pGEX-2T-TKlA40 and TK1A60 deletion
mutants (se later; Kristensen, 1996).
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pGEX-2T plasmid vector
pGEX-2T is a pBR322 derivative that contains the ampicillin resistance gene, and it directs
synthesis of foreign proteins as fusions to a glutathione S-transferase (GST) encoded by
the parasitic helminth Schistosoma japonicum (Smith & Johnson, 1988). The vector is
engineered so that the desired protein is fused to GST via a thrombin recognition site. The
cloned gene is introduced into the multiple cloning site situated downstream of the coding
sequence for thrombin cleavage site, and the cloned protein can be cleaved from the GST
partner with thrombin (Smith & Johnson, 1988). Thrombin cleavage yields the desired
protein with 2 additional amino acids (G and S) at its N-terminus, resulting from the
thrombin recognition sequence (LVPR^GS). The expression of the fusion protein is under
control of lacIQ, that synthesizes 10 times more Lac repressor than the wild type lad gene,
and under control of an IPTG-inducible tac promoter, a hybrid composed of trp and lac
promoter sequences (de Boer et ah, 1983). pGEX-2T was purchased from Amersham
Pharmacia Biotech and is shown in Fig.5.1.
Thrombin
Leu Val Pro Aro^Gly Ser I Pro Gly lie His Ara Asp
CT6 6TT CCG CGTGGA TCCCCG G.GA ATT CAT CGT GAC TGA CTG AGG
BamHI
 S m a | EcoRI Slop codons I
AivvN I
BstE II
Miu I
Figure 5.1. Map of the glutathione S-transferase pGEX-2T fusion vector. From GST Gene Fusion
System Manual, Pharmacia Biotech (1997).
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Recombinant plasmids
The following section describes construction of several recombinant plasmids. All
numbering used is according to Bradshaw & Deininger (1984), where the translation
initiation is at position 58, and therefore codon for amino acid 106 starts at base number
373. The altered bases are in bold type and the restriction sites, if introduced, are in italics.
Construction of pGEX-2T-TKl
pGEX-2T-TKl contains amino acid coding region of TK1 from normal human
lymphocytes. This plasmid was constructed by Dr. Hofbauer (Vienna Biocenter, Austria)
and Dr. Folkers (Swiss Federal Institute of Technology, Zurich, Switzerland), and the
construction procedure has been described in detail (Paper I, Berenstein et al., 2000). For
insertion into the BamHVEcoRl restriction sites of pGEX-2T and introduction of the
thrombin cleavage site between the GST and the TK1 proteins, it was necessary to modify
the N-terminal of TK1 to start with GSMCS instead of MCS and the C-terminal to end
with ILQCMQA instead of ILQCSPAN. Neither the first 10 N-terminal amino acids, nor
the C-terminal amino acids are evolutionary conserved and were therefore expected to be
without importance. This expectation was confirmed by the experimental results.
The plasmid pGEX-2T-TKl is the same as pGEX-2T-TKlVa1106, the latter designation is
used to stress that the TK1 coding sequence contains the code for valine at amino acid
position 106.
Construction of pGEX-2T-TKlMet106
Two pGEX-2T-TKlMet106 plasmids have been constructed in our laboratory using pGEX-
2T-TKlVa1106 as the template DNA.. The codon GTG for valine corresponding to amino
acid position 106 was replaced by codon ATG for methionine using the QuickChange™
site directed mutagenesis kit from Stratagene according to the protocol supplied. This
mutagenesis method utilizes PfuTurbo™ DNA polymerase for high fidelity replication and
the DNA methylation-specific Dpnl endonuclease to digest the parental DNA template.
The cycling conditions were: 16 cycles, 95°C for 30 seconds, 55°C for 1 minute, and 68°C
for 10 minutes in 50 ul volume. Construction of the first pGEX-2T-TKlMet106 plasmid,
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here referred to as pGEX-2T-TKlMetl06A, was performed by a student project group
(Mørch & Petersen, 1997) with the following primers: sense primer
5'-TTCCCTGACATCATGGÆ4rrCTGCGAGGCC(361-390)-3', and the antisense primer
5'-GGCCTCGCAGÆ4rrCCATGATGTCAGGGAA(390-361)-3'. The ATG codon
replacing GTG at position corresponding to amino acid 106 is underlined. The base
changes G to A in the sense primer and C to T in the antisense primer wee introduced in
order to get a control EcoRl restriction site without changing the amino acid.
Construction of the second pGEX-2T-TKlMet106, that did not contain a restriction site, here
referred to as pGEX-2T-TKlMetl06B, was performed by H. Frederiksen (at that time a
master student in our lab.) and me with the following primers: sense primer 5'-
TTTTTCCCTGACATCATGGAATTCTGCGAGGCC(358-390)-3', and antisense primer
5'-GGCCTCGCAGAATTCCATGATGTCAGGGAAAAA(390-358)-3'. We judged that
introduction of an extra base change and generation of a control restriction site was not
necessary due to the high efficiency of generation of the correct mutants by the
QuickChange™ site directed mutagenesis kit. We also believe that properties of
TK1Meti06A a n d TK1Metio6B ^ t h e s a m e and t h e r e f o r e a l j o u r in vitro r e s u l t s are directly
comparable.
Construction of pGEX-2T-TKlVall06X mutants
The plasmid pGEX-2T-LyTKlVa1106 was used as template DNA in PCR reactions, and
mutations into the GTG codon coding for valine 106 were introduced with the Quick
Change™ site-directed mutagenesis kit from Stratagene (according to the instructions of
the manufacturer).
The sense 5'-TTTTTCCCTGACATCGTGGAGTTCTGCGAGGCC(358-390)-3' and
antisense 5'-GGCCTCGCAGAACTCCACGATGTCAGGGAAAAA(390-358)-3'
mutagenic primers were substituted as follows in the target codon for Val-106
(underlined): GCG/CGC for Ala-106, CAG/CTG for Gln-106, GGT/ACC for Gly-106,
CAC/GTG for His-106, ATC/GAT for Ile-106, CTG/CAG for Leu-106, AAA/TTT for
Lys-106, ATG/CAT for Met-106 and ACC/GGT for Thr-106. The codons are given in
sense/antisense primer respectively. The resulting recombinant enzymes were designated
V106A, V106Q, V106G, V106H, V106I, V106L, V106K, V106M, V106T, and rLy-
TKlVa1106 was designated V106WT.
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Construction of pGEX-2T-TKl66136(Val l06)
PCR reaction
Plasmid pGEX-2T-TKl was used as a template in a PCR reaction with a sense primer:
5'- GGGGG^rCCTGCACACATGACCGGAACACC(247-273)-3' designed to contain a
GGG overhang, and an antisense primer:
5 '-CGGCACCGÆ4 JTCTAGATGGCCCCAAATGGCTTCCT(480-445V3'.
BamRl restriction site was introduced to the sense primer, and EcoRl restriction site and an
UAG stop codon (underlined) to the antisense primer. Reactions were run under following
conditions: 30 cycles, 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min in 25 ul volume
with Thermus aquaticus DNA polymerase (Stratagene), and contained 4 |ig/ml template
DNA, 3mM MgCl2, 0.2 mM of each dNTP and 0.36 jiM of each primer in 10 mM Tris-
HC1 buffer (pH 8.3). Two PCR reactions were run independently of each other.
Purification of the PCR products
The PCR product was run on 1.5% TAE agarose. The DNA fragments of the right size
were purified by freezing the agarose block and extracting the water phase with phenol.
DNA was then ethanol precipitated, resuspended in E-buffer and visualized on 1% TBE
agarose gel. The concentration of DNA was at this stage about lng/ul.
Ligation of the PCR product with the pGEX-2T vector and transformation into competent
E.coUMT102
pGEX-2T and the PCR product were separately digested with BamBl and EcoRl, mixed at
the insert: vector ratio of 2 : 1, and ligated with T4 ligase at 16°C over night. The ligation
mixture was transformed into competent MT102 strain.
Screening the transformants for the insert
The transformants were grown up in LB with 100 ng/ml ampicillin and plasmids isolated
with Wizard Plus Minipreps (Promega). The plasmid DNA was digested with BamRl and
Pstl in order to estimate the size of the insert (the pGEX-2T vector has one restriction site
for BamRl at position 930 and one restriction site for Pstl at position 1897, so the digested
vector without insert will give a fragment of 967 base pairs and a fragment of about 4000
base pairs. Because the coding region of the cloned interface was about 220 base pairs,
fragments of about 1190 base pairs and 4000 base pairs were expected). Plasmid minipreps
from 26 transformants obtained in the first PCR reaction have shown 25 transformant
without any insert, and 1 transformant that gave fragments of 1090 base pairs and 4000
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base pairs. Sequencing of the clone has shown a G to A mutation at base position 378,
resulting in a sequence GTGGÆ47rC(373-381) with an EcoKL restriction site about 100
bases earlier than designed. The resulting clone had no AUG stop signal, and was missing
over 30 amino acids.
BamHUPstl digestion of plasmid DNA from 20 transformants obtained in the second PCR
reaction, resulted in 4 clones with the correct insert size, but subsequent sequencing of the
clones has shown no UAG stop signal, nor the expected EcoRl recognition site, but the
original template sequence. Because, with the exception of the stop signal, the sequence of
the clones was correct, I have decided to introduce the UAG stop signal to one of the
clones instead of the codon CTG(466-468) by site directed mutagenesis.
Site directed mutagenesis
Site directed mutagenesis was performed with "QuickChange™ Site-Directed Mutagenesis
Kit". (Stratagene) according to the manufacturers instructions. This mutagenesis method
makes use of PfuTurbo™ DNA polymerase which has 6-fold higher fidelity in DNA
synthesis than Taq DNA polymerase. Following mutagenic primers were used: sense
primer: 5'-CCATTTGGGGCCATCTAGAACCTGGTGCCGCTG(451-483)-3' and
antisense primer: 5'-CAGCGGCACCAGGTTCTAGATGGCCCCAAATGG(483-451)-3'.
The stop codon is underlined. Plasmid DNA was prepared and sequenced from 10
Epicurian Coli XL-1-Blue transformants, 9 of the clones had the correct base sequence.
One of the correct clones was used to transform KY895 (se below).
Construction of pGEX-2T-TKl66136(Met l06)
The codon GTG at positions 373-375 (underlined), corresponding to amino acid 106, was
mutated to ATG by the "QuickChange™ Site-Directed Mutagenesis Kit" (Stratagene) with
following primers : sense primer:
5'-CAGTTTTTCCCTGACATCATGGAGTTCTGCGAGGCCATG(355-393)-3'
and antisense primer:
5'-CATGGCCTCGCAGAACTCCATGATGTCAGGGAAAAACTG(393-355)-3\
The potentially correct plasmids were transformed into Epicurian Coli XLl-Blue
supercompetent cells, plasmids were re-isolated, transformed into BL21 and sequenced.
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Construction of pGEX-2T-TKlA40 and pGEX-2TA60
The two plasmids have been constructed by Tina Kristensen, a former Ph.D. student at our
lab. Because the cloning procedure has not been published, I will describe it shortly here.
The method used was recombination PCR for site-specific mutagenesis developed by
Jones & Howard (1991) and Jones & Winistorfer (1992). For each mutant two separate
PCR reactions were run with pGEX-2T-TKl template (Fig. 5.2). Each PCR reaction
employed a mutagenic primer (primer 1 and primer 3 respectively), which introduced a
stop codon and a control Sad restriction site, and a non-mutagenic primer used to delimit
the amplified fragment (primer 2 and primer 4). The primer set in the second reaction was
complementary in base sequence and antiparallel to the primer set in the first reaction, so
that ends of one PCR product were homologous to the ends of the other PCR product (Fig.
5.2). The recombinant of interest resulted from recombination in vivo.
TK1 cDNA
PCR
TKl cDNA
PCR
Transform
E. coli
In vivo
recombination
Figure 5.2. A sketch of recombination PCR. Numbering refers to the number of primer.
Mismatches are indicated by filled triangles. The two PCR reactions result in two fragments with
homologous ends. After Jones & Winistorfer (1992) and Kristensen (1996).
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Following mutagenic primers were used: sense primer
5'-TACTTCAAGAAGGCCIG4GCrCAGCCTCCGGGCCG(622-657)-3' and antisense
primer: 5'-CGGCCCGGCAGGCTGv4GC7jCAGGCCTTCTTGAAGTA(657-622)-3' to
construct pGEX-2T-TKlA40, and sense primer:
5'-GTCGAGGTGATTGGGTG4GCrCACAAGTACCACTCC(571-606)-3' and antisense
primer: 5' -GGAGTGGT ACTTGTO4 GCTCACCC AATC ACCTCGAC(606-571 )-3' to
construct pGEX-2T-TKlA60. The stop codon is underlined, Sad restriction site is in
italics. The non-mutagenic primers were:
sense primer: 5'-CTTATCAGACCGTTTCCCGCGTGG(3343-3366) and
antisense primer:5'-CCACGCGGGAAACGGTCTGATAAG(3366-3343). The numbering
of the non-mutagenic primers refers to the numbering of pGEX-2T bases according to
Pharmacia Biotech.
The PCR reactions were run in a total volume of 50 ul at following conditions: 0.24 ug/ml
linearized template DNA, 0.36 uM of each primer, 200 uM of each dNTP, 1.5 mM MgCl2,
1.5 units Thermus aquaticus DNA polymerase in Tris-HCl buffer (pH 8.3) containing 50
mM KC1, 0.015% gelatine and 0.1% Tween 20; 30 cycles; 1 min at 95 C, 1 min at 58 C
and 3.5 min at 72 C. The PCR products were purified from low-melting agarose gel and
used to transform DH5a competent cells according to the instructions of the vendor (Gibco
BRL/Life Technologies). The potentially correct plasmids were transformed into E. coli
KY895 and sequenced on both strands with Sequenase™ version 2.0 DNA Sequencing Kit
(United States Biochemical).
Transformation into E. coli
Transformation into Epicurian Coli XLl-Blue Supercompetent Cells
The PCR products obtained by the Quick Change™ site-directed mutagenesis kit were,
according to the manufacturers instructions, digested with the Dpnl restriction enzyme in
order to get rid off the methylated, non-mutated parental DNA. The nicked, digested
plasmid DNA was then transformed into Epicurian Coli XLl-Blue Supercompetent cells
and plated on LB-ampicillin plates according to the manufacturers transformation protocol.
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Transformation into E. coli BL21
Plasmid DNA was prepared from Epicurian Coli XL1 clones obtained by the
QuickChange™ site directed mutagenesis procedure, and transformed into E. coli BL21
by CaCl2 standard method. After propagation in E. coli BL21, plasmid DNA was isolated
by the Wizard kit (Promega) and sequenced.
Transformation into£. co//MT102
MT102 was made competent by CaC^ standard method, and used for transformation of
ligation mixtures. Transformation reactions were spread on LB plates containing 100
ug/ml ampicillin.
Transformation into E. coli KY895
KY895 was made competent by CaCb standard method and transformed with pGEX-2T-
TK166-i36(Vaiio6) p l a s m i d D N A from one of the clones coding for the correct putative
interface sequence. The strain containing this plasmid was named KY895(pGEX-2T-
66-136(Val 106^
DNA sequencing
pGEX-2T-TKlVa1106, pGEX-2T-TKlMetl06A and pGEX-2T-TKl66"136(Vall06) plasmids were
sequenced on both strands by the 2',3'-dideoxynucleoside 5'-triphosphates (ddNTP) chain-
termination method according to the "Step-By-Step Protocols for DNA Sequencing with
Sequenase Version 2.0 T7 DNA Polymerase" (United States Biochemical) with
"Sequenase™ Version 2.0 DNA Sequencing Kit" (United States Biochemical), and with
[a-35S]-dATP (Amersham Pharmacia Biotech).
Plasmids pGEX-2T-TKlVa1106, pGEX-2T-TKlMetl06B, pGEX-2T-TKlVall06X andpGEX-2T-
TK166-i36(Metio6) w e r e s e q u e n c e ( } o n both strands by the ddNTP chain termination method
with "Thermo Sequenase radiolabeled terminator cycle sequencing kit" (Amersham
Biosciences) according to the instructions of the manufacturer. This kit uses four [a-33P]
dideoxynucleotide terminators (ddNTPs), so the radioactive label is incorporated at the
3'end of only properly terminated sequencing reaction products.
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Expression of recombinant proteins
Expression of recombinant TK1 enzymes
BL21(pGEX-2T-TKl) bacterial cultures were grown overnight at 37°C, diluted to A6oo =
0.6 into LB medium with 50 ug/ml ampicillin and adjusted to room temperature at the
laboratory bench. Expression of the GST-TK1 fusion proteins was induced with 0.1 mM
IPTG for 6 hours at 25°C and strong aeration. The bacterial cultures were centrifuged at
4°C and the pellet stored at -80°C.
Expression of recombinant XKl66"136 proteins
KY895(pGEX-2T-TKl66"136(Vall06)) and BL21(pGEX-2T-TKl66-136(Metl06)) were grown
overnight at 37°C in LB medium with 100|ig/ml ampicillin. (The switch to BL21 as the
host strain for the expression of the recombinant protein was due to the possibility of
obtaining higher protein yield; the decision was taken after the experiments with TK166"
i36(Vaii06)
 w e r e finished.) The overnight bacterial cultures were diluted into fresh medium to
A6oo - 0.6 and left at the laboratory bench for temperature adjustment. They were then
grown overnight (KY895 strains) or for approximately 6 hours (BL21 strains) at 25°C with
strong aeration and in the presence of 0.1 mM IPTG (Sigma) to induce the GST fusion
protein. The cells were harvested by centrifugation and stored at -*• 80°C.
Purification of recombinant TK1 enzymes and XKI66"136 proteins
Lysis of bacterial cells and preparation of crude bacterial extract
The bacterial pellet was resuspended in 1/20 of the original culture volume in lysis buffer
(buffer A: 20 mM Tris-HCl, pH 7.5, 5 mM EDTA, 1 mM DTT, 10% glycerol, 1% Triton
X-100, 0.1 mM PMSF, 5 mM benzamidine and 50 mM s-aminocaproic acid) and disrupted
in French Press (SLM Aminco). The bacterial lysate was centrifuged at 4°C for 20 min and
filtered through Whatman GF/C glass micro fibre filter and MFS cellulose acetate 0.45 urn
filter in order to remove bacterial debris.
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Glutathione Sepharose chromatography
Glutathione Sepharose 4B beads (Amersham Biosciences) were home-packed into 25 mm
x 200 mm column and pre-equilibrated at 4° C with PBS, phosphate-buffered saline (140
mM NaCl, 2.7 mM KC1, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.3) containing 1 mM
DTT, 10% glycerol, 1% Triton X-100, 0.1 mM PMSF, 5 mM benzamidin and 50 mM e-
aminocaproic acid (so called PBS wash buffer, or buffer B). The bacterial filtrate was
slowly applied to the column and the unbound proteins were removed by washing with 10-
20 volumes of wash buffer. Thereafter, the column was equilibrated with phosphate-
buffered saline with 0.1% Triton X-100, and moved to room temperature. The fusion
protein was cleaved at room temperature for 1.5-2 hours by recirculation of 1 bed volume
PBS containing 0.1% Triton X-100 and 50 units/ml thrombin (Amersham Biosciences).
The eluate was continuously collected on ice and was named cleavage fraction 1 (cl.#l).
After the cl.#l was collected, the column was washed 4 times with one column volume of
phosphate-buffered saline containing 0.1% Triton X-100. The fractions were collected on
ice and named consecutively cl.#2 to cl.#5. After addition of 10% glycerol, 5 mM DTT, 5
mM MgCh and 1% Triton X-100, the thrombin cleavage fractions were stored at -80°C.
For kinetic and stability experiments where TKlVa1106, TKlMet106 and TK1A40 are
compared, the proteins were desalted by G-25 chromatography and purified further by CM
Sepharose chromatography.
Sephadex G-25 chromatography
G-25 Sephadex column (Amersham Biosciences) was equilibrated with buffer C: 10 mM
K-phosphate buffer, pH 6.0, containing 5 mM MgCl2, 2 mM DTT, 0.5 mM Chaps and
10% glycerol. Thrombin cleavage fractions were applied to the column and eluted with the
same buffer. Protein concentration and conductivity of the eluate was continuously
monitored.
CM-sepharose chromatography
CM-sepharose CL6B (Amersham Pharmacia) column was equilibrated with buffer D: 10
mM K-phosphate, pH 6.0, containing 5 mM MgCl2, 2 mM DTT, 0.5 mM CHAPS and 10%
glycerol. The desalted thrombin fractions were applied, and the column was washed with
50 column volumes of the equilibration buffer D in order to remove the unbound proteins.
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The TK1 proteins were eluted with elution buffer E: 50 raM K-phosphate, pH 8.0, 5 mM
MgCl2, 2 mM DTT, 0.5 mM Chaps and 10% glycerol.
Determination of protein concentration
The method of Bradford (1976) with BSA dilutions of 20-40-60-80-100-120-140-160 and
180 ug/ml as standard was used, unless stated otherwise.
ATP incubation and storage of the purified TK1 enzymes
The thrombin cleavage fractions were diluted to 5 ug/ml in dilution buffer F (50 mM Tris-
HC1, pH 7.5, 5 mM MgCl2, 0.1 M KC1, 2 mM CHAPS, 10 % glycerol and 5 mM DTT) and
the CM fractions were diluted to 5 ug/ml in dilution buffer G (50 mM Tris-HCl, pH 7.5, 1
mM CHAPS, 3 mg/ml BSA and 10% glycerol) with or without 2.5 mM ATP/ MgCl2, and
incubated on ice for 2 hours before storage at -80° C. The enzymes incubated and stored
with and without ATP are referred to as the +ATP and -ATP forms, respectively.
Estimation of subunit molecular size and protein purity by SDS-
polyacrylamide gel electrophoresis
Estimation of subunit size of recombinant TK1 enzymes
Protein samples were denatured for 2 minutes at 94° C in protein loading buffer: 30%
glycerol, 0.4 M Tris-HCl, pH 6.8, 10 mM DTT, 1% SDS, and 0.01% bromphenol blue as
tracking dye, and loaded onto the gel. The samples were run by standard discontinuous gel
electrophoresis in Tris-HCl with 4.5% stacking gel, pH 6.8, 15% separation gel, pH 8.8,
and with Tris-glycine running buffer The separated polypeptides were stained by silver
staining procedure. Protein marker kit from BIO-RAD contained 2 mg/ml of each of the
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marker protein (molecular mass from 14.4 to 94 kDa). It was diluted 100-fold, denatured,
and 2 to 8 ul were applied to the gel.
Estimation of subunit size of recombinant XKl66"136 proteins by tricine/ethylene
glycoI/SDS-polyacrylamide gel electrophoresis
Because the standard SDS-PAGE methods resulted in diffuse protein bands and un-
sufficient resolution of the relatively small XKl66"136 peptide (< 8 kDa), a modified method
was developed. The gel included 30% ethylene glycol in the gel slurry and was run with
tricine instead of glycine in the electrode buffer (Separation Technique File No. 112 from
Pharmacia, made available to me through Ulrik Cordes (personal communication);
Schågger & von Jagow, 1987).
The upper, stacking gel contained 4.5% acrylamide /O.I2% bisacrylamide (Protogel,
National Diagnostics), the lower, separating gel contained 13.5% acrylamide /0.35%
bisacrylamide. The buffer system in both gels consisted of 0.112 M acetate, 0.112 M Tris,
pH 6.5 and both gels included 33% ethylene glycol. The electrode buffer contained 0.2 M
tricine, 0.2 M Tris, pH 8.1-8.3, and 0.55% SDS. Protein samples were diluted
approximately 10-fold into protein sample buffer (0.125 M Tris, pH 6.8, 25% glycerol, 1%
SDS, 10 mM DTT and 0.01% bromphenol blue), denatured for 2-3 minutes at 95°C and
loaded. The gel was pre-run for about 30 minutes at 80 V and run for about 45 minutes at
120 V. It was critical that the gel was not left in fixing and swelling solutions for longer
than 30 minutes and 2 times 15 minutes respectively before silver staining procedure was
performed. "Peptide marker kit MW 2.512 - 16949" (Amersham Pharmacia Biotech) was
used as molecular mass marker. It was resuspended in protein sample buffer to 1 mg/ml
(corresponding to about 0.17 ug/ul of each standard protein), stored at •*• 20°C in small
aliquots, diluted 10-fold before denaturation and 4 to 6 ul were applied to the gel.
Estimation of native molecular size by gel filtration chromatography
Estimation of native size of recombinant TK1 enzymes
The apparent native molecular size was determined on a Superose-12 or Superdex-200
columns (10 x 300 mm) connected to a Gradiphrac automatic sampler (Amersham
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Pharmacia). The column was equilibrated and eluted with 50 mM imidazol-HCl buffer, pH
7.5, containing 5 mM MgCl2, 0.1 M KC1, 5 mM DTT, and 2 mM Chaps (buffer H). The
last two ingredients were added just before the start of the experiment. The columns were
standardized with following proteins: (3-amylase (200 kDa), bovine serum albumin (66
kDa), ovalbumin (45 kDa), carbonic anhydrase (29 kDa) and cytochrome C (12,4 kDa).
The protein samples (200 ul, 5 ug/ml), were injected into the column together with Blue
Dextran 2000 (4 ul from 10 mg/ml) as the internal standard. 200 ul aliquots were sampled
on ice, into glasses containing 100 ul buffer H with 30% glycerol, 2 mM CHAPS and 2.6
mM ATP for preservation of enzyme activity. The final glycerol concentration was 10%,
and the samples could be frozen for later estimation of enzyme activity. The fractions were
assayed according to the standard assay for TK1 activity at 10 or at 100 uM thymidine.
Estimation of native size of TKl66"136 proteins
The apparent native molecular size was estimated on Superose 12 column (10 x 300 mm)
connected to a Gradifrac automatic sampler (Amersham Pharmacia Biochem). The column
was pre-equilibrated with elution buffer H without Chaps (DTT was added to the buffer
just before the start of the experiment). The column was standardized as described above.
200 ul aliquots from the cleavage fractions were injected into the column together with
Blue Dextran 2000 (4 ul from 10 mg/ml). 0.5 ml fractions were collected for estimation of
protein concentration by the method of Bradford (1976).
Thymidine kinase assay
The standard assay conditions for thymidine kinase are: 50 mM Tris-HCl, pH 8.0, 2.5 mM
MgCl2, 2.5 mM ATP, 10 mM DTT, 0.5 mM CHAPS, 3 mg/ml BSA and the indicated
concentration of [methyl-3H]-thymidine in 50 ul total volume. The stock solution of
radioactive thymidine (925 GBq/mmol, Amersham) was diluted with non-radioactive
thymidine in order to get the required specific activity and concentration. The stored
enzymes (at 5 ug/ml) were further diluted, just before the start of the reaction, into 50 mM
Tris-HCl, pH 7.5, 1 mM CHAPS, and 3 mg/ml BSA, with or without 2.5 mM ATP/
MgCl2. The TK1 assay activity was performed by the DE-81 filter paper method: aliquots
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of the assay mix are put on DE filters at different reaction times, the filters are dried, and
the non-phosphorylated thymidine is washed of the DE filter by three washes with
ammonium formiate and one wash with water. The 3H-TMP bound to the filter is eluted
from the paper by a mixture of 0.2 M KC1 and 0.1 M HC1, and counted in a liquid
scintillation counter as previously described (Munch-Petersen et al., 1991).
Enzyme kinetics
The experimental data were fitted to Hill equation, which is obtained from Michaelis-
Menten equation by raising the substrate concentration and the Km value in to the power of
n, the Hill constant:
V-s"
The kinetic parameters and reaction mechanism were determined using the non-linear
regression software from Graphpad Prism®. V is the maximal velocity and K§s like Km in
the Michaelis-Menten equation, defines the substrate concentration s where v=0.5 Fmax
(Cornish-Bowden, 1995).
Detection of GST-TK166136 fusion proteins
Because the cloned TK166"136 had no enzymatic activity, the IPTG induction of the fusion
protein was detected by measuring the product of enzymatic reaction between GST and its
substrates CDNB (l-chloro-2,4-dinitrobenzene) and glutathione. 5 to 50 ul of crude
bacterial extracts were added to 100 mM phosphate buffer, pH 6.5, mixed with 1 mM
reduced glutathione and 1 mM CDNB, and the absorbance A340 recorded at 1 min intervals
for at least 5 min. Usually, the GST fusion protein was detected in small volumes of
bacterial culture, e.g. 2 ml, taken before addition of IPTG and just before harvest of the
cells. Such small volumes could not be subjected to French Press nor the filtration
procedure, but were sonicated (50 W, 3 X 10 sec) instead and centrifuged to remove
bacterial debris.
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Enzyme stability
The stored CM fractions of TKlVaI106 and TKlMet106 enzymes (at 5 ug/ml) were diluted
200-fold into 50 mM K-phosphate buffer, pH 7.5 with 0.5 mM CHAPS and 5 mM DTT,
and incubated at 15° C. 10 ul aliquots were withdrawn at different incubation times, added
to 40 ul standard assay mix with 100 uM thymidine at 37° C, and at 3, 6 and 9 minutes
afterwards, 13 ul aliquots were spotted on the DE-filter. Filters were washed and counted
as described before.
Lymphocytes, cell lines and cell culture conditions
Lymphocytes were isolated by the Isopaque-Ficoll technique from peripheral blood from
healthy volunteers at Roskilde University, Roskilde, Denmark. If destined for isolation of
mRNA, the lymphocytes were grown for 72 hours with PHA as described by Munch-
Petersen et al. (1973). Following cell lines were bought from American Type Culture
Collection: Raji, CEM-C, Molt-3, Reh, K-562, KG-1, RS4;11, AML-193 (the leukemic
cell lines), DLD-1, Het-116, LoVo, SW40 (the colon cancer cell lines), and the HeLa cells.
WI38, the human fibroblast cell line, and WI26 VA4, the SV40 transformed human
fibroblast cell line, were bought from European Collection of Cell Cultures. The cell lines
were cultured in RPMI 1640 medium (Life Technologies, Inc.) containing L-glutamine,
15% fetal bovine serum (Life Technologies, Inc.), and 1% penicillin-streptomycin in
atmospheric air with 5% CO2 at 37° C. Subculturing was performed at 106 cells/ml. All
handling of the cell lines was performed by Jacob F. Christensen (Christensen, 2000)
Isolation of mRNA and amplification of TK1 cDNA
Total RNA was isolated with RNAqueous™ isolation kit (Ambion, Inc.) from eight
leukemic cell lines, non-transformed and SV40 transformed fibroblasts, and lymphocytes
from five healthy donors. The cDNA was amplified with Titan™ one-tube reverse
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transcription-PCR kit (Roche Molecular Biochemicals) using following primers: sense
primer: 5'-GAGAGTACTCGGGTTCGTGAA(22-42)-3\ and antisense primer: 5'-
ATGCAGGGCAGCGTCCAGTAG(825-805)-3' (the numbers are according to Bradshaw
& Deininger, 1984). This resulted in 804 base pair fragment containing the entire coding
region of TK1. The isolation of mRNA and amplification of cDNA was performed by
Jacob F. Christensen (Christensen, 2000).
Isolation of a genomic TK1 DNA fragment containing the codon for
amino acid 106 and amplification of this fragment by PCR
Total genomic DNA was isolated from four colon cancer cell lines, HeLa cells, and
lymphocytes from four healthy donors by the SDS lysis-proteinase K treatment-phenol
extraction method (Sambrook et al., 1989). Fragments of 166 bp containing the codon for
amino acid 106 were amplified by PCR with the sense primer 5'-
AGCGTCTTCGCTGGGGCTCCO1824-11843)-3' and the antisense primer 5'-
TTCCTCTGGAAGGTCCCATCC(11989-11969)-3' at the following conditions: 25-30
cycles, 94° C for 1 min, 55° C for 2 min, and 72° C for 3 min. The numbering is according
to Flemington et al. (1987). Isolation and PCR amplification of genomic TK1 DNA was
performed by Jacob F. Christensen (Christensen, 2000).
Sequencing of the genomic TK1 DNA fragments and of TK1 cDNA
Both strands were sequenced with the Thermo Sequenase radiolabeled terminator cycle
sequencing kit (Amersham Biosciences) with
dideoxynucleotides (Amersham Biosciences).
 the dITP nucleotide master mix and [a-32P]
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NMR experiments
When the induced JKl66 '136 proteins were destined for NMR, the bacterial pellets were
lysed in buffer Al of following composition: 20 mM phosphate buffer, pH 7.5, 5 mM
EDTA, 1 mM DTT, 0.1 mM PMSF, 5 mM benzamidine and 50 mM e-aminocaproic acid
(it was especially important that no glycerol was added and to avoid traces of Tris-HCl).
The proteins were purified by glutathione affinity chromatography as described earlier, but
the buffers contained neither glycerol, nor Triton. Thrombin cleavage was performed
without Triton, in PBS only, and the cleavage time was extended to 2 hours at room
temperature. After thrombin cleavage 5 mM DTT and 5 mM MgC^ were added to the
cleavage fraction of TKl66"136(Vall06), while during later purification of TKl66'136(Metl06), the
concentration of DTT was reduced to 2 mM. The proteins were concentrated by
centrifugation at 4°C through Centrisart membranes (Sartorius) with molecular weight cut-
off size of 5000. The centrifugation time required to concentrate the proteins in the
cleavage fractions approximately 10-fold (from protein concentration 200 - 500 n-g/ml to 4
mg/ml) was 3 days. (About 10% of the protein applied to the Centrisart passed through the
membrane into filtrate). Afterwards, 0.5 M D2-MSH (Aldrich) was added to final
concentration of 2 mM, and D2O (Aldrich) was added to final concentration of 10%. The
samples were stored in 5 mm Wilmad NMR tubes (Fluorochem, England) at 4°C and were
run during one week after they have been prepared.
All experiments have used proton NMR (!H-NMR) spectroscopy and 600 MHz Varian
Unity-Inova NMR spectrometer with a triple resonance gradient probe. All spectra were
run at 10°C with TMS (tetramethylsilane) as reference.
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Chapter 6
The role of a mi no acid 106 in the catalytic
mechanism and oligomerization pattern of human
thymidine kinase 1
Introduction
The first successful cloning of a functional human thymidine kinase 1 gene was performed
by Bradshaw (1983) who isolated genomic TK1 DNA by transformation of TK-deficient
mouse L cells with total HeLa cell DNA. A fragment of this genomic clone was used by
Bradshaw & Deininger (1984) as a hybridisation probe for screening the Okayama-Berg
cDNA library constructed with mRNA from SV40 transformed human fibroblasts
(Okayama & Berg, 1983). A hybridizing clone, called pTKll, with cDNA insert of ca. 1.5
kb and capable of transforming LTK cells to TK+, was sequenced and found to have an
open reading frame of 702 bp corresponding to 234 amino acids (Bradshaw & Deininger,
1984). The whole genomic clone of Bradshaw (1983) was sequenced by Flemington et al.
(1987) who found the human TK gene to be composed of 7 exons. No base differences
were detected between the amino acid coding sequence from HeLa cells (Flemington et al.,
1987) and the sequence of the pTKl 1 clone of Bradshaw & Deininger (1984).
The first TK1 clone that arrived at our laboratory was the pTKl 1 clone of Bradshaw &
Deininger (1984). The amino acid coding region of pTKll was PCR amplified, inserted
into a pET3a vector, and the pET3a-TKl plasmid used to transform E. coli BL21(DE3)
strain (Jensen, 1994). This expression system was T7 RNA polymerase dependent and
IPTG inducible (Jensen, 1994; Munch-Petersen et al., 1995a). The recombinant protein,
later named rTFi-TKl1, was purified, characterized, and found to have the same subunit
size and specific activity as the native TK1 isolated from human lymphocytes, but to differ
from it with respect to regulatory effect of ATP pre-exposure on the kinetic mechanism
1
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and oligomerization properties (Jensen, 1994; Jensen & Munch-Petersen, 1995; Munch-
Petersen et al., 1995a). Thus, pre-assay exposure to ATP induced a reversible enzyme
concentration-dependent transition of the native lymphocyte TK1 from a low activity
dimer (molecular size about 50 kDa, thymidine KQ.S about 15 uM) to a high activity
tetramer (molecular size about 100 kDa, thymidine KQ.S about 0.7 uM). Both forms had the
same &cat value of about 4 s"1 when calculated per subunit of 24 kDa (Munch-Petersen,
1996). However, irrespective of pre-exposure to ATP, the rTFi-TKl behaved as the low
^o.5 tetramer, with Km about 0.4 uM (Munch-Petersen et ah, 1995a). At that time, these
differences were attributed to absence of post-translational modification mechanism in the
bacterial expression system (Munch-Petersen et ah, 1995a).
Because the yield of this expression system was poor, approximately 1 mg of TK1 protein
per litre of bacterial culture, (Jensen, 1994), it was decided to use the pGEX-2T expression
system (Pharmacia Biotech) instead. As described in Chapter 5 (Materials and Methods)
and Paper I (Berenstein et ai, 2000), the amino acid coding sequence of TK1 inserted into
the multicloning site of pGEX-2T was not from HeLa cells, but from normal human
lymphocytes, and accordingly the expressed TK1 was named rLy-TKl2 (Paper I,
Berenstein et al, 2000).
Preliminary kinetic and gel filtration experiments have shown that rLy-TKl behaved as the
native TK1 isolated from human lymphocytes with respect to the regulatory effect of ATP
on the kinetic and oligomerization properties of the enzyme (Kristensen, 1996). Therefore,
absence of post-translational modification in the recombinant enzyme could not explain the
divergent properties of rTFi-TKl and rLy-TKl. By comparison of the sequence of
lymphocyte TK1 cDNA with that of pTKll clone of Bradshaw & Deininger (1984), two
differences were discovered: 1) the lymphocyte TK1 cDNA had a GTG codon for valine at
amino acid position 106, while pTKll cDNA had an ATG codon for methionine, and 2)
the lymphocyte TK1 cDNA had an AGG codon for arginine at position 211, while pTKl 1
had an AAG codon for lysine (Kristensen, 1996; Paper I, Berenstein et ah, 2000). Because
the amino acid 211 is positioned in the non-conserved C-terminal of thymidine kinases,
and furthermore, the replacement of lysine with arginine is conservative, this change was
not considered to be of importance for the properties of the enzyme. The amino acid at site
106, on the contrary, is located in a highly conserved area (Folkers et al., 1991; Paper I,
Berenstein et ah, 2000; se Fig. 4.1), and is valine in all published TK1 sequences of
different mammalian enzymes, in chicken and in vaccinia TK1, but not in the published
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human TK1 sequences that have methionine at position 106 (Bradshaw & Deininger, 1984;
Flemington et al., 1987).
This study was undertaken in order to clarify which amino acid is naturally occurring at the
position 106, and describe the impact on the size, conformation and polarity of the amino
acid 106 on the structure and function of human TK1. The results presented in this chapter
are already published (Paper I, Berenstein et al, 2000; Paper II, Frederiksen et al, 2004).
Results
Expression and purification of recombinant TK1 enzymes
When recombinant proteins are synthesized by E. coli, they often accumulate in insoluble
inclusion bodi'es (Marston, 1986). Use of gene fusions that link the eukaryotic gene to e.g.
bacterial (3-galactosidase gene (Marston, 1986) or to GST gene from S.japonicum (Smith
& Johnson, 1988) increases solubilization of heterologous proteins in E. coli. Formation of
the inclusion bodies could be prevented even further by cultivating E. coli at 25°C instead
of 37°C (Fetzer & Folkers, 1992). Accordingly, the IPTG induction of the recombinant
TK1 proteins was carried out at 25°C.
The recombinant enzymes were expressed as GST fusion proteins and purified by
glutathione sepharose affinity chromatography combined with in situ thrombin cleavage.
The purity of the thrombin cleavage fractions was estimated to be >90% by SDS-PAGE
(Fig. 6.1).
M 1 2 3 4 5_ j6 _7_M.
Figure 6.1. SDS gel electrophoresis of thrombin cleavage fractions. M lanes - marker proteins with
80 ng protein in each band, from bottom to top (kDa): a-lactalbumine (14.4), soybean trypsin
inhibitor (20.1), carbonic anhydrase (30), ovalbumine (43), bovine serum albumine (67) and
phosphorylase B (94). Lanes 1 to 7 contain 0.15 - 0.2 ug protein of respectively: cl.#2 V106WT,
no sample, cl.#l V106WT, cl.#2 V106T, cl.#l V106T, cl.#2 V106Q and cl.#l V106Q.
Shortage for recombinant TK1 expressed from cDNA derived from normal human lymphocytes
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For kinetic and stability experiments where TK1(V1O6WT) and TK1(V1O6M) are
compared, the proteins were purified further by CM Sepharose chromatography. This
procedure results in pure ( 99%) recombinant protein (Fig. 6.2).
V106WT V106M
Figure 6.2. SDS gel electrophoresis of TK1(V1O6WT) and TK1(V1O6M) CM-sepharose fractions.
Approximately 0.55 ug of each protein was applied to the gel. M lanes - marker proteins, from
bottom to top (kDa): a-lactalbumine (14.4), soybean trypsin inhibitor (20.1), carbonic anhydrase
(30), ovalbumine (43), bovine serum albumine (67) and phosphorylase B (94).
The yield of recombinant TKl and the purification achieved from 300 ml bacterial culture
are shown in Table 6.1 with V106M as an example.
Table 6.1. Purification of recombinant TK1(V1O6M)
Volume Activity Protein Specific Yield
activity
ml Units/ Units ug/ml mg Units/mg %
ml total total
Crude extract
50 917 45850 8615 431 106 100
GSH Sepharose (top fraction)
13 579 7527 179 2.3 3272 16
CM Sepharose (top fraction)
1.7 1589 2701 429 0.729 3710 5.9
All data are related to 1 litre of bacterial culture
Units: nmol min"1
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The yield of the recombinant protein was much higher if the purification procedure started
with bigger volume of bacterial culture (>1 litre). The amount of protein related to 1 litre
of bacterial culture was 4 - 8 mg in the thrombin cleavage fractions, and 2 - 4 mg (at
concentration 4 - 8 mg/ml) in the CM top fraction.
The significance of amino acid 106 was investigated by comparing the kinetic and
oligomerization properties of the r L y - T K r a n u 6 (V106WT) with rLy-TKr e t l u t > (V106M)
and rLy-TKl Val106X (VI06X) mutants.
Enzyme kinetics
The thymidine substrate kinetics of TK1(V1O6WT) is compared to the thymidine substrate
kinetics of TK1(V1O6M) at saturating concentrations of ATP in Fig. 6.3.
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Figure 6.3. Thymidine substrate kinetics. A, TK1(V1O6WT), B, TK1(1O6M). The initial velocity of
dTMP formation as a function of thymidine concentration is shown to the left, Hofstee plot of the
same data is shown to the right. Open symbols, +ATP forms, closed symbols -ATP forms. The
experiments were performed on CM-sepharose fractions at 5 ng/ml enzyme protein in the reaction
mixture.
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The recombinant TK1(V1O6WT) behaves essentially as the previously described
endogenous TK1 isolated from human lymphocytes (Munch-Petersen et al., 1993): the -
ATP form of the enzyme displays a nonhyperbolic, "creeping" curve and a biphasic kinetic
pattern in the Hofstee plot, indicating a negative cooperative reaction mechanism (n value
0.4), while the +ATP form displays a rectangular hyperbolic kinetics (n value somewhat
above 1), and a straight line in the Hofstee plot (Fig. 6.3A). Exchange of VallO6 to
methionine (Fig. 6.3B) resulted in a hyperbolic rectangular reaction mechanism with a Hill
coefficient («) about 1, and a straight line in Hofstee plot, independent of preceding
exposure to ATP. The kinetic properties of TK1(V1O6M) turned out to be the same as
those described previously by Munch-Petersen et al. (1995 a) for rTFi-TKl derived from
the pTKl 1 cDNA of Bradshaw & Deininger (1984).
The kinetic values of TK1(V1O6WT) and TK1(V1O6M) are compared in Table 6.2.
Table 6.2. Kinetic values of TK1(V1O6WT) and TK1(V1O6M).
m^ax (umol/min/mg)
^ • c a t vS>CU )
KQ,5 (fiM)
^cat/^o.5 (sec"VM"!)
n
TK1(V1O6WT)
-ATP
20
8.5
15
0.57
0.4
+ATP
17
7.2
0.57
12.6
1.3
TK1(V1O6M)
-ATP
5.6
2.4
0.55
4.4
1
+ATP
5.4
2.3
0.4
5.7
1.1
flATca, value was obtained using the calculated MW of TK1 equal to 25500
The KQ.S value for thymidine of TK1(V1O6WT) -ATP form is about 30-fold higher than
the KQ.5 value of its +ATP form. In contrast, the KQ.S values of the -ATP and +ATP form of
TK1(V1O6M) are equally low, about 0.5, the same as the value of TKl(V106WT) +ATP
form. Though, due to lower Fmax of TK1(V1O6M), its turnover number KcaX is 3 to 4 fold
lower than the Kcal of TK1(V1O6WT), and its kinetic efficiency measured as KCJKQ.S is
also lower than the Kczt/Ko.5 of TK1(V1O6WT)+ATP form. The physiological importance
of transition between a low and high activity form of TK1 will be discussed later.
The effect of replacement of Val 106 with several other amino acids on the kinetic
properties of the enzyme is shown in Table 6.3 and Fig. 6.4.
The thymidine substrate kinetics of V106A, V106I and V106T is essentially the same as
that previously observed for V106WT: the -ATP form of these enzymes displayed
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while their corresponding +ATP forms had low K0.5 values and n values slightly above 1
(Fig. 6.4A). The substrate kinetics of V106G, V106H, V106K, V106L and V106Q was
essentially the same as that of V106M: both the -ATP and +ATP forms seem to have a
hyperbolic reaction mechanism with low K0.5 values and n values above 1, that may
indicate positive cooperativity (Fig. 6.4B and Table 6.3). The ratios between the £0.5
values for the -ATP and +ATP forms supports the division of mutant enzymes into 2
groups. This ratio is 30 or higher for the enzymes belonging to Group I: V106WT, V106A,
VI061 and V106T, whereas it is about 1 for the enzymes belonging to Group II: V106G,
V106H, V106K, V106L, V106M and V106Q (Table 6.3).
Table 6.3. Kinetic parameters of TK1(V1O6WT) and TK1(V1O6X) mutant enzymes
Enzyme
min"1 mg"1
-ATP +ATP -ATP +ATP -ATP +ATP
Group I V106WT-like enzymes
V106WT
V106A
VI061
V106T
11.0±1.3
8.0±0.8
10.3±1.8
8.4±1.9
9.4±0.2
6.6±0.2
8.3±0.3
7.1±0.2
Group II V106M-like enzymes
V106G
V106H
V106K
V106L
V106M
V106Q
3.6±0.2
3.7±0.2
2.2±0.06
4.1±0.1
2.9±0.06
4.9±0.2
3.0±0.1
3.1±0.1
4.1±0.1
3.9±0.1
2.9±0.06
4.2±0.1
27.1±8.5
12.7±3.2
29.4±16.4
43±28
0.4±0.1
0.3±0.2
0.7±0.1
0.4±0.1
0.6±0.08
0.8±0.1
0.6±0.05
0.3±0.03
0.9±0.1
0.4±0.04
0.3±0.1
0.4±0.1
1.2±0.1
0.7±0.1
0.6±0.1
0.8±0.1
0.8±0.07
O.8±O.O6
0.8±0.1
0.8±0.1
1.9±0.4
1.6±0.7
1.4±0.1
1.9±0.2
1.5±0.1
1.5±0.1
1.2±0.05
1.3±0.1
1.2±0.1
1.2±0.1
1.7±0.4
2.0±0.4
1.4±0.1
1.8±0.1
1.5±0.1
1.6±0.1
45
42
33
108
1.3
0.8
0.6
0.6
1.0
1.0
The enzymes within each group are arranged in alphabetical order of their one-letter code. The best fit ± SE
to all data is given.
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Figure 6.4. The initial velocity of dTMP formation as a function of thymidine concentration for
TKl (V106WT) and TKl (V106X) enzymes. Open symbols, +ATP forms; closed symbols -ATP
forms. A, V106WT-like enzymes and B, V106M-like enzymes. The experiments were performed
on thrombin cleavage fractions at 5 ng/ml enzyme protein in the reaction mixture.
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Native molecular size
Initially, the effect of replacement of Val 106 with methionine on the native molecular size
under conditions of gel filtration experiments was investigated (Fig. 6.5)
O.000
1.0 1.5 2.0
Figure 6.5. Gel filtration of TK1(V1O6WT) and TK1(V1O6M). 0.6 ug protein from thrombin
cleavage fractions was applied on Superose column. Left hand scale, V106WT (circles), right hand
scale, V106M (squares). The enzymatic activity was estimated at 10 uM thymidine. The molecular
mass markers ( | ) are (in kDa): BSA (66), ovalbumine(45), carbonic anhydrase (29) and
cytochrome c (12.4).
The apparent sizes of the -ATP form of V106WT and V106M was respectively 50 and 100
kDa, and according to the subunit size of 24-25 kDa, the V106WT eluted predominantly as
a dimer, while V106M eluted predominantly as a tetramer. In the presence of ATP
V106WT enzyme eluted as a tetramer (Fig. 6.6).
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Figure 6.6. Gel filtration of TK1(V1O6WT) +ATP and -ATP forms. 1 ug and 0.6 ug from
respectively +ATP and ATP form protein from thrombin cleavage fractions were applied on
Superose column. Left hand scale, +ATP form (open symbols); right hand scale, -ATP form
(closed symbols). The enzymatic activity was estimated at 10 \xM thymidine. The molecular mass
markers (I) are (in kDa): BSA (66), ovalbumine(45), carbonic anhydrase (29) and cytochrome c
(12.4).
123
The behaviour of the recombinant enzymes was in agreement with the previous
observation for the native Ly-TKl (Munch-Petersen et al., 1993) and the rTFi-TKl
(Munch-Petersen et al, 1995a,) derived from the cDNA clone of Bradshaw & Deininger
(1984).
Because the activity of the dimeric form of TK1-ATP does not attain Vmax at 10 uM
thymidine, we determined the proportion of enzyme present as dimer/tetramer by
estimation of the enzymatic activity in gel filtration fractions of different V106X mutants
at the almost saturating thymidine concentration of 100 uM. The results are shown in
Fig.6.7.
The enzyme concentration applied to the column was 3.25 ug/ml, because we wanted to
mimic the physiological concentration of TK1 protein calculated to be about 4 ug/ml in S
phase cells (Munch-Petersen et al., 1993; Munch-Petersen et al., 1995). The recombinant
mutant enzymes could be divided into two groups according to the oligomerization pattern
of their -ATP form. V106A, V106I and V106T eluted from Sephadex column essentially
as V106WT, and were called "dimeric enzymes", because a substantial part of each
enzyme eluted with an approximate size of 50 kDa, i.e. as a dimer (Fig. 6.7A). hi contrast,
V106G, V106H, V106K, V106L and V106Q eluted similarly to V106M with an
approximate size of 100 kDa, i.e. as tetramers, and therefore called "tetrameric enzymes".
In each case, small, varying proportion of enzyme protein eluted as a dimer (Fig. 6.7B).
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Figure. 6.7. Gel filtration of TK1(V1O6X) mutants on Superdex column. A, dimeric enzymes,
B, tetrameric enzymes. Approximately 0.65 ug protein from thrombin cleavage fractions was
injected. The molecular mass markers ( I) are (in kDa) from left to right: p-amylase (200), BSA
(66), ovalbumine (45). carbonic anhydrase (29) and cytochrome c (12.4).
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Enzyme stability
In Fig. 6.8 the stability of V106WT with V106M at 15°C is compared. Since V106M lost
more than 50% of its activity within 4 minutes at 25°C, stability experiments were not
performed at this temperature. Also at 15°C, V106M was much less stable than V106WT,
with ti/2 values of about 40 and 390 minutes respectively. Analogously, the dimeric
enzymes were found to be much more stable than the tetrameric enzymes when the
respective -ATP form was diluted to 25 ng/ml into enzyme dilution buffer and incubated at
4°C for 30 minutes: the dimeric enzymes retained 80-100% of their enzymatic activity,
while the tetrameric enzymes retained only 0.5-3%.
200 300 400
min
Figure 6. 8. Enzyme stability of TK1(V1O6WT), circles, and of TK1(V1O6M), squares, at 15° C in
phosphate buffer. The bars show standard deviation derived from two or three independent
determinations. CM-sepharose fractions were used for these experiments.
Polymorphisms in the human TK1 gene
In order to uncover naturally occurring bases and the resulting amino acids at positions 106
and 211 in the human TK1 gene, sequencing reactions were performed on:
(a) genomic DNA fragments of 166 base pairs containing the codon for amino acid 106
from four colon cancer cell lines, HeLa cells, and lymphocytes from four healthy donors,
(b) the complete coding region of TK1 cDNAs from eight leukemic cell lines, lymphocytes
from five healthy donors, and one nontransformed and one SV40 transformed fibroblast
cell line. Altogether, the codon for amino acid 106 was examined in genomic and cDNA
from seven healthy donors and 15 cell lines. The results are summarized in Table 6.4.
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Table 6.4 Polymorphisms in DNA and amino acid sequence of TK1 cDNAs
Source of cDNA
pTKll
Lymphocytes from healthy
Donor 1
Donor 2
Donor 3
Donor 4
Donor 5
Leukemic cell lines
RS4;11
Molt-3
Reh
KG-1
AML-193
K562
Raj i
CEM-C
Fibroblasts
WI38
WI26
90
CCC
Pro
donors
CCC
Pro
CC(C/T)
Pro/Pro
CC(C/T)
Pro/Pro
CC(C/T)
Pro/Pro
CC(C/T)
Pro/Pro
CCT
Pro
CC(C/T)
Pro/Pro
CC(C/T)
Pro/Pro
CCC
Pro
CC(C/T)
Pro/Pro
CCT
Pro
CC(C/T)
Pro/Pro
CCT
Pro
CCT
Pro
CCC
Pro
115
CAG
Gin
CAG
Gin
CAG
Gin
CAG
Gin
CAG
Gin
CAG
Gin
CAG
Gin
CAG
Gin
(C/T)AG
Gin/Stop
CAG
Gin
CAG
Gin
CAG
Gin
CAG
Gin
CAG
Gin
CAG
Gin
CAG
Gin
Nucleotide position
279
GAG
Glu
GAG
Gin
GA(G/A)
Glu/Glu
GA(G/A)
Glu/Glu
GAG
Glu
GAG
Glu
GAG
Glu
GAG
Glu
GAG
Glu
GAG
Glu
GAG
Glu
GAG
Glu
GAG
Glu
GAG
Glu
GAG
Glu
GAG
Glu
282
GCG
Ala
GCG
Ala
GC(G/A)
Ala/Ala
GCG
Ala
GC(G/A)
Ala/Ala
GC(G/A)
AW Ala
GCA
Ala
GC(G/A)
Ala/Ala
GC(G/A)
Ala/Ala
GCG
Ala
GC(G/A)
Ala/Ala
GCA
Ala
GCG
Ala
GC(G/A)
Ala/Ala
GC(G/A)
Ala/Ala
GCG
Ala
373
ATG
Met
GTG
Val
GTG
Val
GTG
Val
GTG
Val
GTG
Val
GTG
Val
GTG
Val
GTG
Val
GTG
Val
GTG
Val
GTG
Val
GTG
Val
GTG
Val
GTG
Val
GTG
Val
651
GCC
Ala
GCC
Ala
GCC
Ala
GCC
Ala
GCC
Ala
GCC
Ala
GCC
Ala
GCC
Ala
GCC
Ala
GCC
Ala
GCC
Ala
GCC
Ala
GC(C/T)
Ala/Ala
GCC
Ala
GCC
Ala
GCC
Ala
689
AAG
Lys
AGG
Arg
AAG
Lys
AAG
Lys
AAG
Lys
AAG
Lys
AAG
Lys
AAG
Lys
AAG
Lys
AAG
Lys
AAG
Lys
AAG
Lys
AAG
Lys
AAG
Lys
AAG
Lys
AAG
Lys
The numbers are according to Bradshaw & Deininger (1984) and correspond to the underlined bases,
where the polymorphism is located. Bases/amino acids that differ from the sequence of Bradshaw &
Deininger (1984) are in bold. Differences in only one allele are in parentheses.
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In each case the GTG codon for valine 106 was found on both alleles, and in one case -
from the very first donor, called donor 1, from which the pGEX-2T-TKl plasmid was
derived - a substitution of A with G at nucleotide position 689 in both alleles, resulted in
change of lysine to arginine at amino acid position 211. hi Reh cells, C substituted with T
in one of the alleles at nucleotide position 115, changed the CAG codon for glutamine to
the stop codon TAG at amino acid position 20. The other polymorphisms revealed did not
involve any change of the amino acids. Nucleotide positions 90 and 282 appeared to be
more prone to polymorphism and have been previously described in the human
lymphoblastoid cell line, TK6 (Grosovsky et ah, 1993), and recently in breast and
colorectal cancer solid tumours (Gilles et ah, 2003). Our results regarding the nucleotide
position 373 was confirmed by both groups: G instead of A in both alleles was invariably
found, which resulted in valine codon for amino acid 106 (Grosovsky et ai, 1993; Gilles et
ai, 2003).
Discussion
The results illustrate two important points: 1) it is most likely valine and not methionine
that is amino acid 106 in TKl, and 2) amino acid 106 has profound effect on the kinetic
and oligomerization properties of TKl. It remains to be explained why methionine at
position 106 was found in previous investigations of TKl derived from SV40 transformed
fibroblasts (Bradshaw & Deininger, 1984) and from HeLa cells (Flemington et al., 1987).
As the differences might be due to different origins of the mRNA from which the cDNA
was synthesized, cDNA and genomic DNA from various human cells and cell lines, also
from SV40 transformed fibroblasts and HeLa cells, was sequenced. hi each of the 22
independent isolations of genomic DNA and cDNA valine was found at position 106. The
findings have later been supported by TKl sequences from Burkitt lymphoma lymphocytes
and from uterus tissue deposited in Genbank in 2001 by Strausberg for the NIH
Mammalian Gene Collection (MGC) Project (gi:23503074) and by the already mentioned
work of Gilles et al. (2003). The implications of the found polymorphisms for the function
of TKl in vivo are presented in General Discussion (Chapter 9) at the end of this thesis.
Initially, it was shown that mutation of valine 106 to methionine changed TKl to a less
stable enzyme, and a permanent tetramer with low £"0.5 towards thymidine (iTo.5 0.4-0.6
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uM, molecular size 100 kDa) irrespective of pre-exposure to ATP. For further
investigation of the role of amino acid 106 for the function and structure of TK1 valine 106
was mutated to amino acids differing in size, conformation and polarity. After expression
and purification, the effect of the mutated amino acids on kinetic and oligomerization
properties of TK1 was examined.
The recombinant enzymes could be divided into two groups. Group I, the dimeric
enzymes, contained VI06A, VI061 and V106T, and shared their properties with V106WT:
i.e. in gel filtration experiments they eluted as both dimers and tetramers, with native
molecular sizes of respectively 50 and 100 kDa, their -ATP form had high K0.5 values 13
to 43, nonhyperbolic velocity vs. thymidine substrate curves, and the Hill coefficients
below 0.8, indicating a negative co-operative reaction mechanisms. Hence, the
hydrophobicity of the residue at site 106 was not critical for the function and conformation
of TK1. Group II, the tetrameric enzymes, which contained V106G, V106H, V106K,
V106L, and V106Q, shared their properties with V106M: i.e. they showed decreased
stability when compared to Group I enzymes, in gel filtration experiments they eluted
essentially as tetramers (native molecular size of 100 kDa), both their -ATP and +ATP
forms had low £0.5 values 0.3-1.2 uM, and the Hill coefficients were between 1.4 and 2
indicating positive co-operative reaction mechanism. If a mutant enzyme elutes with high
proportion of its activity as a tetramer, it could be expected to have a lower £0.5 value than
an enzyme eluting with higher proportion of its activity as a dimer. Comparison of Fig.
6.8A and Table 6.2 shows that this is not the case. An explanation can be offered by the
predicted secondary structure of TK1 as compared to enzymes of dNK/TK2 group
(Chapter 4) whose 3D structure has been solved. Because TK1 is smaller than the other
enzymes, one side of a-helix (probably a3) may constitute subunit interface, and the other
side of the same helix may be involved in substrate interaction. In this way, a mutation at
amino acid position 106 results not only in perturbation of dimer-tetramer transition, but
also interferes with the substrate interaction.
The amino acids at site 106 in Group II enzymes differ in size, as well as in conformation
and polarity. Thus, these properties do not appear to explain the decreased stability, the
decreased KQ.S value, nor the conformational changes. On the other hand, the amino acids
at site 106 in Group I enzymes, are except for alanine of similar size and conformation, but
of different polarities. Grouping of VI061 with V106WT was expected, but absence of
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nonpolar V106L and presence of polar V106T, was not. A property shared by the side
chains of valine, isoleucine and threonine is branching at their (3-carbon atom. P-branching
amino acids are considered to destabilize a-helices because of steric clashes. Although
leucine has the same hydrophobicity, size and conformation as valine and isoleucine, it
differs from these amino acids by having a branch not on (3-, but on its y-carbon atom. The
long hydrophobic side chain of leucine resembles the side chain of methionine in its length
and the absence of the branched P-carbon. Also the a-helical propensity of leucine is very
different from that of valine, isoleucine and threonine, but similar to that of methionine,
and nearly as high as that of alanine. This may explain why the properties of V106L are the
same as of V106M and the other tetrameric enzymes. V106A belongs clearly to the
dimeric enzymes, but with its somewhat lower Km for thymidine than seen for the other
Group I enzymes, VI06A might be an intermediate between the dimeric and tetrameric
enzymes.
Initially, it was attempted to replace Val-106 with phenylalanine (codon GTG was changed
to TTC), but it was not possible to express the V106F mutant protein. This may be due to
the steric distortion of the a-helix by the bulky side chain of phenylalanine, giving a
misfolded enzyme that is broken down in E. coli. On the other hand, a small side chain,
like glycine, and to some degree alanine, will not sufficiently serve to stabilize the local,
presumably helical structure.
Dimer-tetramer transition, which is dependent on enzyme concentration and pre-exposure
to ATP (Munch-Petersen et al, 1993; Munch-Petersen et al, 1995a; Paper I, Berenstein et
al, 2000), has been suggested to be of significance for the fluctuation of TK1 activity
during the cell cycle, with a low activity dimer dominating at low TK1 concentration
during Gl, and a high activity tetramer dominating in the S phase with high TK1
concentration (Munch-Petersen et al, 1995a). Such transition would require an enzyme
with substantial conformational flexibility. P-branching amino acids may have a regulatory
role in such conformation dependent transitions, as they are known to increase the strain
within an a-helix, and so to destabilize helix-helix interaction (Dao-pin et al, 1990; Deber
et al, 1992; Deber et al., 1993). Actually, valine-106 in human TK1 is preceded by
another p-branched residue, isoleucine-105, and among the thirty residues in the segment
91-121, there are three a-helix breaking glycines and ten P-branching amino acids. Hence,
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the whole segment is likely to maintain conformational flexibility of TKl in response to
cell cycle and substrate binding.
Sequence homology of TKl to deoxyribonucleoside kinases with solved 3D structures -
HSV1-TK and the cellular kinases dNK, dGK (Johansson et al, 2001) and dCK (Sabini et
al, 2003) - is too low (about 10%) for a reliable homology model. However, despite the
low sequence identity (10%) between HSV1-TK and the cellular kinases, they had very
similar core structures (Eriksson et al, 2002). Therefore, TKl may have the same overall
structure as the other nucleoside kinases. A prediction of the secondary structure of TKl
(Cuffed al, 1998; Cuff & Barton, 1999; Cuff & Barton 2000, se Chapter 4) places VallO6
in the middle of an a-helix which in aligns in CLUSTAL W (Higgins & Thompson, 1996)
with a-helix 4, one of the interface helices of HSV1-TK (Wild et al, 1997). This suggested
that the area surrounding Val-106 may be integrated into the oligomerization interface. The
role of amino. acid 106 and the sequence surrounding it for dimer-tetramer transition has
been confirmed by cloning the putative interface fragment of TKl, XKl66"136, and
investigating the influence of V106M mutation on the oligomerization properties of the
fragment. As described in the next chapter (Chapter 7), TKl66"136(Vall06) eluted as a mixture
of dimer and tetramer in gel filtration experiments, whereas rfKl66"136(Metl06) eluted as
tetramer only. Such oligomerization pattern supported my assumption that the fragment
TKl66"136 is an integral part of TKl oligomerization interface, and that amino acid 106 is
indeed of significance for the subunit arrangement of the enzyme molecule.
Evolutionary conservation of valine at amino acid position 106 (or at position
corresponding to this number) in TKl sequences originating from viral and animal species,
further supports its importance for the structure and function of TKl.
The size and conformation of amino acid 106 were concluded to be more important than
polarity for structure and function of TKl. Valine-106 not only contributes to
hydrophobicity of the putative a-helical interface, but also has the capacity to modulate
subunit interaction that underlies the substrate and cell cycle regulated activity of TKl,
known to be crucial for balancing the DNA precursor pools.
It will be extremely interesting to compare these results with the that of an X-ray structure
of TKl once it will become available.
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Chapter 7
The putative interface fragment of human TK1
Background for the present investigation
The two methods commonly used for determination of protein structure are X-ray
crystallography and nuclear magnetic resonance (NMR). The human thymidine kinase has
been up to now refractory to crystallization attempts. NMR techniques do not require
crystals and the protein structure can be examined in solution, but the size of the protein
limits the use of NMR. Today, depending on the method and on the NMR spectrometer,
the upper limit is for proteins of 20-30 kDa. Because the subunit size of TK1 is 25 kDa,
and the enzyme exists as a dimer and/or tetramer, it is to big for NMR analysis. Besides,
the NMR methods demand 1-2 mM protein solutions, i.e. 10 mg/ml for a 10 kDa protein,
with the additional requirements of greater than 95% purity and complete solubility at
these high concentrations.
hi order to get information about the structure of TK1 and not to be limited by the size of
the enzyme, I have cloned and expressed in E. coli a fragment of the TK1 gene coding for
amino acids 66-136, and named it
 TKl66-136(Van06) . Substitution of Val-106 with
methionine by site directed mutagenesis gave TKl66"136(Metl06). The TK166"136 fragment was
supposed to be the interface domain of TK1, as it aligned in CLUSTAL W (Higgins &
Thompson, 1996) with one of the dimer interface a-helices of the Herpes TK (a-helix 4).
The interface domain of TK1 might be involved in subunit interaction between monomers
and/or between pairs of dimers during the formation of dimers and/or tetramers,
respectively. Besides Val-106 which was shown to be critical for dimer/tetramer formation
(Paper I, Berenstein et al., 2000), this TK1 domain contains other putative function-
essential sites: 1) the magnesium binding site with the conserved Asp-97 and 2) Phe-
128,Gln-129,Arg-130,Lys-131, a group of conserved amino acids in the putative thymidine
binding site. The
 TKl66-136(Van06) and TKl66-I36(Metl06) peptides were characterized by gel
filtration and NMR.
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Introduction
Many biological functions involve binding of proteins to other proteins and association of
subunits into homo- or hetero-oligomeric proteins. Understanding of sources of affinity
and specificity at interfaces can provide insights into principles of protein interaction.
Modification and blocking of protein-protein interactions, as well as predicting protein-
protein interaction sites is of direct relevance to the design of drugs against diseases such
as BSE and Alzheimer, cancer, viral and other infectious diseases. Nearly two decades ago,
Wlodawer et al. (1989) suggested a molecule inhibiting dimerization of HIV protease as a
drug against the HIV virus, and 10 years ago, dimerization inhibitors of human glutathione
reductase were suggested as possible antimalarial agents (Nordhoff et al., 1993). Today,
many potent inhibitors of dimerization of HIV protease, HIV reverse transcriptase, HIV
ribonucleotide reductase, and Herpes virus DNA polymerase have been described (Zutshi
et al., 1998, and references therein; Archakov et al., 2003, and references therein).
Interfaces and their properties
Protein-protein associations are to a large degree stabilized by hydrophobic interactions,
but because hydrophobic forces are not specific, they would lead to all kinds of incorrect
interactions in a cell (Chothia & Janin, 1975). Another fundamental aspect of protein-
protein interactions is complementarity that applies both to the shape and to the charge of
groups on the surface of proteins (Jones & Thornton, 1995). Only complementary surfaces
can form proper hydrogen bonds and van der Waals contacts in order to close-pack
together. Incorrect associations would result in poor packing and loss of hydrogen bonds to
water (Chothia & Janin, 1975).
The ability of certain proteins to form complexes depends on the properties of their
interfaces. The definition of which residues form the interface relies on the distance
between any two atoms belonging to two residues from different chains: if the distance is
less than 5.0 Å, or less than the sum of the corresponding van der Waals radii plus 0.5 Å,
the residues are considered as belonging to the interface (Tsai et ah, 1996). The interfaces
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can be imagined to stabilize both the association between the subunits, and the tertiary
structure of the individual subunits (Miller et ah, 1987). Some aspects of the recognition
sites in oligomeric proteins (as opposed to enzyme-inhibitor, or antibody-antigen
complexes) will be shortly described here based on the literature from the last 3 decades. It
is striking that although continuously larger data sets from protein data bases and more
complicated algorithms are being used, the general conclusions remain valid.
Size of interfaces
When two proteins interact, they bury part of their solvent accessible surface into each
other. Argos (1988) calculated water-accessible surface area (in Å2) for isolated subunits
from several proteins and then the accessible surface area for the respective oligomers. His
calculations suggested that dimers lose about 12% of their accessible area (the average loss
was 5-6% per monomer bound), trimers lose over 17% and tetramers nearly 21%. The
percent area lost by oligomerization decreased as the number of amino acids in the
monomer increased, because a minimum area is required for stable binding and smaller
domains need to associate a greater percentage of their water accessible surface area
(Argos, 1988). Later analysis of Jones & Thornton (1996) show an average interface area
of about 1000 Å2 for each monomer of homodimers.
Composition of interfaces
The analysis of amino acid composition of the interfaces has shown that the hydropathy of
the interfaces lies between that of the buried (hydrophobic) and exposed (hydrophilic)
protein surfaces (Argos, 1988; Janin et ah, 1988; Jones & Thornton, 1996). Jones &
Thornton (1995) calculated that on average interfaces contain 68% non-polar atoms
(carbon) and 32% polar (nitrogen, oxygen and sulphur), and in term of residues contain
47% hydrophobic, 31% polar and 22% charged. Homodimers, that rarely occur or function
as monomers, were observed to have interfaces of higher hydrophobicity than heterodimers
and antibody-antigen complexes (Jones & Thornton, 1996; Jones & Thornton, 1997). All
interfaces had strong bias for large hydrophobic residues (Phe, Tip, Tyr) as well as Met
and to a lesser extent, Leu (Argos, 1988; Ofran & Rost, 2003). Non-polar residues lie, Leu,
Phe, Val, Cys and Met contributed together with 33% to the subunit interface area, while
charged residues Asp, Glu and Lys contributed much more to the accessible surface (33%)
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than to interfaces (14%) or to buried surface (15%) (Janin et al., 1988). Leucine and
arginine were pointed out to be those residues that make the largest contribution (about
10% each) to the subunit interface area (Janin et al., 1988). Especially Arg, in contrast to
Lys, occurs often at the interfaces, about 5 times as frequent at subunit interfaces as inside
the subunits (Janin et al., 1988; Ofran & Rost, 2003). Ser, Ala and Gly are on average
underrepresented (Ofran & Rost, 2003).
Energetic interactions between residues of interfaces
As mentioned before, hydrophobic side chains are the critical driving force in association
of protein molecules. When percentage frequency of amino acid residues in the interface
was plotted against their hydrophobicity, the interfaces were revealed as the hydrophobic
patches on the surfaces of proteins (Jones & Thornton, 1995). Also, when proteins
available as X-ray structures in their complexed form were analysed for clusters of
interface residues it was shown, that the binding sites correspond to a large extent to the
strongest hydrophobic patches (Young et al., 1994).
Analysis of energetic contributions of individual amino acids to protein-protein binding
(measurements of the change in free energy of binding upon mutation of different amino
acids to Ala) revealed that the free energy was not distributed evenly across interface;
instead, there were so called "hot spots" of binding energy made up of small subset of
residues in the dimer interface (Bogan & Thorn, 1998). These hot spots were enriched in
Trp, Tyr, Arg and Ile (Bogan & Thorn, 1998). (He appeared in hot spots 10 times as
frequently as leucine and no reason for this could be found (Bogan & Thorn, 1998)). The
aromatic residues are often found protruding from one subunit to the other, thus physically
anchoring the two subunits together (Jones & Thornton, 1995). Arginine is capable of
multiple types of favourable interactions: The guanidium group of Arg is the H-bond donor
in 33% of all polar interactions between subunits (Janin et al, 1988); Arg is also capable of
forming a salt bridge with its guanidium motif and hydrophobic interactions with its three
methylene carbon atoms (Bogan & Thorn, 1998). Removal from the solvent was a
necessary condition for a residue to be energetically important for binding and could be
accomplished by a surrounding seal of energetically unimportant residues (Bogan &
Thorn, 1998). Also hydrophilic bridges across the binding interface have been found to
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show positive correlation with the binding free energy and to significantly stabilize
complexes in several cases (Xu et ah, 1997).
Preferences on residue pairing across subunit interface
The overall trends on residue pairing preferences were summarized by Glaser et al. (2001):
the largest residue-residue preferences were recorded for pairs of large hydrophobic
residues, as Trp and Leu, and the smallest preferences for small residues like Gly and Ala,
presumably because the interaction strength is proportional to the interaction area (Glaser
et ah, 2001). Hydrophobic-hydrophobic interactions were most common, but also contacts
between the charged residues were observed. They followed charge complementarity, as
Arg-Glu pairs, or could make hydrophobic contacts with their aliphatic chains, while their
charged groups were solvent exposed and/or involved in hydrogen bonding (Glaser et al.,
2001). Contacts between residues in Cys-Cys pairs could be divided into two groups - with
or without disulfide bonds (Glaser et al, 2001). Cysteine bridges were observed more
often than expected in interfaces of both homo-and hetero-complexes (Ofran & Rost,
2003). All other amino acids showed preference for interaction between identical residues
only at interfaces of homo-dimers (Ofran & Rost, 2003). On average, identical residues
with the same sequence position in the two interacting subunits made less than 2.5% of all
interactions (Argos, 1988). Met was the amino acid that was remarkably involved in self-
interactions (ratio of composition of this amino acid in self-interaction to its composition in
all proteins was 4.88), and was followed by His and Phe (the ratio 2.55 and 2.11). The ratio
for Val was 1.76 (Argos, 1988).
Secondary structure of interfaces
Interfaces differ a lot with respect to their secondary structures. The dimer interfaces of
deoxyribonucleoside kinases consist, for example, exclusively of a-helixes (Eriksson et ah,
2002), while the dimer interface of thymidylate synthase is formed by an association
between five-stranded P-sheets present in each monomer (Hardy et ah, 1987). Miller
(1989) and Tsai et al. (1996) using a nonredundant set of proteins generalized that an
average interface consists of an uncharged central region that could be formed by a-
helixes, P-sheets, or a/ P (and a+P) structures, and an outer, charged region formed by
loops that make hydrogen bonds both to the main chain and side chain from another
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subunit. Based on the percentage frequency of a and (3 secondary structure in the interface
residues, Jones & Thornton (1995) classified 53.1% of the protein interfaces in their data
set as a, 21.8% as p, 12.5% as a/ P, and 12.5% as coil. A motif that occurs frequently in
protein-protein interfaces is the four-helix bundle (Lin et al., 1995), which has already
been described in Chapter 4 for the interfaces of dNK and dGK (Johansson et al., 2001).
Helices make a bundle if they have sufficient mutual contact and geometry (Lin et al.,
1995).
Results
Induction of GST- JKI66"136 fusion proteins and detection by CDNB assay
The cloned T K I 6 6 " 1 3 6 proteins had no enzymatic activity, and therefore the magnitude of
induction by IPTG was estimated by measurements of expression of the GST part of the
fusion protein. Fig.7.1 shows the reaction between GST-TK166 '136 fusion proteins and
GST substrate, CDNB.
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Figure 7.1. CDNB assay for GST-TRl36"136 fusion proteins. A.
 TKl66-136(Vall06) (KY895 as host
bacteria, overnight induction with IPTG), B. TKl66'136(Metl06) (BL21 as host bacteria, 6 hours
induction with IPTG). The assay was performed on 5 or 50 ul bacterial extract as described in
Materials and methods. A340 values were normalized to 1 ml bacterial extract.. Filled symbols,
before addition of IPTG; open symbols, after incubation with IPTG.
The fold of induction in different experiments, as estimated with the CDNB assay, varied
from about 200 to 600 for both
 T K l 6 6 - 1 3 6 ( V a n 0 6 ) with KY895 as host bacteria and TKI66"
i36(Meti06) ^ ^
 B L 2 ] a s h o s t bacteria. The density of the bacterial culture increased no more
than 10-fold during the same time period.
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Purification of TKl66"136 polypeptides by glutathione Sepharose chromatography
The purification procedure is summarized in Table 7.1.
Table 7.1. Purification of
 TKl66-136(Va"06) and of TKl66-136(Me"06)
66-136(MetlO6)
Volume Protein Volume Protein
ml mg/ml
Crude 50 13.06
Set 50 12.31
mg total
653
616
Pooled wash/equilibrium fractions
90
Cleavage fractions #1 and #2
3.2 0.81
Cleavage fractions #3, #4 and
4.8
Reduced GSH wash
4.8
25
2.6
#5
0.087
16
ml
50
50
266
8.9
13
13
mg/ml
5.59
4.13
0.56
mg total
279
207
21
4.9
0.2
2.9
All data are related to 1 litre of bacterial culture
The amount of protein in "crude" and "set" fractions of xKl66"136(Vall06) is most probably overestimated due to
the presence of 1% Triton. TKl66"136(MetI06) was purified without Triton.
From 1 litre KY895 and BL21 cultures 2 to 3 mg of TKl66"I36(Vall06) and 4 to 6 mg of
TKl66-136(Metl06) respectively, usually was obtained.
Estimation of subunit molecular size and protein purity of TKl66136 proteins
The mass of the cloned XKI66"136 was calculated from the amino acid composition:
C^THDRNTMEALPACLLRDVAQEALGVAVIGIDEGQFFPDIV/MEFCEAMANAGK
TVIVAALDGTFQRKPFGAI136 to be 7.7 kDa (including the two additional amino acids,
G and S, resulting from the fhrombin recognition sequence). Standard SDS-PAGE methods
are not suitable for peptides smaller than 10 kDa, and accordingly, I have initially tried to
increase acrylamide concentrations up to 20% in the separation gel, and to include about 7
M urea in the gel and/or elecrode buffer (Swank & Munkres, 1971; Schleif & Wensink,
1987) without success. Instead, including 30% ethylene glycol in the gel, and replacing
glycine with tricine in the electrode buffer gave good results (Fig. 7.2). The molecular size
of the heavy protein band corresponds to 7.9 kDa, in agreement with the value calculated
from the amino acid composition.
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Figure 7.2. SDS-ethylene glycol gel electrophoresis of cleavage fractions after glutathione
sepharose chromatography. Left gel:
 TKl66-136(VaI106), right gel: TKl66-136(Metl06). Lanes 1 and 4,
Pharmacia marker proteins consisting of a mixture of myoglobines (in kDa from top to bottom:
16.9, 14.4, 10.7, 8.2 and 6.2). Lanes 2 and 3, 1 ul of the first two cleavage fractions (cl. #1 and
cl.#2) corresponding to 0.8 and 0.7 ug protein for TKl66'I36(Vall06), and 0.4 and 0.6 ug for TK166"
136(MetlO6)
Further purification of the cloned TK166'136
As could be seen from Fig. 7.2 several contaminating bands were present in the cleavage
fractions. Due to the hydrophobic nature of the cloned interface further purification of the
TK1 " cleavage fraction was attempted on prepacked hydrophobic columns -
Butyl Sepharose and Phenyl Sepharose (Pharmacia). Interaction of TKl66"136(Vall06) with
Butyl Sepharose was too weak at the conditions applied and 90% of the protein appeared
in the wash fractions, while interaction with Phenyl Sepharose was so strong that the
protein did not elute with low salt buffer. However, it was eluted with addition of 30%
isopropanol or 20% acetonitrile, but unfortunately precipitated upon storage.
Because the percentage of contaminating proteins in the cleavage fractions was judged to
be less than 10% (Fig. 7.2), the degree of purity of the protein preparations was judged to
be sufficient for further analysis, and no further purification attempts were performed.
Estimation of apparent molecular size by gel filtration
It can be seen from Fig. 7.3, that TKl66~136(Vall06)was eluted as two separate peaks of about
29 kDa and 12 kDa., while TKl66"136(Metl06) was eluted as a single sharp peak of about 29
kDa. According to subunit size of 7.7 kDa, the TKl66"136(Vall06) is judged to elute as a dimer
and a tetramer, while xKl66"136(Metl06) elutes exclusively as a tetramer. These results are in
agreement with the results obtained for the active recombinant enzymes Ly-TKl and
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, MetlO6Ly-TKl , as described in the previous chapter and in Paper I (Berenstein et ah, 2000)
and Paper II (Frederiksen et al, 2004).
40-t
Figure. 7.3. Gel filtration of TKl66"136 proteins. About 100 ug of
 TKl66-136(VaI106) (open symbols) and
TKl66"136(Metl06) (closed symbols) from the thrombin cleavage fractions were injected into Superose
12 column. The molecular mass markers (I) are (from left to right in kDa): P-amylase, 200; bovine
serum albumin, 66; ovalbumine, 45; carbonic anhydrase, 29; lysozyme, 12.4.
NMR analysis1
The ID (one-dimensional) spectra are the first step in characterization of proteins by NMR.
The spectra are shown in Fig. 7.4 for the
 TKl66-136(Vall06) and in Fig. 7.5 for the TKl66"
136(MetlO6)
' i ' ' ' ' i ' ' ' ' i
11 10 >
Figure 7.4. ID spectrum of
 TKl66-136(Vall06).
!
 Se Appendix 1 for introduction to NMR principles
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Figure 7.5. ID spectrum of TKl66-'36(Metl06)
The signal-to-noise ratio is satisfactory and the chemical shift dispersion appears to be quite
good. The purification of jKl66"136(Metl06) was successful, as apart from amino acid
resonances only a signal for water can be seen (at about 4.8 ppm). TK166-136(Val 106) spectrum
shows two additional signals - at 2.5 and 2.6 ppm, probably residual impurities from
methylene groups of e-aminocaproic acid).
Resonances of several chemical groups can be identified in the ID spectra. The strongest
resonances in ID spectra are observed in the region 1 ppm, where most of the resonances
from valine, threonine, leucine and isoleucine methyl groups are overlapped. At the extreme
left from about 7 to 11 ppm are the resonances of the amide protons, and in-between
methylene groups are observed at 2-3 ppm, Ca protons at 4-5 ppm, and the protons of the
aromatic rings at 6-7.5 ppm. The resonances for aromatic amino acids show partial overlap
with side chain and backbone amide protons (Wuthrich, 1986). Spectra of both TKl66"136
proteins indicate that the proteins might be either folded into a-helix, or are random coils.
When residues are found in [3-strand or extended conformation their JH chemical shift for
Ca protons and for amide protons in the ID spectrum is on average moved about 0.4 ppm to
the higher ppm values (Wishart, et ah, 1991).
Either COSY or NOESY experiment is usually run in order to assess if the protein of
interest will give 2D spectra of required quality. Here NOESY was chosen, the results are
shown in Fig. 7.6 and Fig. 7.7. As can be seen, the cross-peaks that are present overlap and
are very broad. In small molecules, with molecular weights up to 10000, the line widths of
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the resonances are usually narrow, they get broader in larger molecules (Wiithrich, 1995).
Because resolution depends inversely on resonance line width, overlap of cross-peaks in 2D
NMR spectra is a major problem in studies of larger proteins.
F l
(ppm) —
1 -
Figure 7.6. 2D NOESY spectrum of
 TKl66"'36(VaU06)
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Figure 7.7. 2D NOESY spectrum of TKl66'136(Metl06)
An obvious reason for broadened cross-peaks in Fig. 7.6 and 7.7 is the self-assembly of the
cloned interface into dimers and tetramers (TKl66'136(Vall06)) and into tetramers (TK166"
i36(Metio6)^
 E a c h s u b u n i t contributes signals to the NMR spectra, and it is difficult to
distinguish between the intra-subunit and inter-subunits cross-peaks (Ferentz & Wagner,
2000). The residual contaminating proteins in preparations of JKI66"136 or the residual
thrombin could not have any effect on my results. The concentration of TK166"136 was 0.5
mM, while thrombin concentration was about 1 uM, and the concentration of the high MW
contaminating proteins was judged to be below 5% of the total protein. Even in-cell (in vivo)
NMR-experiments where all proteins in a bacterial cell were labelled with an NMR-active
isotope, only resonances from the protein of choice, overexpressed by induction2, were
visible (Serber & Dotsch, 2001).
' The highest overexpression levels possible are up to 30-50%, and can be obtained in yeast or in insect cells.
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Discussion
The amino acid composition of the cloned xKl66"136(Vall06) fragment and its predicted
secondary structure is shown in Fig. 7.8. It contains 71 amino acids plus Gly and Ser that
come from the thrombin recognition site (Fig. 7.8).
I ii 21 31 41 51 61 71-
A
GSCTHDRNTMEALPACLLRcVAQEALGV—, K-:i DEGQFFPD J vEK KAf-lANAGK'i • IV. .r.LDGTFQRKPFGAI
Jalign EEE H—HHHHHHH EEEEEE
jfreq --E HHHH HE EEEEE HHHHHHHHH EEEEEE
jhmin EEE EEEEE E EEEEEE EEEEEEEEEE
jnet --E HHHHHH EEEEE HHHHHHHHH EEEEEE
jpssm HHHHHHH EEEEE HHHHHHHHHH EEEEE
jpred HHHH EEEEE HHHHHHHHH EEEEEE
B
GSCTHDRNTMEALPACLLBI>VAUK;ALGV;\V;^.[DEGQFFPDiMr.l-: KAM'WAGKTv :. V \ALDGTFQRKPFGAI
jalign EEEE H--HHHHHHH EEEEEE
jfreq — E H-H HHEEH EEEEE HHHHHHHHH EEEEEE
jhmm EEE EEEEEE E EEEEEEE EEEEEEEEEE
jnet --E HHHHHH EEEEE HHHHHHHHH EEEEEE
jpssm HHHHHHHH EEEEE HHHHHHHHHH EEEEEE
jpred HHHd.Hh EEEEE HHHHHHHHH EEEEEE
Chou-Fasman H nH H HHHHH HH H H H H
Figure 7.8. Amino acid sequence and the predicted secondary structure of the cloned putative
interface fragment
 TKl66-136(Vall06) (A) and TKl66-136(Met106^ (B) by the Jpred method of Cuff &
Barton (2000). H - a-helix, E - p-strand, „-„ means residues that cannot be classified as either a-
or P-structure. Chou & Fassman (1978) prediction for a region corresponding to a3 is also shown.
The numbers of a-helixes and p-strands are the same as in Fig. 4.3 for the entire TKl subunit.
43 out of the 71 residues, or 60%, are non-polar (Gly and Ser that come from the thrombin
recognition site are not taken into account while discussing properties of the putative TKl
interface). Leaving out the two Met residues with the somewhat nucleophilic sulphur gives
41 out of 71, or 58% of hydrophobic residues. This high number of hydrophobic residues,
among them 5 Phe, 5 Leu, 5 He and 6 Val, as well as presence of charged residues 5 Glu, 5
Asp, 3 Arg and 2 Lys, correspond well to the description of amino acid content in interfaces.
The secondary structure algorithm predicts the putative interface to form two a-helixes and
two {3-strands (Fig. 7.8). According to the model of 3D structure of TKl described in
Chapter 4, the two P-strands belong to the core of the enzyme and the interface is probably
made by the a-helixes, a2 and a3 and by loops that surround them. The helices account for
12 out of the 71 residues, or 17% of the total cloned fragment. The helices though might be
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rather weak. a2 of XKl66"136 consists of only 4 residues and has no stabilizing hydrogen
bond between the CO group and NH group of the main chain (from residue n to residue «+4)
a2 of TKl66~136(Metl06) consists of 6 residues and contains two hydrogen bond between the
CO and NH groups of the main chain. Still, it is a weak helix compared to helices of over 8
amino acids, where the central residues have two hydrogen bonds between the
corresponding CO and NH groups. Such central residues must be more geometrically
constrained than the end residues. Jpred prediction of a-helix 3 (IV106EFCEAMA) as a
genuine a-helix is supported by CD spectroscopy study of synthetic peptides (Behrends et
al., 1996). Though, both TKl66"136 peptides contain two negatively charged residues Glu-107
and Glu-110 spaced 3 positions from each other. Because of the twist of the a-helix they
must be close to each other in space and the repulsive forces probably destabilize the helix.
Presence of P-branching amino acids in both a2 and a3 helices (Val-84, Ileu-105, Val-106)
is another helix destabilizing factor. This effect is pronounced in aqueous solution but not in
the hydrophobic environment (Li & Deber, 1994). It can be imagined that the remainder of
TKl protein creates the proper environment necessary for the correct folding of the interface
in vivo.
These a2 and a3 helices are homologous to the a4- and a6-helices from each subunit of the
dimer interface of dNK and dGK, that together make the four-helix bundle. The interacting
residues of the dNK interface are four aromatic, four aliphatic and four small. a2- and a3-
helices of the putative TKl interface contain one aromatic and six aliphatic residues that
together with the charged Asp, Glu and Arg might make the interacting residues of putative
TKl interface. The putative TKl interface helices are shorter, 4 and 9 amino acids
respectively, as compared to 19 and 18 amino acids in the dNK interface helices and cannot
be classified as the four-helix bundle until the structure of TKl has been elucidated.
When the a3-helix (aa 105-114 in the fragment, but 104-113 in the whole TKl) is subjected
to helical wheel analysis (Fig. 7.9) it becomes obvious that the helix is polar on one side and
hydrophobic on the other side.
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Figure 7.9. Helical wheel analysis of TK1 sequence ^FFPDIVEFCEAMANA115 (performed by a
package from: http://marqusee9.berkelev.edu/kael/helical.htm)
As could be seen from the gel filtration experiments
 of TKl66-136(Vall06) and TKl66-136(Met106),
the exchange of Val to Met results in a permanent tetramer form of the fragment. Therefore
the residue at position 106 and the neighbouring residues may be strongly assumed to
belong to the oligomerization interface. We do not know if the tetramer is a dimer of dimers,
where another interface region is involved, or if the tetramer is formed through interaction of
the same two helices from each of the four subunits. These two possibilities should be
distinguished by comparison of well-resolved (3D or 4D) NMR resonances for TK166"
i36(vaii06)and TK166-i36(Metio6) I f p o s s M i t y 1} i s c o r r e c t , then the interactions that lead to the
formation of tetramers cause less environmental change for the residues at the studied
interface than if the possibility 2) is correct. The environmental change for the interface
residues and/or the conformational change induced by complex formation will be reflected
in changed chemical shifts. Such shift perturbations measurement have been described to
locate interfaces on the individual binding partners (Gronenhorn & Clore, 1993; Zuiderweg,
2002).
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Chapter 8
Investigation of the C-terminally truncated TKl -
TK1A40
Introduction
The C-terminal residues in human and mouse TKl are known to be essential for the
specific degradation of the enzyme at mitosis and for the cell cycle regulated expression of
TKl (Kauffman & Kelly, 1991; Kauffman et al., 1991; Sutterluety et al, 1996; Ke &
Chang, 2004). Sequence KEN present in the C-terminal part of human TKl (Fig. 8.1) has
been shown to be responsible for mitotic degradation via a ubiquitin-proteasome pathway:
it is required for recognition by an ubiquitin E3 ligase - anaphase-promoting complex
(APC) complexed with its activator protein Cdhl (Ke & Chang, 2004). The KEN box has
been demonstrated to be targeting signal for APC-Cdhl complex in several cell cycle-
regulated proteins, including the R2 subunit of mouse ribonucleotide reductase (Pfleger &
Kirschner, 2000; Chabes et al, 2003). The C-terminal region of other proteins, for example
of ornithine decarboxylase and of transcription factor IRF-1 (interferon regulatory factor)
are also found to be critical for their turnover (Ghoda et al, 1992; Nakagawa & Yokosawa,
2000; Zhang et al, 2003).
177GADKYHSVCRLCYFKKASGQPAGPDNKENCPVPGKPGEAVAARKLFAPQQILQCSPAN
194SGQPAGPDNKENCPVPGKPGEAVAARKLFAPQQILQCSPAN
Figure 8.1. Sequence of amino acid residues removed from TKl upon construction of TK1A60 and
TK1A40 respectively. The putative a- and P-forming residues according to JPred (se Fig. 4.3), and
the KEN box (recognition sequence for proteolysis by anaphase promoting complex) are also
shown.
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Progressive deletion of three, six, ten, twenty and thirty C-terminal residues from mouse
TK resulted in stepwise loss of its growth-dependent regulation: The TKA30 protein was
constitutively expressed because it was resistant to mitosis-specific degradation
(Sutterluety et al., 1996). Mouse TK C-terminally truncated by 37 residues, i.e. with Q196
as the last one, had full enzymatic activity, while if truncated by 44 residues, i.e. with
Y189 as the last one, had no activity (Mikulits et al., 1997). Here, it is interesting to notice
that thymidine kinase of vaccinia virus, highly homologous to human TK1, has no C-
terminal domain, and its last amino acid corresponds to residue 192 in the human enzyme
(Fig. 4.1). The absence of TK C-terminal domain in vaccinia virus (Fig. 4.1) parallels the
absence of cell cycle regulation and a constantly high vaccinia TK activity in the infected
cell, which might be of evolutionary advantage for replication of the virus. The residues up
to position 192 in the human TK1 might then be important for the activity of the enzyme.
Two C-terminally truncated TK1 mutants, TK1A40 (A41) and TK1A60 (A58), were
constructed by introduction of stop codons at positions 194 and 177 respectively into the
amino acid sequence of TK1 (described in Materials and methods; Kristensen, 1996). The
original purpose was to create TK1 mutants with lower molecular weight, and therefore
susceptible to NMR analysis, but at the same time preserving the enzymatic activity of the
wild type protein. Both TK1A40 and TK1A60 were expressed in E. coli as GST-fusion
proteins and both had GST activity, while only TK1A40 showed thymidine kinase
enzymatic activity (Kristensen, 1996). According to prediction of TK1 secondary structure
in Fig. 4.3, deletion of 58 C-terminal amino acids removes the last P strand (P5) and the
last a helix (a5), while removal of 41 amino acids from the C-terminal leaves the P5 strand
intact, and only removes a5 helix (Fig. 8.1). Comparison to the 3D structure of HSV1 TK
shows that the (35 strand and the few following residues are important for binding of ATP
(among others Gln-331 that makes a single hydrogen bond to the adenosine moiety of ATP
in HSV1 TK; Wild et al., 1997). The residues of TK1 removed in A58, but preserved in
A41, are: G177ADKYHSVCRLCYFKKA193. Asp-179 might be the putative hydrogen
acceptor corresponding to Gln-331 of HSV1 TK, and Arg-186 might supply hydrogen
bonds to the phosphates of ATP.
When mouse thymidine kinase was synthesized in vitro in a coupled
transcription/translation system, the enzymatic activity of a C-terminally truncated TKA30
mutant was 1.5 to 2-fold higher than the activity of the wild type (Posch et al., 2000). The
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authors hypothesized that the C-terminus limits the access of substrates to the active sites,
so that deletion of the C-terminal resulted in better accessibility for substrates and in higher
specific activity of the TKA30 protein (Posch et al, 2000).
In order to uncover the role of the C-terminal domain we have performed in vitro
characterization of kinetic and oligomerization properties of TK1A40.
Results
Subunit and native molecular size
The subunit molecular size of TK1A40 was, as expected, about 20 kDa (Kristensen, 1996,
and Fig. 8.2).
Figure 8.2. SDS gel electrophoresis of CM-Sepharose fraction of TK1A40 (left lane).
Approximately 0.5 ug protein was applied to the gel. The standard proteins (in kDa) are from top to
bottom: phosphorylase B (94), bovine serum albumine (67), ovalbumine (43), carbonic anhydrase
(30), soybean trypsin inhibitor (20,1) and a-lactalbumin (14,4).
The apparent native molecular size of TK1A40 as determined by gel filtration on the
Superdex column was about 45 kDa (Fig. 8.3A). According to the subunit size, TK1A40
eluted predominantly as a dimer, but with a pronounced shoulder of apparent molecular
size of about 70 kDa, which corresponds to the tetrameric form of the enzyme.
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Figure 8.3. Estimation of native molecular size by gel filtration. About 1 ug protein (200 ul from
solution of 5 ug/ml) of TK1A40 (A) and of TK1 wild type (B) was injected into a Superdex 200
column precalibrated with (from left to right) following standard proteins (|): bovine serum
albumine (67 kDa), ovalbumine (45 kDa), carbonic anhydrase (29 kDa) and cytochrom C (12.4
kDa).
Absence of a separate tetrameric peak of TK1A40 (Fig. 8.3 A) is surprising compared to the
elution profile of TK1 wild type (Fig. 8.3B), where the dimeric and tetrameric peaks are
well separated (apparent molecular sizes of about 50 kDa and 100 kDa). Also, the
tetrameric form of TK1A40 elutes later than expected, and so seems smaller than its
calculated size. A plausible explanation might be that the absence of the presumably
disordered C-terminal makes the tetrameric form of TK1A40 much more compact than the
corresponding tetrameric form of TK1 wild type.
Enzyme stability
As shown in Fig. 8.4, the stability of TK1A40 at 15°C is considerably higher than that of
the wild type enzyme. The un-truncated, wild type TK1 lost 50% of its activity within 6.5
hours (tj/2 ~ 6.5 hours), while TK1A40 had barely lost any activity in this period (tj/2 ~ 43
hours). Recent experiments performed at 25°C and 37°C confirm the higher stability of C-
terminally deleted TK1, and show that increase in stability is proportional to the length of
the deletion. The order of several C-terminally truncated TK1 proteins from the most to the
least stable was: TK1A40, TK1A30, TK1A20 and TK1 wild type (Chunying Zhu, personal
communication). As it is very likely that the terminal 40 amino acids are disordered (se
discussion), it is probable, that as the disordered stretch in a protein sequence increases, its
thermodynamic stability decreases, and the quicker is the process of transition of the whole
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protein from a folded, native state to an unfolded, denatured state. The compact structure
of TK1A40 might increase its thermostability.
Figure 8.4. Stability of TK1A40 as compared to non-truncated TK1. TK1A40 (squares) and the
wild type TK1 (circles) were incubated in phosphate buffer at 15°C. Each point is derived from at
least two experiments, the bars are the standard error of the mean (SEM). A somewhat lower initial
value of TK1A40 enzyme activity at time "0" was repeatedly seen. The curves were fitted by non-
linear regression analysis with Graphpad Prism software.
Enzyme kinetics
Fig. 8.5 is an example of the thymidine substrate kinetics of TK1A40. Experiments were
performed at saturating concentrations of ATP for both the TK1A40-ATP (incubated and
stored without ATP) and TK1A40+ATP (incubated and stored with ATP) forms of the
enzyme.
Figure. 8.5. Thymidine substrate kinetics of TK1A40 with enzyme concentration of 1 ng/ml in
the assay mixture. A. The initial velocity of dTMP formation as a function of thymidine
concentration. B. Hofstee plot of the same data. TK1A40-ATP form, closed symbols,
TK1A40+ATP form, open symbols.
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The kinetic mechanism of TK1A40 (Fig. 8.5) is the same as the mechanism of TK1 wild
type enzyme described earlier (Munch-Petersen et al, 1993; Paper I, Berenstein et al.,
2000). TK1A40-ATP displays a nonhyperbolic, "creeping" binding curve and a biphasic
kinetic pattern in Hofstee plot (n value 0.64), while TK1A40+ATP gives a straight line
indicating a hyperbolic rectangular reaction mechanism (n value 1.1). The KQ.S values
determined here were respectively 2.5 uM and 0.6 uM for the -ATP and +ATP form of
TK1A40, and the Fmax values were approximately 17 and 20 umol/min/mg for the -ATP
form for the +ATP form respectively. Independent estimation of the specific activity
performed at 100 and 120 uM thymidine have given values of 22,1 ±1,8 umol/min/mg (n
= 5) for the -ATP form, and 27,2 ± 2,3 umol/min/mg (n = 8) for the +ATP form.
Simultaneous estimation of the specific activity at 100 and 120 uM thymidine has given
20,9 ± 1,4 umol/min/mg (n = 4) for TK1-WT-ATP and 20,0 ± 1,0 umol/min/mg (n = 4) for
TKl-WT+ATP. The kinetic values of TK1A40 are compared to TKl-WT in Table 8.1.
Table 8.1. Kinetic values of TKl-WT and of TK1A40
Fmax (umol/min/mg)
Kcat (sec )
^0.5 (UM)
KcJK0.5 (sec^uM'1)
TK1
-ATP
20
8,5
15
0,57
WT
+ATP
20
8,5
0,5
17
TK1A40
-ATP
22
7,8
2,5
3,1
+ATP
27
9,6
0,6
16
"Calculations of KcM were made using the calculated MW of TKl-WT equal to 25500 and MW of
TK1A40 equal to 21400.
J^max of TK1A40 is somewhat higher than Fmax of TKl-WT, but Kcat is practically the same,
as is K0.5 and KcJK0.5 of the +ATP form. On the other hand, the -ATP form of TK1A40
has 5-6-fold lower K0.5 and therefore 5-6-fold higher K^JKQ.S {i.e. 5-6-fold higher
enzymatic efficiency) than the TKl-WT enzyme. Thus, exposure of TK1A40 to ATP
increases substrate affinity about 4-fold (^ 0.5 values 2,5 and 0,6 respectively for the -ATP
and +ATP form), whereas exposure of TK1 wild type to ATP increased substrate affinity
20-30-fold (K0.5 values about 15 and 0.5 uM respectively for the -ATP and +ATP form
(Munch-Petersen et ah, 1993; Paper I, Berenstein et al, 2000).
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Discussion
The C-terminal region in human and mouse TK1 has been shown to be dispensable for
TK1 activity in vivo, and at the same time, to be essential for the specific degradation of
the enzyme at mitosis and for the cell cycle regulated expression of TK1 (Kauffman &
Kelly, 1991; Kauffman et aL, 1991; Sutterluety et aL, 1996; Ke & Chang, 2004). In order
to get more insight into the role of the C-terminal region, I have determined kinetic,
oligomerization and stability properties of TK1A40 in vitro, and analyzed amino acid
composition of the 40 C-terminal residues.
Kinetic aspects
The about 6-fold decrease in KQ,*-, for thymidine, as demonstrated here for the -ATP form
of the C-terminally truncated TK1, is in agreement with the hypothesis of Posch et al.
(2000) that the C-terminal limits access of substrate to the active site. This decrease in KQ.S
can also explain the finding that the C-terminal truncation increases kinetic activity of the
mouse thymidine kinase (Posch et aL, 2000). In the wild type human TK1 enzyme, binding
of ATP which induces formation of the tetrameric form (Munch-Petersen et aL, 1993;
Paper I, Berenstein et aL, 2000) may at the same time induce a conformational change that
pulls the C-terminal auto inhibitory domain away from the active site, thus permitting
better access for the substrate. Removal of the C-terminal increases substrate accessibility
considerably (6-fold lower KQ.S), but pre-assay ATP exposure of TK1A40 is necessary to
reduce the KQ.S value further to 0.5 uM.
Aspects of the in vivo and in vitro stability of TK1A40
The higher in vivo stability of the C-terminally truncated TK1 (Kauffman & Kelly, 1991;
Kauffman et aL, 1991; Sutterluety et aL, 1996) can be explained by the recent finding of
Ke & Chang (2004), that a KEN motif in the C-terminal targets TK1 for destruction by
Cdhl-APC complex (se Chapter 2). Other research groups have demonstrated that the
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KEN box is a recognition signal for proteolytic degradation of several cell cycle-regulated
proteins (Pfleger & Kirschner, 2000) including ribonucleotide reductase (Chabes et ah,
2003). SCF ubiquitination complexes may also be utilized to control cell-cycle expression
of TK1. The findings of Chang and collaborators showed that TK1 is hyperphosphorylated
on serine (s) residues during mitosis in several human cell lines (Chang et ah, 1994), that
the primary mitotic phosphorylation site is S13 (Chang et ah, 1998) and that
phosphorylation of S13 contributes to the cell-cycle regulated degradation of TK1 via the
SCF ubiquitine ligase and proteasome-mediated proteolytic pathway (Ke et ah, 2003).
Still, at least in mouse cells, a proteasome-independent mechanism might as well be
involved, because proteasome inhibitors failed to stabilize substrate-binding mutants of
mouse TK in proliferating fibroblasts (Posch et ah, 2000). Here, it is interesting to note
that in the mouse TK, the residue corresponding to human E204 in the 203KEN box is
deleted (Fig. 4.1).
KEN is not the only proteolytic sequence known. Another one is PEST - sequences
enriched in proline (P), glutamate (E), serine (S) and threonine (T) (Rechsteiner & Rogers,
1996). PEST sequences are often present in unstructured regions of the protein, and there
appears to be a statistical preference for location of these sequences in the C-terminal
regions of proteins involved in cell cycle regulation (Wright & Dyson, 1999). An
algorithm PEST-FIND that produces a score from -50 to +50 and defines sequences with a
score above 0 as possible PEST sequence, defines residues K192ASGQPAGPDNK203 as a
poor PEST sequence with a score of -10 . Many PEST sequences are conditional and
phosphorylation of serines and threonines within such PEST regions are needed to activate
a latent degradation signal (Rechsteiner & Rogers, 1996). Analysis of amino acid sequence
of TK1 for potential phosphorylation sites by NetPhos 2.0 (at www.cbs.dtu.dk. Center for
Biological Sequence Analysis) gives six serine residues high score values (position
nr/score: 13/0.996, 30/0.908, 33/0.951, 62/0.886, 63/0.979 and 183/0.986), while S194 and
S 31 located in the C-terminal, get very low scores: 0.056 and 0.012 respectively. This very
low score of S231is in agreement with results of Chang et ah (1998) who found no
difference in phosphorylation level between wild-type TK1 and JK1S231A mutant in
mitotically blocked cells. Besides serine residues, also T168 and Y181 get high prediction
scores as possible phosphorylation sites in the C-terminal: 0.992 and 0.952 respectively. It
seems reasonable to suppose that phosphorylation of residues outside the PEST region, for
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example the above-mentioned S13, might as well induce conformational changes in the
protein and thus expose it to proteolytic enzymes.
Another proteolytic motif - AQP, enriched in alanine, glutamine and proline, is present in
EBNA, Epstein-Barr virus nuclear antigen (Rechsteiner & Rogers, 1996). It has been
observed that cloned EBNA proteins are expressed at higher amounts in lymphoma cell
lines if their polyproline region is deleted (Peng et al., 2000). Among the last 41 C-
terminal amino acids of TK1 are 7 prolines, 6 alanines and 4 glutamines, the AQP residues
together stand for 17 of the 41 amino acids. Presence of the weak PEST motif and of AQP
motif in the human TK1 may facilitate the interaction with the proteolytic machinery in
vivo. Especially prolines have been proposed to be involved in protein-protein binding
because of 1) the flat hydrophobic surface of the proline ring which binds well to other
hydrophobic surfaces, and 2) the fact that proline is a good hydrogen bond acceptor,
possibly thanks to the electron-donating potential of the methylene group attached to the
amide nitrogen (Williamson, 1994). The pro line-rich C-terminal of TK1 contains 3 lysines,
K203, K211 and K220 which could serve as sites for binding and conjugation of ubiquitin
to the enzyme.
The increased in vivo stability of C-terminally truncated TK1 does not provide a simple
explanation for the finding that also in vitro stability of the truncated recombinant enzyme
gets increased. A plausible explanation can be offered by a hypothesis that the C-terminal
of TK1 is disordered1. The proportion of eucaryotic proteins with disordered regions has
been estimated to be as high as 52-67%, with 35% of these proteins being completely
disordered, 16% displaying disorder at their C-terminal ends, 30% at N-terminal end and
17% at internal regions (Vucetic et al., 2003). Examples of enzymes having disordered,
function-dispensable termini are: human topoisomerase I with disordered N-terminal
domain (Stewart et al, 1996), and the tumour suppressor phosphatase, PTEN with
disordered C-terminal domain which decreased the catalytic activity (Vazques et al.,
2000). The disordered regions have been found involved not in catalytic, but in different
regulatory functions related to their disorder: molecular recognition and signalling through
binding to proteins, DNA, different RNAs, and in mediation of posttranslational
modification such as phosphorylation or proteolysis (Dunker et al., 2002). Phosphorylation
and proteolysis are known to be involved in regulation of lifetime and enzymatic activity
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of human TK1 (Ke et al, 2003; Ke & Chang, 2004). The possibility that AQP residues and
the KEN box of TK1 serve as a proteolytic signal has already been mentioned. This fits
with the assumption that in the disordered regions the specific residues are not masked by
the folded structure, and therefore make an easily accessible target for the proteolytic
enzymes. Several reports describe these disordered regions to undergo in vitro protease
digestion orders of magnitude faster than the ordered regions (Stewart et al., 1996; Fontana
et al, 1997).
Some amino acids, like P, A, E, S and Q occur more often in disordered proteins than in
ordered proteins (so called disorder-promoting amino acids), while W, F, Y, C, I, L, V and
N are depleted in the disordered regions (called order-promoting amino acids) and T, N
and D are ambivalent (Dunker et al, 2001; Vucetic et al, 2003). P, A, E, S and Q make
together 21 out of the 41 C-terminal amino acids of TK1 (Fig. 8.1). High content of
proline, which is the poorest a-helix- and p-strand-forming residue, and relatively high
content of hydrophilic amino acids (41% in the C-terminal of TK1) that are prone for
interactions with the solvent, can be imagined to result in lack of structure as opposed to
folding into a compact globular domain.
A simple tool to identify regions of disorder is newly developed GlobPlot algorithm which
is based on a sum of the propensity for amino acids to be in an ordered or a disordered
state (Linding et al, 2003).
1
 There is no general definition of disorder. It can be described as the lack of regular structure and a high
degree of flexibility in the polypeptide chain.
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Figure 8.6. Prediction of disorder in TKl according to GlobPlot predictor (http://globplot.embl.de).
Curve going uphill indicates increased disorder/flexibility and downhill segments indicate
globularity, domains or structured regions. The server sends by default the analysed sequence to
SMART and Pfam databases (Bateman et ah, 2002; Letunic et al, 2002), and displays any
obtained homologous domains as coloured boxes (here blue) layered on the graph.
The GlobPlot predicts 11 consecutive residues (5NLPTVLPGSPS16) in the N-terminal and
20 consecutive residues in the C-terminal of TKl (193ASGQPAGPDNKENCPVPGKP212)
to be disordered. (Fig. 8.6). Altogether, 13.2% of TKl protein is predicted to be disordered
and 77.4% of the protein is predicted to be globular. For comparison, only the 10 C-
terminal residues out of total 250 residues of dNK, or 4%, are predicted to be disordered,
while 85.2% of the dNK sequence is predicted to be globular (http://globplot.embl.de). The
increased amount of predicted disorder in TKl might reflect the problems encountered
during crystallization of this protein prior to X-ray structure determination.
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Chapter 9
General discussion
The cytosolic thymidine kinase, TK1 is a cell-cycle regulated enzyme. Its activity
fluctuates with DNA synthesis and is low or absent in quiescent cells, while being high in
dividing cells. The control of TK1 activity is effected on transcriptional and several post-
transcriptional levels, as described in Chapter 3. On the enzymatic level, native TK1
isolated from lymphocytes, has been shown to be regulated by pre-assay exposure to ATP:
Incubation of the pure enzyme with ATP at 4°C induced enzyme concentration-dependent
reversible transition from a dimer with low catalytic activity and non-hyperbolic thymidine
substrate kinetics to a tetramer with a 20- to 30-fold higher catalytic activity and
hyperbolic kinetics, but with the same maximal velocity (Munch-Petersen et al., 1993). To
further investigate the effect of ATP, two expression plasmids were constructed: pET3a-
TK1 which contained the amino acid coding region of TK1 cDNA from the pTKll clone
of Bradshaw & Deininger (1984) and pGEX-2T-LyTKl which contained the amino acid
coding region from normal human lymphocytes (Paper I, Berenstein et al., 2000).
Surprisingly, the recombinant TK1 expressed from the pET3a-TKl did not show the
regulatory effect of ATP, which at that time was explained by the absence of post-
translational modification of the enzyme in E. coli cells (Munch-Petersen et al., 1995). On
the other hand, preliminary kinetic and gel filtration experiments with rLy-TKl have
shown that it behaved as native lymphocyte TK1 with respect to the regulatory effect of
ATP. By comparison of the sequence of lymphocyte TK1 cDNA with that of pTKl 1 clone
of Bradshaw & Deininger (1984) it was discovered that lymphocyte TK1 cDNA had a
GTG codon for valine at amino acid position 106, while the TK1 cDNA in the pTKll
clone had a ATG codon for methionine at this position (Kristensen, 1996; Paper I,
Berenstein et ah, 2000).
This study was started in order to determine which amino acid is naturally present at
position 106 in human TK1 and what is the effect of amino acid 106 on properties of the
enzyme. Sequence analysis of altogether 22 TK1 genomic and cDNAs from healthy,
leukemic or transformed cell lines revealed a GTG codon each time in both alleles. Thus,
the experimental results presented in this thesis demonstrate that it is valine and not
methionine that is the naturally occurring amino acid at position 106 in the human
thymidine kinase. As described in Chapter 6 and Chapter 7 valine was found to be of
158
prominent importance for structure and enzymatic mechanism of TKl. Valine 106 is
conserved among vertebrates and viruses from the pox family, and is positioned in a highly
conserved area of TKl. This area, important for catalytic activity and regulation of
function of TKl, is predicted to form an amphipathic helix facilitating subunit interaction,
i.e. the interface (Fig. 7.9, and Eriksson et al., 2002). I have cloned, expressed, and purified
the putative interface domain of rLy-TKl, rLy-TKl66"136, with valine or methionine as
amino acid 106. Investigation of oligomerization properties of rLy-TKl66"136 confirmed the
importance of amino acid 106 for the subunit arrangement of the enzyme, because in gel
filtration experiments
 rLy_xKl66"136(VaU06) interface fragment eluted as a mixture of a dimer
and a tetramer, while
 rLy-TKl66"I36(Metl06) eluted as a tetramer only (Fig. 7.3).
The shift between a dimer and a tetramer, which according to the results described in this
thesis, is possible for TKl with Val-106, but not with Met-106, may have an important
physiological role as proposed in a model of Munch-Petersen et al. (1995a): To correlate
the thymidine kinase activity with DNA synthesis in the S phase, TKl shifts from a low
activity dimer with apparently negative cooperativity in Gl, to a high activity tetramer with
apparently hyperbolic reaction mechanism in S phase. (Fig. 9.1). This transition is
dependent on ATP and enzyme concentration and can be considered as an additional
regulation of TKl activity, on the top of transcriptional and post-transcriptional regulation.
m
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Figure 9. 1. Model for the fluctuation between the dimer and tetramer forms of thymidine kinase
during the cell cycle. In the Gl phase with low TKl concentration, the dimer TKl dominates. With
increasing concentrations during S-phase, more TKl will be in the tetramer form. After Munch-
Petersen et al. (1995a).
This model has recently been extended by Li C.L. et al. (2004) who used our recombinant
TKl with valine 106 for investigation of how serine 13 phosphorylation effects the activity
of TKl. As described in Chapter 3, serine 13 has previously been shown to be the site of
heavy mitotic phosphorylation (Chang et al., 1998). SI 3D substitution which mimics
phosphorylation was found to have a perturbed pattern of ATP induced tetramerization: the
equilibrium was shifted from a tetramer to a dimer and was paralleled by an 10-fold
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increase in Km (Li et al., 2004). Because the concentration of TKl remains high in G2
phase and in early mitosis (Ke & Chang, 2004) these results explain the previously
observed downregulated activity of phosphorylated TKl at G2/M phases in proliferating
cells (Chang & Huang, 1993; Chang et al, 1994; Chang al, 1998). Fig. 9. 2 illustrates the
role of phosphorylation in the regulation of TKl activity during the cell cycle.
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Figure 9. 2. Model of the role of phosphorylation in the quaternary structure and functional
regulation of TKl in the cell cycle. During progression from GI to S phase expression of TKl
increases and TKl protein is predominantly in its tetrameric form. In G2/M phase TKl becomes
phosphorylated and the oligomeric equilibrium shifts towards the dimeric form. After Li et al.
(2004).
How to reconcile the effect of Ser-13 phosphorylation on dimer-tetramer transition with
the proposal that the area around amino acid 106 in TKl is the monomer-monomer and/or
the dimer-dimer interface? A possible answer might be that formation of the tetramer from
a pair of dimers requires the Ser-13s to be very close in space and, if phosphorylated, the
negative charges repulse each other. In any case, phosphorylation of TKl is involved in
transition between a low activity dimer with apparently negative cooperativity and a high
activity tetramer with apparently hyperbolic reaction mechanism, and therefore
phosphorylation regulates TKl activity as well as biosynthesis of dTTP. Recently, a
HI2IN mutation in human mitochondrial TK2 that caused the loss of negative
cooperativity with thymidine as substrate in the recombinant TK2, has been described
(Wang et al, 2003). The mutation was found in patients with the mitochondrial DNA
depletion syndrome combined with fatal functional defects in muscles (Saada et al., 2001).
This finding underlined the importance of proper regulation mechanism of the enzymes
involved in salvage of deoxynucleosides for integrity of the organism during lifetime.
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It remains to be explained why methionine at position 106 was found in previous
investigations of TK1 derived from SV40 transformed fibroblasts (Bradshaw & Deininger,
1984) and from HeLa cells (Flemington et al, 1987). Because of the prominent difference
between the Val-106 and the Met-106 forms of TK1 for the thymidine affinity and dimer-
tetramer transition of human TK1, the earlier research performed with recombinant TK1
expressed from the pTKll clone, i.e. with methionine at position 106, might not have
yielded representative data. We have found several polymorphisms in the coding sequence
of the TK1 gene, but none of them in the codon for amino acid 106. Our results were
supported by sequencing results performed on TK1 gene from the human lymphoblastoid
cell line, TK6 (Grosovsky et al, 1993), from Burkitt lymphoma lymphocytes and from
uterus tissue deposited in Genbank in 2001 by Strausberg for the NIH Mammalian Gene
Collection (MGC) Project (gi:23503074), and recently in breast and colorectal cancer solid
tumours (Gilles et al, 2003). Most of the polymorphisms observed occurred in one allele
only, and at the third base position in the codon, so they did not result in amino acid
change. Besides the change from lysine to arginine at amino acid position 211, found in
lymphocytes from the very first donor, only one other polymorphism resulted in amino
acid change: a C to T transition in the cell line Reh changed the CAG codon for amino acid
20 in one allele to TAG, a stop codon. Thus, only a truncated TK1 polypeptide of 19 amino
acids will be expressed from this allele, the cells will depend on TK1 synthesis from the
other allele, and may become more vulnerable to DNA damage. Previous observation of
Kristensen et al. (1994) in our laboratory, that in chronic lymphatic leukaemia
lymphocytes, high level of TK1 mRNA is present without accompanying TK1 enzyme
activity, may be explained by presence of a stop codon in one, or more probably, both
alleles at the tk locus.
"Silent" polymorphisms that do not introduce any amino acid change may still be
important for the expression and function of TK1 in the living cell. Silent mutations may
change a "high usage codon" to a "low usage codon" , which will result in less efficient
translation of the gene. Kim et al (1997) have shown that the human erythropoietin (EPO)
gene with human high-frequency codons gave a considerably higher level of expression in
mammalian cells than the gene with yeast high frequency codons. Opposite situation,
where a "low usage codon" will be changed to a "high usage codon" with resulting higher
expression of TK1, may be also detrimental to the cell. An example of importance of silent
mutations for gene function comes from investigations on polymorphisms in XPD excision
repair gene: psoriasis patients had a higher risk of early basal cell carcinoma if they were
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AA homozygotes at a specific nucleotide position, than patients with AC or CC genotypes
(Dybdahl et al, 1999).
Val-106 might have been selected over Met-106 during natural evolution due to the
physiological advantage of dimer - tetramer transition of TK1 protein, and may be also
because of the higher thermal stability of the Val-106 enzyme. Though, the lower stability
of TK1 (V106M) in vitro might be of no relevance in vivo. At enzyme assay conditions,
where ATP/MgCl2 (2.5 mM), Chaps (0.5 mM) and BSA at 3 mg/ml are present, both Val-
106 and Met-106 enzymes are stable (Munch-Petersen, personal communication). With the
total protein concentration of 200 - 300 mg/ml (Ellis, 2001), 2 mM ATP (Ferraro et ah,
1992) and approximately 1 uM thymidine (Holden et al., 1980) in the cell cytoplasm, TK1
(V106M) might have the same stability as V106WT. The molecular crowding1 of the
living cell might bring still another regulatory mechanism of TK1: The putative flexible C-
terminal of TK1 can be imagined to be occupied by/interact with other proteins, and in
such case the catalytic activity may correspond to the higher catalytic activity of TK1A40.
The molecular mechanism behind the effect of valine/methionine substitution is not clear
and must await the 3D structure of TK1 to be solved. Obtaining a monomeric and active
TK1, preferably with full or nearly full activity, would have greatly facilitated structural
studies of the molecule. The fact that no monomeric TK1 mutants have so far been created,
in spite of several attempts, could be due to the fact that dimerization of TK1 subunits is
essential for catalysis: Both subunits might be needed to keep the catalytic pocket in shape,
or it might be the dimerization that brings the substrate binding site and the catalytic centre
together. For example, residues from both subunits of thymidylate synthase contribute to
each active site (Hardy et ah, 1987). The second scenario was suggested for Rnase T: the
substrate-binding site and the catalytic centre of the same subunit are believed to be located
far away from each other, but the centres from different subunits are brought together
through homodimerization to form fully functional active sites (Zuo & Deutscher, 2002).
1
 When macromolecular species occupy a large fraction of the total volume in a given medium, the medium
is referred to as "crowded" rather than "concentrated", as no individual macromolecular species may be
present at high concentration (Minton, 2000).
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TK1 should in principle be functional as a monomer, because each subunit contains the
necessary information for substrate binding and catalytic activity. Based on structure
designed, for example, by Swiss PDB Viewer program (also called "Deep View"), amino
acids at chosen positions of the putative dimer interface could be substituted to introduce
electrostatic repulsion into the monomer-monomer interface, but without destabilization of
the monomer 3D structure. This strategy has been used successfully for creating several
biologically active, monomeric insulins2, where negative charges were inserted to oppose
negative charges on the complementary interface, as e.g. in the B9 Ser to Asp mutant
(Brmgeetai, 1988).
If monomers of TK1 turn out to be genuinely devoid of enzymatic activity, drugs that
inhibit dimerization of TK1 could be designed for possible use as an aid in anticancer
therapy.
In conclusion:
Two regions of human recombinant TK1 have been the subject for structure-function
studies in the present investigation: 1) the internal region surrounding amino acid 106
while stressing the role of the residue 106, and 2) the C-terminal stretch of the last 40
amino acids.
We have shown that valine is the naturally occurring amino acid at position 106 in the
human thymidine kinase, that amino acid 106 and the sequence surrounding it are
associated with reversible dimer-tetramer transition, and that the p-branching of amino acid
at site 106 may be important for such conformational transitions.
Investigation of the C-terminally truncated TK1 (TK1A40) revealed that it is profoundly
more stable in vitro than the non-truncated TK1.1 propose that disorder (the lack of regular
structure) and flexibility in the stretch of the last 40 amino acids can explain the higher in
vitro stability.
2
 The 3D structure of insulin has been known since 1969.
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Summary
Thymidine kinase 1 catalyses phosphorylation of thymidine to thymidylate (dTMP) using
ATP as the phosphate donor. Due to the ubiquitous nucleotide kinases, intracellular dTMP
is quickly phosphorylated to dTTP. dTTP in turn, is an important allosteric effector of
ribonucleotide reductase, and a cell with defect TK1 activity has diminished ability to
balance its supply of both purine and pyrimidine DNA precursors. TK1 is a cell cycle
regulated enzyme, its activity parallels DNA synthesis rate, and its expression is carefully
regulated on transcriptional, post-transcriptional, translational and post-translational levels.
The co-substrate ATP has been shown to be a regulator of the catalytic activity of TK1, as
well.
Because markedly different enzymatic properties were observed between endogenous TK1
isolated from human lymphocytes and a recombinant enzyme expressed from a TK1
cDNA clone present in the NCBI GenBank database (where mRNA from transformed
human fibroblasts was used as cDNA source), and because DNA sequencing of
lymphocyte TK1 cDNA showed a GTG codon for valine at amino acid position 106, and
not ATG codon for methionine as in the GenBank database, we suspected the GenBank
sequence to be wrong. Further, we wanted to investigate if amino acid 106 had any effect
on the enzymatic properties. Therefore, the investigations described in the experimental
part of this Ph.D. thesis were undertaken.
The naturally occurring amino acid at position 106 of human thymidine kinase 1 was
identified by sequencing 22 independent isolations of genomic DNA and cDNA from
healthy donors, leukemic cell lines, colon cancer cell lines, and transformed and
nontransformed fibroblast cell lines. In each case a GTG codon for valine was found at this
position in both alleles. Because amino acid 106 is located in a highly conserved area of
the protein and is valine in other mammalian and pox-viral thymidine kinases, valine is
most probably the naturally occurring amino acid at this position in human TK1.
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The effect of valine or methionine at position 106 on the properties of the enzyme has been
studied with the recombinant TK1 containing Val-106 (V106WT) or Met-106 (V106M).
TK1(V1O6WT) and TK1(V1O6M) were cloned, expressed, purified and characterized with
respect to enzymatic and oligomerization properties. The properties of recombinant TK1
(V106WT) were the same as those of the native TK1 isolated from human lymphocytes:
pre-assay ATP exposure induced an enzyme concentration-dependent reversible transition
from a dimer to tetramer with about 30-fold higher catalytic activity (KQ.S towards
thymidine was about 15 and 0.5 uM, respectively, Fmax was the same). Substitution of Val-
106 with methionine gave TK1(V1O6M), which was a permanent tetramer with high
catalytic activity even without pre-exposure to ATP (KQ.*, towards thymidine was about 0.5
uM for both the ATP pre-exposed and the ATP unexposed enzyme forms). Furthermore,
TK1(V1O6M) was considerably less stable than TK1(V1O6WT); tm values at 15°C were
respectively about 40 and 390 minutes.
The role of size, conformation and polarity of amino acid 106 for the function and structure
of human TK1 was examined by creation of nine recombinant mutant enzymes at amino
acid site 106 and their characterization with regard to native size, kinetic properties and
stability. Based on the obtained results the recombinant mutant enzymes could be divided
into two groups: Group I with VI06A, VI061 and V106T behaved like V106WT, i.e. pre-
assay exposure to ATP induced reversible transition from a dimer with low catalytic
activity (X0.5 towards thymidine from about 13 to 43 uM) to a tetramer with high catalytic
activity (#0.5 towards thymidine from about 0.3 to 0.9 uM). Group II with V106G, V106H,
V106K, V106L and V106Q behaved like V106M in that they were permanently high
activity tetramers (K0.5 towards thymidine from 0.3 to 1.2 |xM, both in the absence and
presence of ATP). The stability of enzymes from Group II was much lower than the
stability of Group I enzymes. The amino acids at site 106 in Group I enzymes are, except
for alanine, of similar size and conformation, but different polarities, and the hydroxyl
moiety of threonine does not seem to cause any disturbances. The common property of the
side chains of valine, isoleucine and threonine is branching at the P-carbon atom
considered to destabilize ex-helices because of steric clashes. Destabilization of helix-helix
interaction by (3-branching amino acids adds conformational flexibility to the enzyme
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protein and might be crucial for dimer-tetramer transition of TKl. The dimer-tetramer
transition seems to play an important physiological role in the regulation of TKl activity.
The role of amino acid 106 and the sequence surrounding it for dimer-tetramer transition
was examined by cloning, expression and characterization of the putative interface
fragment
 TKl66-I36(Vall06) and of its mutated form TKl66-136<Metl06>: The results from gel
filtration experiments confirmed that amino acid 106 and the neighbouring residues are
involved in dimer-tetramer transition, as the xKl66"136(Vall06) fragment eluted as a mixture
of a dimer and a tetramer, whereas 7Kl66"136(Metl06) fragment eluted as a tetramer only.
The C-terminal of TKl is known to have a regulatory role in vivo for cell cycle-regulated
expression of this enzyme. In order to uncover the role of the last 40 C-terminal residues of
TKl for the kinetic, oligomerization and stability properties, the TK1A40 recombinant
mutant enzyme was cloned, expressed and characterized in vitro. The properties of
recombinant TK1A40 were similar to the native TKl isolated from human lymphocytes
and to the recombinant TK1(V1O6WT): pre-assay ATP exposure induced an enzyme
concentration-dependent reversible transition from a dimer to tetramer with higher
catalytic activity (KQ.$ towards thymidine was about 2.5 and 0.5 uM, respectively). The
lower Æ0.5 towards thymidine for the ATP unexposed TK1A40 as compared to the ATP
unexposed TK1(V1O6WT) may be explained by a C-terminal limiting access of the
substrate to the active site. The in vitro stability of TK1A40 was found to be considerably
higher than the stability of TK1(V1O6WT), with ty2 values of about 43 hours and 6.5 hours
respectively. It is very likely that this higher stability of TKl A40 is due to the absence of a
disordered stretch of the C-terminal amino acids.
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Dansk resumé
Thymidin kinase 1 katalyserer fosforylering af thymidin til thymidin monofosfat (dTMP)
ved hjælp af ATP som fosfat donor. Intracellulær dTMP fosforyleres hurtigt videre til
dTTP af allestedsnærværende nukleotid kinaser. dTTP har en nøgleposition i reguleringen
af ribonukleotid reduktase, som er et vigtig enzym i både purin og pyrimidin DNA-
prekursor metabolismen. En celle med en defekt thymidine kinase er derfor dårligere end
den normale celle til at afbalancere sin dNTP-pool, og har større sandsynlighed for
forstyrrelser under DNA syntesen og DNA repair.
Det eksperimentelle arbejde i denne afhandling udspringer fra den observation at TK1
isoleret fra humane lymfocytter har andre enzymatiske egenskaber end den rekombinante
TK1, der er udtrykt fra en TK1 cDNA klon baseret på mRNA fra transformerede humane
fibroblaster. Klonens DNA sekvens er den officielle TK1 sekvens som findes i NCBI
GenBank databasen. Da DNA sekventering af en TK1 klonet fra lymfocyt DNA blev
udført i Munch-Petersens laboratorium, fandtes overraskende en GTG kodon for valin i
site 106, og ikke ATG kodon for methionin som i NCBI databasen. Arbejdet i denne
afhandling handler om at klarlægge hvilken aminosyre der er på site 106 i human TK1,
samt belyse denne aminosyres rolle for de enzymatiske egenskaber.
Den naturligt forekommende aminosyre i site 106 i den humane TK1 er blevet identificeret
ved at sekventere 22 uafhængigt isolerede genomiske DNA og cDNA fra raske donorer,
leukæmiske cellelinier, koloncancer cellelinier, samt transformerede og ikke
transformerede fibroblast cellelinier. Resultaterne viste at kodon for valin forekom i site
106 på begge alleler i samtlige undersøgte donorer og cellelinier. Da site 106 er placeret i
proteinets højt konserveret område, og er valin i andre mammale og pox-virale thymidin
kinaser, er det mest sandsynligt at valin er den naturligt forekommende aminosyre i site
106 i den humane TK1.
Betydningen af valin og methionin i site 106 for egenskaberne af TK1 er blevet undersøgt
med det rekombinante TK1 enzym. TK1 indeholdende Val-106 (V106WT) og Met-106
(V106M) blev klonet, udtrykt, oprenset og karakteriseret med hensyn til deres enzymatiske
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egenskaber og den native molekylevægt (kvarternære struktur). Det blev påvist at TK1
(V106WT) opførte sig som det native TK1 enzym oprenset fra humane lymfocytter - uden
tilstedeværelse af ATP var TK1(V1O6WT) en dimer og inkubationen med ATP inducerede
en enzymkoncentrationsafhængig reversibel tetramerisering af denne dimer. Tetramer-
formens katalytiske aktivitet var omkring 30 gange højere end dimer-formens: K0.5 værdier
overfor thymidin var henholdsvis omkring 0.5 uM og 15 uM, mens Fmax værdien var den
samme. Ved at mutere Val-106 til methionin blev TK1(V1O6M) fremstillet, og enzymet
viste sig at være en permanent tetramer med høj katalytisk aktivitet (Ko,5 omkring 0.5 uM
uafhængigt af ATP-inkubationen inden den enzymatiske assay). Ydermere var
TK1(V1O6M) væsentlig mindre stabil end TK1(V1O6WT); tm værdier var henholdsvis 40
og 390 minutter.
For yderligere at undersøge betydningen af størrelsen, konformationen og polariteten af
aminosyre 106 i den humane TK1, blev ni rekombinante site 106-mutant-enzymer
fremstillet og karakteriseret med hensyn til enzymatiske egenskaber, nativ størrelse og
stabilitet. Udfra de enzymatiske egenskaber kunne de rekombinante enzymer inddeles i to
grupper: Gruppe I med TK1(V1O6WT) lignende egenskaber, og gruppe II med
TK1(V1O6M) lignende egenskaber. Gruppe I indeholdt V106A, V106I og V106T.
Ligesom TK1 (V106WT), var de overvejende i dimer-form uden tilstedeværelse af ATP,
mens inkubationen med ATP inducerede reversibel tetramerisering med en samtidig
overgang fra en form med lav katalytisk aktivitet (ÅT0.5 for thymidin fra omkring 13 til 43
uM) til en form med høj katalytisk aktivitet (X0.5 fra omkring 0.3 til 0.9 uM). Gruppe II
indeholdt V106G, V106H, V106K, V106L og V106Q. Gruppe II enzymer var permanente
tetramerer med høj katalytisk aktivitet (£0.5 fra omkring 0.3 til 1.2 uM, uafhængigt af
forudgående inkubationsperiode med ATP). Stabiliteten af Gruppe II enzymer var meget
lavere end Gruppe I enzymer. Aminosyrer i site 106 i Gruppe I enzymer, med undtagelsen
af alanin, ligner hinanden med hensyn til størrelse og konformation, men har forskellig
polaritet. Den polære hydroxyl kæde på threonin adskiller sig fra de hydrofobe sidekæder
på valin og isoleucin, dog har disse tre aminosyrer en fælles egenskab: en forgrening på P-
carbonatomet som vides at destabilisere a-helix strukturen og helix-helix interaktioner på
grund af steriske forstyrrelser. Denne virkning af aminosyrer med (3-carbonatomets
forgrenede sidekæder kan gøre konformationen af enzymproteinet mere fleksibel, og kan
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være afgørende for dimer-tetramer overgangen hos TK1. Den reversible dimer-tetramer
overgang formodes at spille en vigtig fysiologisk rolle under reguleringen af TK1 aktivitet.
Betydningen af aminosyre 106 og regionen omkring site 106 for dimer-tetramer
overgangen blev undersøgt ved at klone, udtrykke og karakterisere det formodede
interfacefragment
 TKl66-136(Vall06) og dets mutant TKl66-136(Metl06>. Det fremgik udfra den
native molekylevægtsbestemmelse ved gelfiltrering, at xKl66"136(Vall06) optræder som en
blanding af dimer og tetramer, mens 7Kl66"136(Metl06) optræder udelukkende som tetramer.
Resultatet bekræftede at aminosyre 106 og den omkringliggende region er vigtig for dimer-
tetramer overgangen hos TK1.
Et andet område af TK1 som jeg undersøgte var C-terminalen. TK1 er et celle-cyklus
reguleret enzym og mange rapporter har peget på at de C-terminale aminosyrer har en
vigtig rolle for den mitotiske nedbrydning af TK1 in vivo. For at afdække betydningen af
de sidste 40 C-terminale aminosyrer for egenskaber som stabilitet, nativ molekylestørrelse
og enzym kinetik, blev TK1A40 rekombinant enzym (de sidste 40 aminosyrer er fjernet)
karakteriseret in vitro. TK1A40 opførte sig som den native lymfocyt TK1 og den
rekombinante TK1(V1O6WT) med hensyn til den reversible effekt af ATP inkubation
forud for den enzymatiske assay: ATP inducerede en reversibel overgang fra en dimer-
form til en tetramer-form med højere katalytisk aktivitet (Kos overfor thymidin henholdsvis
omkring 2.5 og 0.5 uM). Den lavere K0.s for den ikke ATP-eksponerede form af TK1A40
end for den ikke eksponerede TK1(V1O6WT) kan forklares ved at de C-terminale
aminosyrer forhindrer substratet i at komme til enzymets aktive site. In vitro stabilitet af
TK1A40 var væsentlig højere end stabiliteten af TK1(V1O6WT), med tm værdier på
henholdsvis 43 timer og 6.5 timer. Det diskuteres i denne afhandling hvorvidt forskellen
skyldes den formodede fleksibilitet og manglen på den ordnede struktur i det C-terminale
område.
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Appendix 1
Introduction to NMR principles
(Protein NMR without tears and physical principles)
In principle, all 2H atoms in a protein can be observed by NMR. The basics of this
technique as applied to protein structure can be best understood if one regards a single
amino acid. Fig. Ap. 1A and Ap. IB show a ID and a 2D COSY spectrum of valine:
CH}
H C CH5
*H3N - C—COO
H
n
6 r4
i
0
CB
Figure Ap. 1A. ID spectrum,
of valine.
From Poulsen et al. (1997)
8
Figure Ap. IB. 2D COSY spectrum
of valine.
Fig. Ap. 1A shows how the different hydrogen atoms of valine can be resolved depending
on the atom to which the JH is bonded (a, (3 and y refer to the carbon atom of valine). The
resolution is due to different resonance positions of the H atoms and is given by the
chemical shift (ppm, i.e. in parts per million relative to a reference substance). The
chemical shift is determined primarily by the chemical group in which the 'H atom is
found, and also in a smaller degree on environment of this group. For example, in an ideal
random polypeptide coil all CH3 group resonate at about lppm, NH groups at about 8 ppm,
and multiple copies of a specific amino acid have identical chemical shifts and cannot be
distinguished. In globular proteins chemical shift dispersion arises because interior peptide
segments are shielded from the solvent and are nearest neighbours to other protein
segments (Wuthrich, 1986). Still, less than 10% of the resonance lines are shifted from
their random coil class into the chemical shift ranges of other classes of protons (Wuthrich,
1986).
When a second frequency axis is added to the 1D method, one gets a 2D NMR experiment
- the resonances are spread in two dimensions and the spectral analysis is facilitated. In 2D
(Fig. Ap. IB) experiments the diagonal corresponds to the ID spectrum, while the off-
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diagonal peaks (so called cross-peaks) contain information about connections between
resonances on the diagonal (Roberts, 1993). The connections observed depend on the kind
of experiment that is being carried out and on the machine setting: in COSY (correlated
spectroscopy, Fig. Ap. IB) one can observe through-bond connections between resonances
of nuclei separated by one, two or three up to four covalent bonds, in NOESY (nuclear
Overhauser effect spectroscopy) one can observe through-space connections between the
resonances of nuclei which are close together (i.e. below 5 Å) in space (Roberts, 1993).
All Val residues, for example, can be identified, but not distinguished from each other in
COSY spectra and remain isolated entities, because COSY has no observable spin-spin
coupling across the peptide bond which connects neighbouring residues (Redfield, 1993).
These assignments are deduced from the through- space lH-*H interactions of the nuclear
Overhauser effect (NOE). Each cross-peak can be attributed to a distance between a pair of
H atoms, irrespective if protons at distances up to 5 Å originate from neighbouring
residues or from residues that are far apart in the amino acid sequence (Billeter et ah,
1982). The well-resolved resonances (ideally as in Fig. Ap.2) can be assigned to specific
amino acids in the sequence.
Figure Ap. 2. A small region from a 'H-NOESY spectrum of a protein. The cross-peaks are
identified by the amino acid position and the proton type (from Billeter et ah, 1990).
The sequential assignment procedure was developed by Wiithrich and collaborators
(Wiithrich et ah, 1982; Billeter et ah, 1982) and consists of two steps. The first step utilizes
COSY and involves identification of spin-spin coupled resonances that belong to a
particular amino acid. Alanine residues for example are easily identified because Ala is the
only amino acid whose a-proton and the P-methyl group make up a spin system that has a
typical spin-coupling pattern. The second step utilizes NOESY to identify through-space
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connections (d) between for example Ha, Hp and amide proton of one residue to the amide
proton of the next residue (daN, d^N and dNN, respectively, se Fig. Ap. 3). In the sequential
assignment strategy unique segments of two or three amino acids are identified by NMR
and then by comparison with the known amino acid sequence attributed to discrete
positions in the protein.
Figure Ap. 3. ^ - 'H NOESY connectivities that are useful for identification of secondary structure
(from Wuthrich et ah, 1984).
For example if a NOESY cross-peak corresponding to d„d},i +1) or d^dij. +1) indicates a
dipeptide Val-Ala and this sequence occurs only once , the assignment problem is solved.
If multiple sites containing Val-Ala are present, a tripeptide containing Val-Ala must be
identified by NMR and then matched to the known sequence (Wuthrich, 1995). At the
same time the sequential and medium range (up to five consecutive residues) NOE patterns
give information about secondary structure (Fig. Ap. 3). In (3-strands strong da^i,i +1)
NOEs are observed, while in helical structures strong £/##(/, z+1) are observed. Also
dap(i,i+3) and dadjj +4) NOEs shorter than 4.5 Å are characteristic for helical
conformation (Wuthrich et ah, 1984). Following sequence-specific resonance assignment,
the NOE peak intensities1 are quantified and converted into distances and into backbone O
and side chain xi dihedral angles. In the next step structure calculations are performed to
obtain atomic models consistent with the NMR-derived constrains, and finally, the
structures are improved taking energy considerations into account (Kaptein et ah, 1991;
Wuthrich, 1995).
The intensity of an NOE is related to r-6 where r is the distance between the interacting nuclei.
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Abbreviations and glossary
Enzymes
ADA, adenosine deaminase
ADK, adenylate kinase
CAT, chloramphenicol acetyltransferase, often used as a reporter gene
CDK, cyclin dependent kinase
dCK, deoxycytidine kinase
dGK, deoxyguanosine kinase
dNK, (=Z)w-dNK) the multisubstrate nucleoside kinase from Drosophila melanogaster
dNT, deoxynucleotidase
dUTPase, dUTP pyrophosphatase, produces the dTTP precursor dUMP and decreases
cellular dUTP levels
GST, glutathione-S-transferase
HSV TK, Herpes simplex virus thymidine kinase
PNP, purine nucleoside phosphorylase
TK, thymidine kinase
TK1, the cell cycle regulated, cytoplasmic thymidine kinase
TK2, the constitutive, mitochondrial thymidine kinase
TP, thymidine phosphorylase, also called pyrimidine phosphorylase
Deoxyribonucleosides and deoxyribonucleotides
dAdo, dAMP, dADP, dATP, deoxyadenosine, mono-, di-, and triphosphate
dCyd, dCMP, dCDP, dCTP, deoxycytine, mono-, di-, and triphosphate
dGuo, dGMP, dGDP, dGTP, deoxyguanosine, mono-, di-, and triphosphate
dlno, dIMP, dIDP, dITP, deoxyinosine, mono-, di-, and triphosphate
dN, dNMP, dNDP, dNTP, any deoxyribonucleoside and its mono-, di-, and triphosphate
dThd, dTMP, dTDP, dTTP, deoxythymidine, mono-, di-, and triphosphate, the same as
respectively Thd, TMP, TDP and TTP
dUrd, dUMP, dUDP, dUTP, deoxyuridine, mono-, di-, and triphosphate
Nucleoside analogues
AraA, 9-P-D-arabinofuranosyladenine
AraC, 1- P-D-arabinofuranosylcytosine
AraG, 9-(3-D-arabinofuranosylguanine
AraT, 1 -(3-D-arabinofuranosyl-thymidine
AZT, 3' -azido-2' ,3' -dideoxythymidine
BvdU, E-5-bromovinyl-2'-deoxyuridine
CdA, 2-chloro-2' -deoxyadenosine
ddC, 2'-3'-dideoxycytidine
FdUrd, 5-Fluoro-2'-deoxyuridine
FIAU, l-(2'-deoxy-2'fluoro l-P-D-arabinofuranosyl)-5-iodouracil
FLT, 3'-fluoro-2',3'-dideoxythymidine
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Other abbreviations
3D, three dimensional
AP-1, activating protein 1, a collective term referring to homo- or heterodimeric
transcription factors composed of Jun, Fos or ATF (activating transcription factor) subunits
that bind to a common DNA site, the AP-1 binding site TGACTCA
APC, anaphase promoting complex (cyclosome), a ubiquitin-conjugation protein complex
ARF, alternative reading frame
BLAST, Basic Local Alignment Search Tool
bZIP, basic region leucine zipper proteins, a family of transcription factors that bind to
palindromic AP-1 regulatory elements and activate many genes involved in cell growth
and differentiation. The bZIP domain consists of a basic region, contacting DNA, and a
homo- or heterodimer-forming region called the leucine zipper.
CBP, CREB-binding protein, together with another co-activator - p300 promotes
transcription by acetylating histones and recruiting basal transcription factors TFIIB, TBP
(TATA-binding protein), and RNA polymerase II holoenzyme.
CDNB, l-chloro-2,4-dinitrobenzene
CDP, CCAAT displacement protein
CHAPS, 3-(3-cholamidopropyl)-dimethylammoniol-l-propylsulfonate, a detergent
CKI, CDK inhibitor protein
CLL, chronic lymphatic (B-cell) leukaemia
COSY, NMR correlation spectroscopy
CREB, cAMP-response element-binding protein
DTT, dithiothreitol
E-box, a cis-element present in the promoter and enhancer regions, has sequence
C ANNTG and is recognized by a variety of helix-loop-helix transcription factors, eg. USF
(upstream stimulatory factor)
E2F, a family of cellular transcription factors
EC, Enzyme Commission, appointed by the International Union of Biochemistry, works
out systematic ways of classification and naming of enzymes, first report appeared in 1964
EGF, epidermal growth factor
h, human in for example hTKl, human TK1
hnRNA, heterogeneous nuclear RNA, a collective term referring to pre-mRNA and other
nuclear RNAs of various sizes
hsp, heat-shock protein
HSV, Herpes simplex virus
IGF-1, insulin-like growth factor-1
IPTG, isopropyl-1 -thio-|3-D-galactopyranoside
GO cells, quiescent, non-proliferating cells withdrawn from the cell cycle
Gl phase, The period in the cell cycle where cell prepares for DNA synthesis
G2 phase, the period in the cell cycle where cell prepares for mitosis
Km, the Michaelis constant (- substrate concentration at Vz Fmax)
M-phase, mitosis phase
MDS, mitochondrial DNA depletion syndrome
MNGIE, mitochondrial neurogastrointestinal encephalomyopathy, a severe mitochondrial
dysfunction
mtDNA, mitochondrial DNA
n, Hill constant
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NCBI, National Center for Biotechnology Information, established in 1988 in USA as a
national resource for molecular biology information
NMR, Nuclear magnetic resonance
NOE, nuclear Overhauser effect
NOESY, nuclear Overhauser enhanced spectroscopy
p53, tumor suppressor protein, has apparent molecular weight of 53 kDa. p53 gene is
mutated in more than 50% of human cancers
PDGF, platelet-derived growth factor
PHA, phytohemagglutinin
PMSF, phenylmethylsulfonyl fluoride
PRPP, 5-Phosphoribosyl-l-pyrophosphate
Run-on assay (nascent chain assay) for transcription rate of a gene, isolated nuclei are
briefly incubated with 32P-labeled NTPs, the labelled RNA is hybridised to the specific
gene, and radioactivity in total RNA and in this specific RNA is counted Thus, a fraction
of total RNA produced from that gene can be measured
Rb, Retinoblastoma protein, tumor suppressor
SD, standard deviation
SE, standard error
Set, first fraction collected during protein purification on an affinity column. The volume
of set fraction corresponds to the volume of the input which was applied to the column
S-phase, The period of the cell cycle where DNA is duplicated
SCF, ubiquitin ligase complex (from the name of the major compound proteins: Skpl-
cullin/Cdc53-Fbox
SIC, S-phase cyclins inhibitor in budding yeast, corresponds to inhibitor p27 in
mammalian cells
T lymphocytes (T cells), interact with infected host cells through receptors on T-cell
surface (killer T cells), or interact with macrophages and produce interleukines that
stimulate B and T cells to proliferate
UTR, untranslated region, noncoding regions at the ends of the primary RNA transcript
x, the maximal velocity
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